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ABSTRACT 
Activated receptor tyrosine kinases recruit many signalling proteins to initiate 
downstream cell proliferation and survival pathways, including phosphatidylinositol 3-kinase 
(PI3K), a heterodimer consisting of a p85 regulatory protein and a p110 catalytic protein.  Our 
laboratory has previously shown the p85α protein also has in vitro GTPase activating protein 
(GAP) activity towards Rab5 and Rab4, small GTPases that regulate vesicle trafficking events 
for activated receptors.  Expression of a p85α protein containing an arginine to alanine 
substitution at position 274 (p85R274A) that affects its GAP activity, caused sustained levels of 
activated platelet-derived growth factor receptors (PDGFRs), enhanced downstream signalling, 
and resulted in cellular transformation.  Together with other data, this suggested that in 
p85R274A-expressing cells, PDGFRs are more rapidly trafficked through the endocytic 
pathway, which reduces opportunities for sorting events necessary for receptor degradation.  Our 
laboratory has observed previously that p85 was capable of binding to both Rab5-GDP, as well 
as Rab5-GTP, which is an atypical characteristic of GAP proteins, whereas p110β had previously 
been reported to bind Rab5-GTP selectively.  Based on these observations, this thesis project was 
designed to test the hypothesis that both proteins contributed GAP activity towards Rab5, with 
p85 providing a catalytic arginine residue (R274) and p110β providing switch stabilization 
functions specific to the GTP-bound state.  To accomplish the thesis objective, cells expressing 
individual p85 defects (lacking GAP activity, R274A; or lacking p110-binding ability through 
deletion of residues 478-513, Δ110) were compared to cells expressing a double mutant missing 
both functions. Stable clonal NIH 3T3 cell lines were generated and selected in G418 and clones 
expressing similar levels of FLAG-tagged p85 wild type or mutants compared to the control cell 
lines (NIH 3T3, FLAG-vector control, p85 wild type, and p85R274A) were chosen for analysis.  
A time-course of PDGF stimulation showed that cells expressing p85R274A or 
p85Δ110+R274A have sustained phosphorylation levels of the PDGFR, reduced rates of PDGFR 
degradation and sustained MAPK/Erk signalling. Contrary to the cellular transformation 
previously reported for p85R274A-expressing cells, expression of p85∆110+R274A did not lead 
to cellular transformation. These divergent results suggest that p85-associated p110 serves two 
functions. As the catalytic subunit of PI3K, one function is the localized generation of PI3,4,5P3 
lipids at the plasma membrane for Akt activation, and possibly during receptor endocytosis 
where it could impact MAPK/Erk activation/deactivation kinetics and cell transformation.  These 
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results support a second function for p110 in the regulation of PDGFR activation/deactivation 
kinetics and PDGFR half-life, both strongly influenced by alterations in PDGFR trafficking.  
This suggests that p110β may regulate PDGFR trafficking by providing Rab5-GTP switch 
stabilization that complements the catalytic arginine residue (R274) within p85, and that p85α 
and p110β work together as a Rab5 GAP.  
The role of PDGFR in the localization of the RabGAP function of p85 to specific 
subcellular compartments was also examined. It was hypothesized that PDGFR may help 
localize the RabGAP function of p85 to vesicles containing Rab5 or Rab4 through the binding of 
p85 to phosphorylated tyrosine residues on activated PDGFR. Stable cell lines expressing 
individual p85 defects (lacking GAP activity, R274A; or lacking PDGFR-binding ability through 
site-directed mutation of residues 358 and 649 from arginine to alanine, ΔR; or a double mutant 
missing both functions) demonstrated that p85R274A or p85∆R+R274A expression leads to 
sustained PDGFR activation and signalling, and to delayed PDGFR degradation in response to 
PDGF stimulation. The sustained signalling observed resulted in cellular transformation in cells 
expressing p85R274A or p85∆R+R274A. The data suggests that PDGFR does not play a role in 
the localization of the RabGAP activity of p85. 
The findings of this study elucidates important non-canonical functions of the PI3K 
heterodimer and contributes to our understanding of how specific mutations in both p85 and 
p110β within regions implicated in the regulation of RabGAP activity can alter signalling events 
and lead to enhancement of tumour-associated phenotypes. 
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1.0 INTRODUCTION AND LITERATURE REVIEW 
1.1 Signal Transduction Pathways 
Cells interact with and respond to stimuli generated from their external environment 
through a process referred to as signal transduction. The stimuli may include either scarcity or 
availability of hormones, nutrients, or oxygen (Schuller, 1991). Communication of information 
between the exterior and interior parts of a cell directs and regulates the many signal transduction 
pathways (also referred to as ‘signalling cascades’) that lead to normal cellular functions. 
Cellular responses to these signals include either amplifying or diminishing events that lead to, 
for example, cell proliferation and survival (McKay and Morrison, 2007).  
Signal transduction pathways are initiated by an interaction between the external stimulus 
usually referred to as the ligand, and receptors that are expressed on the plasma membrane (Biarc 
et al., 2011; Citri and Yarden, 2006; Dengjel et al., 2009; Madhani, 2001; McKay and Morrison, 
2007). Examples of these cell surface receptors include receptor tyrosine kinases (RTKs) and G-
protein coupled receptors (GPCRs). The information is transferred across the membrane through 
the receptor to intracellular effector molecules. These effector molecules then activate a cascade 
of signalling events that culminate in the stimulation of cell proliferation, survival and 
differentiation (Aaronson, 2005; Heldin and Westermark, 1999; Lemmon and Schlessinger, 
2010).  
Activation of signalling within the cell is regulated by a variety of factors including post-
translational modifications and compartmentalization of both receptors and intracellular effector 
molecules. The most common post-translational modification for the activation or deactivation of 
these proteins is phosphorylation of tyrosine, threonine or serine residues (Burnett and Kennedy, 
1954; Cozzone, 1988; Olsen et al., 2006; Pawson and Scott, 2005; Walton and Dixon, 1993). 
Signalling proteins can also be modified by ubiquitination, prenylation, myristoylation, 
glycosylation, methylation or acetylation (Biarc et al., 2011; Yang and Seto, 2008). This can 
result in a change in binding affinity or specificity of the receptor for the ligand, or changes in 
the conformation or localization of the protein. Ultimately, these changes determine whether the 
protein is active or not, and can thus enhance or terminate a signal.  
Due to a protein’s role in cell proliferation and survival, it is very important for every 
step within a signal transduction pathway be tightly regulated. The control of synthesis and 
degradation regulates protein levels; whereas the initiation, duration and intensity of signalling 
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mediated by the protein are regulated by post-translational modifications and 
compartmentalization. Deregulation of any of these processes can lead to pathological 
conditions, including cancer, diabetes and heart diseases (Robertson et al., 2000; Tonks, 2006).  
Cancer has been classically referred to as a group of diseases that results from the 
abnormal regulation of cell proliferation. The transformation of a normal cell into a tumour cell 
is a multistage process that may be initiated by external agents (such as tobacco products, 
viruses, X-rays, UV radiation, and chemicals) as well as genetic factors, both inherited and non-
inherited (Croce, 2008; Danaei et al., 2005; Merlo et al., 2006). Among these genetic factors are 
the over-expression of wild type or constitutively active cell surface receptors; as a result of gene 
amplification, increased gene expression, and more recently defects in receptor trafficking and 
degradation (Bache et al., 2004; Bacus et al., 1990; Haeder et al., 1988; Liu and Tsao, 1993; 
Peschard and Park, 2003; Tripathy, 2005). Alterations in the structure and function of the 
intracellular signalling molecules have also been shown to lead to certain malignancies, 
including carcinomas, sarcomas, leukemias and lymphomas (Blume-Jensen and Hunter, 2001). 
More insight into the regulation of signal transduction is therefore necessary for the development 
of appropriately targeted therapeutics for cancer patients. 
 
1.2 Receptor Tyrosine Kinases (RTKs) 
A group of cell surface receptors that have been implicated in cancers are the receptor 
tyrosine kinases (RTKs). RTKs are a large family of plasma membrane spanning receptors with 
an intracellular tyrosine kinase domain (Alvarez et al., 2006; Gavi et al., 2006; Hunter, 2000; 
Schlessinger, 2000). This family includes the well-characterized epidermal growth factor 
receptor (EGFR) as well as the platelet-derived growth factor receptor (PDGFR). The typical 
structure of RTKs includes an N-terminal extracellular ligand binding domain, a single α-helical 
transmembrane domain and a C-terminal intracellular domain that contains an intrinsic tyrosine 
kinase domain (Cowan-Jacob, 2006; Garrett et al., 2002; Garrett et al., 1998; Li and Hristova, 
2010; Ogiso et al., 2002). The tyrosine kinase domain also contains regulatory sites that are 
phosphorylated by the receptor itself or other kinases in order to fully activate the receptor 
signalling pathway (Hubbard et al., 1998; Hunter, 1998; Pawson and Scott, 2005). Members of 
the RTK family are subdivided into 20 groups according to their ligand specificity as well as 
structural differences in their extracellular and tyrosine kinase domains. The subfamilies include, 
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but are not limited to, EGFR, PDGFR, insulin receptor (IR), insulin-like growth factor receptor 
(IGFR), vascular endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor 
(FGFR) and nerve growth factor receptors (NGFR) (Aaronson, 2005; Aaronson, 1991; Alvarez 
et al., 2006; Lemmon and Schlessinger, 2010; Robinson et al., 2000). These RTKs might have 
cell-dependent expression patterns and certainly respond to specific growth factor ligands, all of 
which contribute to the cell’s ability to test its environment at any given time and, once it has 
consolidated all of the input signalling data, to respond in an appropriate manner. 
The RTK binds to its ligand, the growth factor, to activate the cascade of signalling 
events. Binding of the growth factor to the extracellular domain of receptors causes a 
conformational change within the receptor that unmasks the dimerization region (Alvarez et al., 
2006; Heldin and Ostman, 1996; Heldin et al., 1982; Lemmon and Schlessinger, 1994; Ogiso et 
al., 2002). This leads to dimerization of the receptor either to itself (e.g. homodimerization) or 
another subfamily member (e.g. heterodimerization) (Burgess et al., 2003; Garrett et al., 1998; 
Schlessinger, 2002). In the absence of ligand, RTKs generally exist as monomers. Exceptions to 
this include the insulin receptor (IR) and the insulin-like growth factor receptor (IGFR) 
subfamily members. These RTKs exist as constitutive heterodimers of α and β chains linked by 
disulfide bonds (Garrett et al., 1998; Ottensmeyer et al., 2000). Upon binding of the ligand, e.g. 
insulin or the insulin-like growth factor, two individual α/β-chain heterodimers are brought into 
close enough proximity that dimerization between two α chains occurs and signalling is initiated. 
Another exception to the canonical ligand binding and dimerization mechanism exhibited by 
RTKs is ErbB2, a member of the EGFR subfamily, which has a constitutively exposed 
dimerization region and is able to bind other receptors independent of growth factors (Burgess et 
al., 2003; Ferguson, 2008; Garrett et al., 2003).  
Upon ligand binding and dimerization, the receptor undergoes further conformational 
changes within the tyrosine kinase domain that relieves the inhibition on the activation loop and 
allows for trans-autophosphorylation of the kinase domain (Alvarez et al., 2006; Bae and 
Schlessinger, 2010; Ferguson, 2008; Heldin and Westermark, 1999). Other tyrosine residues 
within the intracellular domain are then phosphorylated by the receptor. These phosphorylated 
tyrosine residues serve as docking sites for intracellular signalling molecules that contain a Src 
homology 2 (SH2) or phosphotyrosine binding (PTB) domain, and activate several distinct signal 
transduction pathways including; the phosphatidylinositol 3'-kinase (PI3K)/Akt and the 
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Ras/MAPK pathway (Biarc et al., 2011; Cross et al., 2000; Pawson, 1992, 1994, 2002; Pawson 
and Scott, 2005; Schlessinger, 2000; Ueki et al., 2002). These signal transduction pathways play 
various roles in cell survival. The PI3K/Akt and the Ras/MAPK pathways are described in 
greater detail in Sections 1.3.1 and 1.3.2. 
Signalling from the RTK is regulated by phosphorylation and dephosphorylation of 
residues within the receptor by the action of kinases (catalyze phosphorylation events) and 
phosphatases (catalyze dephosphorylation events) (Burnett and Kennedy, 1954; Hunter, 1998; 
Olsen et al., 2006; Pawson and Scott, 2005; Tonks, 2006; Walton and Dixon, 1993). Just as 
importantly, RTK signalling can also be terminated by internalization of the activated ligand-
receptor complex followed by either deactivation and recycling of the receptor or degradation of 
the receptor by the lysosomal pathway (Holler and Dikic, 2004; Mukherjee et al., 1997; 
Sigismund et al., 2005; Sorkin and Von Zastrow, 2002). Internalization and trafficking of the 
ligand-receptor complex is referred to as endocytosis and has been reviewed in Section 1.4. 
The mechanisms for regulating growth factor receptor function are similar for most 
RTKs. The following discussion will focus on the regulation and function of the receptor for the 
platelet-derived growth factor, and will be compared to other RTKs as needed. 
 
1.2.1 Platelet-derived Growth Factor (PDGF) Ligand and its Receptor  
The platelet-derived growth factor (PDGF) is a major mitogen for fibroblasts, connective 
tissue and smooth muscle cells, and activates a cascade of signalling events that are important for 
mitosis (hence ‘mitogen’) and that involve the stimulation of cell growth and changes in cell 
shape and motility (Alvarez et al., 2006; Heldin et al., 1982; Schlessinger, 2000). PDGF belongs 
to the cystine knot superfamily of growth factors. The cystine knot superfamily derives its name 
from the fact that all its members have six cysteine residues involved in homo- and/or 
heterodimeric disulfide bond formation (McDonald and Hendrickson, 1993; Vitt et al., 2001). 
The PDGF subfamily is made up of four gene products located on four different chromosomes; 
PDGF-A (chromosome 7), PDGF-B (chromosome 22), PDGF-C (chromosome 4) and PDGF-D 
(chromosome 11) (Betsholtz et al., 1986; Deuel et al., 1981; LaRochelle et al., 2001; Li et al., 
2000b; Ross et al., 1986; Uutela et al., 2001). There is about 25% amino acid sequence identity 
between all four forms of PDGFs, and among the individual PDGFs, PDGF-A and PDGF-B 
share 50-60% sequence identity, while PDGF-C and PDGF-D share 42-50% identity (Alvarez et 
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al., 2006; Fredriksson et al., 2004; Heldin and Westermark, 1999; LaRochelle et al., 2001). All 
forms of PDGF have a C terminal growth factor domain. PDGF chains C and D differ from 
chains A and B by the presence of an N-terminal C1r/C1s urchin endothelial growth factor-like 
protein and bone morphogenic protein 1 (CUB) domain (Reigstad et al., 2005). 
PDGFs exist and function as five distinct dimers; namely, PDGF-AA, PDGF-AB, PDGF-
BB, PDGF-CC and PDGF-DD (Figure 1.1) (Reigstad et al., 2005; Tallquist and Kazlauskas, 
2004). Both PDGF-A and PDGF-B can form homodimers or can form a heterodimer involving 
the A and B chains. In contrast, PDGF-C and PDGF-D are only able to form homodimers. PDGF 
dimerization occurs within the endoplasmic reticulum resulting in inactive precursor PDGF 
dimers (Fredriksson et al., 2004; Tallquist and Kazlauskas, 2004). The precursor PDGF-AA, 
PDGF-AB and PDGF-BB dimers are further processed by proteolytic cleavage during protein 
maturation and exocytic events within the trans-Golgi network, and are secreted in their 
biologically active forms (Fredriksson et al., 2004; Tallquist and Kazlauskas, 2004). On the other 
hand, cleavage of the CUB domain and activation of PDGF-CC and PDGF-DD dimers occur 
after secretion of inactive dimers into the extracellular environment (Fredriksson et al., 2004; 
Tallquist and Kazlauskas, 2004). The main site of PDGF synthesis is within the megakaryocytes, 
bone marrow precursor cells that differentiate into platelets. In quiescent cells, PDGF is stored 
within the alpha granules of platelets. PDGF can also be synthesized by fibroblasts, smooth 
muscle cells, endothelial cells, macrophages, glial cells and astrocytes (Heldin and Westermark, 
1999; Linder et al., 1979).  
Dimeric forms of PDGF bind to the receptor and initiate signal transduction pathways. 
Two structurally related isoforms of the PDGF receptor (PDGFR) has been discovered to date, 
PDGFRα and PDGFRβ (Claesson-Welsh, 1994a, b). These genes for the α and β isoforms are 
located on chromosomes 7 and 22, respectively. PDGFRα is a 170 kDa protein and the β isoform 
is 180 kDa. They are glycoproteins with sites for both N-linked and O-linked glycosylation. Like 
all other RTKs, PDGFRs contain an extracellular domain, a transmembrane domain and a 
tyrosine kinase domain (Figure 1.1). The N-terminal extracellular domain contains five 
immunoglobulin-like domains, and there is 30% amino acid sequence identity between the 
extracellular domains of the α and β isoforms (Claesson-Welsh, 1994b). Immunoglobulin-like 
(Ig-like) domains 1 to 3 are linked by disulfide bridges and are thought to be important for 
ligand-receptor binding, with domain 2 being the most essential domain for PDGFRα and  
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Figure 1.1: Homo- and heterodimers of PDGFR and the ligands that bind to them. The 
PDGF subfamily is made up of four gene products located on four different chromosomes; 
PDGF-A (chromosome 7), PDGF-B (chromosome 22), PDGF-C (chromosome 4) and PDGF-D 
(chromosome 11). PDGFs exist and function as five distinct dimers; namely, PDGF-AA, PDGF-
AB, PDGF-BB, PDGF-CC and PDGF-DD. There are two structurally related isoforms of the 
PDGFR, namely PDGFRα and PDGFRβ. PDGFRs contain an extracellular domain, a 
transmembrane domain and a tyrosine kinase domain. The N terminal extracellular domain 
contains five immunoglobulin-like domains. The PDGF dimers have different affinities for the 
three isoform specific PDGFR dimers. The PDGFR-αα dimer interacts with PDGF-AA, -AB, -
BB and -CC. The PDGFR-αβ dimer interacts with PDGF-AB, -BB and -CC. The PDGFR-ββ 
dimer interacts with PDGF-BB and -DD.  
	   7	  
domains 2 and 3 both being essential for PDGFRβ (Claesson-Welsh, 1994a; Heldin et al., 1998; 
Heldin and Westermark, 1999). Ig-like domain 4 plays a role in stabilization of receptor homo-
/heterodimers (Heldin et al., 1998; Heldin and Westermark, 1999). The C-terminal intracellular 
region of PDGFR can be further divided into, (i) the region between the cytoplasmic side of the 
plasma membrane and the tyrosine kinase domain referred to as the juxtamembrane domain 
(about 49 amino acids), (ii) the catalytically active tyrosine kinase domain is characterised by a 
kinase domain separated into two regions by a non-catalytic sequence of 100 hydrophilic amino 
acids referred to as the kinase insert, and (iii) the C-terminal tail or regulatory region. Studies 
have shown that between the α and β isoforms of the PDGFR there exists an 83% amino acid 
sequence identity between the juxtamembrane domains, 87% between the first half of the 
tyrosine kinase domain, 74% between the second half of the tyrosine kinase domain, 35% 
between the kinase insert and 27% between the C-terminal tail (Claesson-Welsh, 1994a, b).  
Upon binding of the ligand, the PDGFRα and PDGFRβ isoforms interact to form the 
following homo- or heterodimers: PDGFRαα, PDGFRαβ and PDGFRββ (Figure 1.1). These 
receptor dimers have different affinities for the ligand dimers (Figure 1.1). The combination of 
receptor dimers and the various ligand dimers allows for different signalling responses. PDGF-
AA dimers bind exclusively to PDGFRαα, whereas PDGF-DD binds exclusively to PDGFRββ. 
PDGF-AB and PDGF-CC both bind PDGFRαα and PDGFRαβ receptors (Figure 1.1) (Claesson-
Welsh, 1994a, 1996; Fredriksson et al., 2004; Reigstad et al., 2005). As mentioned earlier, 
dimerization of receptors induces a conformational change within the activation loop of the 
receptor kinase domain that exposes the ATP binding site, which leads to receptor activation via 
trans-autophosphorylation. Trans-autophosphorylation occurs on the tyrosine residue 849 for 
PDGFRα and tyrosine residue 857 for PDGFRβ isoforms (Claesson-Welsh, 1994a, b). Following 
receptor activation, numerous tyrosine residues within the intracellular region are 
autophosphorylated by the receptor itself or phosphorylated by other intracellular signalling 
proteins. For instance, PDGFRβ is autophosphorylated at tyrosine residues 562, 581, 589, 716, 
740, 751, 763, 771, 775, 778, 1009 and 1021, and can be phosphorylated by the Src-like 
nonreceptor tyrosine kinase Abl at residues 686, 934 and 970 (Claesson-Welsh, 1994b; 
Srinivasan et al., 2009). The phosphorylated tyrosine residues provide sites for recruiting 
signalling molecules to the receptor. A representation of cellular proteins and the tyrosine 
phosphorylated residue that they bind to is illustrated in Figure 1.2 (Claesson-Welsh, 1994a, b).  
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Figure 1.2: The two PDGFR isoforms utilize different phosphorylated tyrosine residues as 
docking sites for downstream signalling molecules. Following receptor activation, signalling 
molecules are able to interact with the receptor through the binding sites created by 
phosphorylated tyrosine residues. The PDGFRα is phosphorylated on at least 8 sites and is 
known to bind to 5 different protein families. The PDGFRβ binds to SH2 or PTB domains of at 
least 9 different protein families. This figure represents a summary of some cellular proteins that 
bind to phosphorylated PDGFRα or PDGFRβ, and the tyrosine phosphorylated residue that they 
bind to.   
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The differences in amino acid sequences in the intracellular region of both α and β 
receptors may account for the recruitment of specific downstream substrates and differential 
activation of PDGF-mediated signalling pathways. Two examples of these signalling pathways 
are described in Sections 1.3.1 and 1.3.2 (the PI3K/Akt and the Ras/MAPK pathways).  
The outcome of signal transduction pathways initiated by PDGF is controlled by the 
tyrosine phosphorylation signature of the isoforms, as well as by their expression pattern within 
different cell types. PDGFR α and β are expressed in fibroblasts, neurons, vascular smooth 
muscle cells, kidney mesangial cells and pericytes (Alvarez et al., 2006; Heldin and Westermark, 
1999). Platelets and myoblasts exclusively express PDGFRα while mammary epithelial cells, 
macrophages, liver cells and myeloid hematopoietic cells express the β isoform (Alvarez et al., 
2006). 
Both receptor isoforms play important roles in proliferation, migration, membrane 
ruffles, cytoskeletal rearrangements, turnover of phosphatidylinositols and inositol phosphatases 
and calcium fluxes (Claesson-Welsh, 1994a). Involvement of PDGFRα in cell migration and the 
turnover of phosphatidylinositols is purported to be cell type-dependent (Claesson-Welsh, 
1994a). PDGFRα, but not PDGFRβ, is required for the timing of cell differentiation during 
oligodendrocyte maturation (Claesson-Welsh, 1994a), while PDGFRβ is involved in 
angiogenesis (Claesson-Welsh, 1994a). 
 
1.3 Signalling pathways associated with the Platelet-derived Growth Factor (PDGF) 
 Signalling pathways/cascades initiated by PDGF are numerous and diverse. Examples 
include the Ras/MAPK pathway and the Phosphatidylinositol 3'-kinase (PI3K)/Akt pathway 
(Alvarez et al., 2006; Cross et al., 2000; Fruman et al., 1998; McKay and Morrison, 2007). 
Signalling from PDGF activates anti-apoptotic cascades that ultimately result in cell growth, 
differential and survival (Datta et al., 1999). The Ras/MAPK pathway and the PI3K/Akt pathway 
are reviewed below. 
 
1.3.1 The Ras/MAPK Signalling Pathway 
 Receptor activation through phosphorylation events creates signalling scaffolds on the 
cytoplasmic domain of PDGFR that help to recruit binding partners and/or substrates. For 
example, phosphorylated tyrosine residues (pTyr) 579, 740, 751 and 771 within the PDGFR are 
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all possible binding sites for the Src homologous and collagen (Shc) adapter protein (Alam et al., 
2009; Claesson-Welsh, 1994a; Finetti et al., 2009; Heldin et al., 1998). Binding of Shc –  via its 
phosphotyrosine binding (PTB) domain – to the PDGFR initiates the Ras/MAPK signalling 
cascade. Shc also contains a Src homology 2 (SH2) domain that may play a role in the binding of 
Shc to the receptor (Figure 1.3) (Alam et al., 2009; Finetti et al., 2009). Both PTB and SH2 
domains have recognition motifs for interacting with phosphorylated tyrosine residues within 
specific motifs (Alam et al., 2009; Finetti et al., 2009). The activated PDGFR phosphorylates 
Shc on Tyr317 (Heldin et al., 1998). This pTyr317 residue recruits the Growth factor receptor-
bound protein 2 (Grb2) adaptor via its own SH2 domain (Egan et al., 1993; Li et al., 1994; 
Reebye et al., 2012). Grb2 can also be recruited directly to the activated receptor (e.g. EGFR) 
through its SH2 domain (Claesson-Welsh, 1994a; Giubellino et al., 2008; Heldin et al., 1998; 
Jang et al., 2009; Li et al., 1994). Grb2 exists as a complex with Son of Sevenless (Sos), the 
guanine nucleotide exchange factor (GEF) for the G-protein Ras (Heldin et al., 1998; Heldin and 
Westermark, 1999; Li et al., 1994). Binding of Grb2 to Shc therefore relocalizes Sos closer to its 
target, the GDP-bound Ras (Bos et al., 2007; Egan et al., 1993; Margarit et al., 2003; Pierre et 
al., 2011; Reebye et al., 2012; Rojas et al., 2011; Sondermann et al., 2004; Vigil et al., 2010). 
Ras alternates between a guanosine diphosphate (GDP)-bound “off” state and a guanosine 
triphosphate (GTP)-bound “on” state by the control of GTP hydrolysis (Fehrenbacher and 
Philips, 2009; Rojas et al., 2012; Rojas et al., 2011; Roskoski, 2010). Sos catalyzes the exchange 
of GDP for GTP resulting in an active conformation for the Ras protein (Ahearn et al., 2012; 
Freedman et al., 2006; Margarit et al., 2003; Sondermann et al., 2004). Conversely, Ras can be 
deactivated by hydrolyzing GTP to GDP, which is enhanced by GTPase activating proteins 
(GAP) (Ahearn et al., 2012; Bos et al., 2007; Vigil et al., 2010). Regulation of small monomeric 
G-proteins such as Ras is discussed in greater detail in Section 1.4.1.3.1.  
Ras recruits and activates the serine/threonine protein kinase activity of Raf (Avruch et 
al., 2001; Barnard et al., 1995; Fehrenbacher and Philips, 2009; Leicht et al., 2007; Rojas et al., 
2012; Roskoski, 2010). Raf contains a Ras binding domain (RBD) and, as the name suggests, the 
RBD binds to Ras. Raf can be phosphorylated by several other kinases to fully activate its 
activity (Matallanas et al., 2011; Maurer et al., 2011; Roskoski, 2010). In turn, Raf 
phosphorylates the mitogen activated protein kinase (MAPK)/Erk kinase (MEK), e.g. on serine  
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Figure 1.3: Ras/MAPK Signalling Cascade induced by PDGF. The binding of PDGF to 
PDGFR induces receptor dimerization and initiates signalling events that result in activation of 
Ras and a cascade kinase phosphorylation of MEK and MAPK/Erk.  Binding of the Shc adapter 
protein to the PDGFR initiates the Ras/MAPK signalling cascade. The Grb2/Sos complex is 
recruited by Shc, relocalizing Sos closer to its target, Ras. Activation of Raf induces activation of 
Raf, which in turn phosphorylates and activates MEK. MEK activates MAPK/Erk by 
phosphorylation. MAPK/Erk translocates to the nucleus and regulates transcription of genes 
involved in cell survival such as CREB, Bad or p21.   
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218 and 222 for MEK1, and serine 222 and 226 on MEK2 (Keshet and Seger, 2010; Sebolt-
Leopold and Herrera, 2004; Shaul and Seger, 2007; Yoon and Seger, 2006; Zheng and Guan, 
1994). The role of MEK in this signalling cascade is that of a dual specificity tyrosine and 
serine/threonine kinase which is capable of phosphorylating threonine 183 and tyrosine 185 on 
MAPK1, and threonine 202 and tyrosine 204 in MAPK3 (Keshet and Seger, 2010; Payne et al., 
1991; Rubinfeld and Seger, 2005; Shaul and Seger, 2007). When MAPK/Erk is phosphorylated, 
it is activated and it can, in turn, phosphorylate cytoplasmic and nuclear proteins, as well as 
transcription factors by translocating to the nucleus (McKay and Morrison, 2007; Plotnikov et 
al., 2011; Rubinfeld and Seger, 2005; Yoon and Seger, 2006). Some transcription factors 
regulated by the Ras/MAPK signalling cascade include c-Fos, c-Jun, c-myc and cAMP response 
element-binding protein (CREB) (De Luca et al., 2012; Plotnikov et al., 2011; Yoon and Seger, 
2006). Phosphorylation of these intracellular targets by the Ras/MAPK signalling cascade elicits 
either activating or inhibitory events that contribute to the transcriptional regulation of genes 
required for entry into the cell cycle and survival of the cell (Plotnikov et al., 2011; Yoon and 
Seger, 2006).  
 
1.3.2 The Phosphatidylinositol 3'-kinase (PI3K)/Akt Signalling Pathway 
 The PI3K/Akt signalling cascade is activated by class IA PI3Ks. PI3Ks phosphorylate  
phosphatidylinositols (PI) on the 3ʹ′ hydroxyl position of the inositol ring. An in-depth 
description of the PI3K family can be found in Section 1.3.2.1, below. Class IA PI3Ks exist as a 
heterodimeric complex consisting of a p85 regulatory subunit and a p110 catalytic subunit. In 
quiescent cells, p85 inhibits the kinase activity of the p110 subunit (Cuevas et al., 2001; Yu et 
al., 1998b). The p85 regulatory subunit of PI3K has SH2 domains with which it can bind directly 
to the PDGFR on tyrosine residues 740 and 751 (Franke et al., 1995). The receptor-p85 
interaction relieves the inhibitory effects of p85 on p110 and brings p110 close to its lipid 
substrates phosphatidylinositol-4,5-bisphosphate (PI4,5P2) located within the membrane lipid 
bilayer (Figure 1.4) (Cuevas et al., 2001; Yu et al., 1998b).  
PI3,4,5P3, generated by PI3K, is a second messenger that recruits and activates proteins 
that contain a pleckstrin homology (PH) domain, such as the serine/threonine kinases 3-
phosphoinositide dependent protein kinase-1 (PDK1) and Akt (also known as protein kinase B, 
PKB) (Burgering and Coffer, 1995; Coffer et al., 1998; Franke et al., 1997; Franke et al., 1995).  
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Figure 1.4: PI3K/Akt Signalling Cascade induced by PDGF. The binding of PDGF to 
PDGFR induces receptor dimerization and initiates signalling events that result in activation of 
PI3K and the generation of the PI3,4,5P3 second messenger. PI3,4,5P3 recruits Akt and PDK1 
and results in the full activation of Akt. Akt phosphorylates and activates genes involved in cell 
survival. Activation of mTORC1, and eventually S6K, culminated in activation of protein 
synthesis. Activation of MDM2, a negative regulator of p53, promotes cell cycle progression. 
Phosphorylation of GSK3, Bad/Bcl-xL or FoxO inhibits their activities and drives the cell 
towards cell cycle progression and cell survival. PTEN counteracts the effects of PI3K by 
dephosphorylating PI3,4,5P3 at the 3ʹ′ position.  
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PDK1 phosphorylates and activates Akt on threonine 308 (Thr308) (Le Good et al., 1998). 
Complete activation of Akt requires phosphorylation of serine 473 (Ser473) either by 
autophosphorylation or by the mammalian target of rapamycin complex (mTORC). When both 
Thr308 and Ser473 are phosphorylated, Akt then dissociates from the plasma membrane and 
phosphorylates numerous cytoplasmic and nuclear substrates, including glycogen synthase 
kinase 3 (GSK3), p70 ribosomal S6 protein kinase (S6K) and Bad, which are responsible for cell 
cycle entry, protein synthesis and anti-apoptotic events, respectively (Pullen et al., 1998). Akt 
signalling is central to a host of pathways with extensive crosstalk at various levels of the signal 
amplification cascade. For example, p110 can bind to Ras and activate the Ras/MAPK signalling 
pathway. Growth signals initiated by the PI3K/Akt pathway can be attenuated by phosphatase 
and tensin homologue protein (PTEN), a protein phosphatase that dephosphorylates PI3,4,5P3 at 
the 3ʹ′ position. This event hinders the recruitment of Akt to the plasma membrane and inhibits 
full activation of Akt and any associated downstream signalling. 
 
1.3.2.1 Phosphatidylinositol 3′-kinase (PI3K): Classification and subunits 
PI3Ks are heterodimers comprised of regulatory and catalytic components and are 
grouped into three classes based on the specific components of the heterodimer, on the specific 
substrates that they target and on upstream stimuli that activate the PI3K complex (Table 1.1) 
(Domin and Waterfield, 1997). Class I PI3Ks phosphorylate the 3ʹ′ position of PI4,5P2  and form 
heterodimers consisting of a regulatory and a catalytic subunit (Domin and Waterfield, 1997). 
They are further divided into class IA and IB depending on whether they are activated by RTKs 
or G-protein coupled receptors (GPCRs) (Domin and Waterfield, 1997). PI3Ks belonging to 
class IA form heterodimeric complexes consisting of catalytic subunit ranging in size from 110 
to 120 kDa and a regulatory subunit ranging in size from 50 to 85 kDa. There are three class IA 
catalytic subunit isoforms expressed by separate genes; p110α, p110β, and p110δ expressed by 
Pik3ca, Pik3cb, and Pik3cd respectively (Hiles et al., 1992; Hu et al., 1993; Vanhaesebroeck et 
al., 1997). These subunits are structurally identical and consist of protein domains such as; (i) an 
adapter binding domain (ABD) with which it binds the regulatory subunit, (ii) an N-terminal Ras 
binding domain (RBD) for binding p21ras-GTP (Ras), (iii) a protein kinase-C homology (C2) 
domain for lipid binding, (iv) a helical domain, and (v) a C-terminal lipid kinase domain (Figure 
1.5) (Holt et al., 1994; Rodriguez-Viciana et al., 1996).  
	   15	  
Table 1.1: PI3K classification  
 
Class  Regulatory 
subunit(s) 
Catalytic 
subunit(s) 
Substrate(s)  Product(s) 
IA p85α 
p55α 
p50α 
p85β 
p55γ 
p110α 
p110β 
p110δ 
Phosphatidylinositol-
4,5-bisphosphate 
(PI4,5P2) 
Phosphatidylinositol-
3,4,5-trisphosphate 
(PI3,4,5P3) 
IB p101 p110γ PI4,5P2 PI3,4,5P3 
II None C2α 
C2β 
C2γ 
Phosphatidylinositol 
(PI) and 
Phosphatidylinositol-
4-phosphate (PI4P) 
Phosphatidylinositol-3-
phosphate (PI-3-P) and 
Phosphatidylinositol-
3,4-bisphosphate 
(PI3,4P2) 
III p150 Vps34 PI PI3P 
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Figure 1.5: The p110 subunit of PI3K class IA. Domain structure of class IA p110 subunits. 
All three isoforms have the same domain structures consisting of an adaptor protein binding 
domain (ABD), a Ras binding domain (RBD), a protein kinase-C-homology 2 (C2) domain, a 
helical domain, and a catalytic domain. 
 
 
 
There are five regulatory subunits referred to as the p85 regulatory subunits because the 
larger p85α and p85β isoforms were characterized first (Figure 1.6) (Vanhaesebroeck et al., 
2005). They include p85α, p55α, p50α, p85β and p55γ and are able to dimerize with any of the 
p110 isoforms (Antonetti et al., 1996; Dhand et al., 1994; Pons et al., 1995). It is now known 
that the p85α and its splice variant isoforms, p55α and p50α, are products of the Pi3kr1 gene, 
while p85β and p55γ are products of the Pi3kr2 and Pi3kr3 respectively. p85α and p85β are 
homologous to each other and contain; (i) an N-terminal SH3 domain, (ii) two proline rich 
domains, (iii) a GTPase activating protein (GAP) domain (also referred to as a breakpoint cluster 
region homology (BH) domain, (iv) two SH2 domains and (v) an inter-SH2 (iSH2) domain 
(Figure 1.6) . The shorter forms p55α, p50α and p55γ lack the SH3 and GAP domains (Antonetti 
et al., 1996; Pons et al., 1995). p55α and p55γ have 35 unique amino acids at the N-terminus 
while the p50α isoform has only five amino acids within this same region (Antonetti et al., 1996; 
Pons et al., 1995).  
Class IA heterodimers consisting of p110α are activated by RTKs, while those containing 
p110β are activated by both RTKs and GPCRs. Both p110α and p110β are ubiquitously 
expressed, in contrast to the p110δ subunit that is expressed exclusively in haemopoietic cells of 
the immune system. Class IB PI3Ks act downstream of signals induced by GPCRs and consist of 
a single regulatory subunit p101 dimerized to a single p110γ catalytic subunit. They are 
expressed in platelets and neutrophils. 
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Figure 1.6: The p85 regulatory subunit family of the PI3K class IA. Domain structure of p85 
regulatory subunit family. p85α, p55α and p50α are encoded by Pik3r1, while encodes Pik3r2 
encodes p85β and Pik3r3 encodes p55γ . The smaller isoforms lack the N-terminus  SH3 - GAP 
region. 
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Class II PI3Ks lack a regulatory subunit and consist solely of a carboxy-terminal C2 
(CalB) domain. There are three isoforms namely, C2α, C2β and C2γ (Table 1.1). Class II PI3Ks 
generate both PI3P and PI3,4P2. Class III PI3Ks is a complex consisting of a Vps34 catalytic 
subunit and a p150 regulatory subunit. They produce PI3P that is very important in the endocytic 
pathway (discussed in Section 1.4).  
 
1.3.2.2 The role of p85 in PI3K signalling and trafficking of receptor 
The canonical function of the p85 subunit of PI3K has been to regulate the catalytic 
subunit, p110. The p85 regulatory subunit of PI3K is essential for the activation of the PI3K 
signalling cascade. Stability of the p110 catalytic subunit of PI3K is dependent on heterodimeric 
association with p85 and vice versa. Even though p85 and p110 classically exist as heterodimers, 
there are instances where a pool of ‘free’ p85 generated by an increase in expression of p85 has 
been observed. ‘Free’ p85 exists as p85-p85 homodimers by forming weak interactions between 
the SH3 domain of one p85 subunit and the first proline rich domain of the other p85 subunit, 
and between the GTPase activating protein (GAP) domains of p85 (Figure 1.7). Homodimers of 
p85 are in part responsible for regulation of PI3K signalling by concealing the SH3-proline rich-
GAP region of p85 in quiescent cells and only expose these domains in response to growth factor 
stimulation. Upon growth factor stimulation, p85 homodimers dissociate, making them available 
to bind other intracellular molecules. For instance, ‘free’ p85 can be co-immunoprecipitated with 
X-box-binding protein 1 (XBP-1) in response to insulin (Park et al., 2010). The interaction 
between the GAP domain of p85 and XBP-1 was shown to be necessary for the nuclear 
translocation of XBP-1.  
To form the p85-p110 heterodimer, various contacts are made between the C-terminal 
half of p85 and the entire structure of p110. This not only stabilizes p110, but also regulates its 
function (Figure 1.7). In order to regulate the function of p110, the first (i.e. N-terminal) SH2 
domain (nSH2) of p85 interacts with the calcium binding-homology (C2), helical and kinase 
domains of p110. The inter-SH2 (iSH2) domain of p85 and the C2 domain of p110 also make 
contacts. Additionally, the second, more C-terminal SH2 domain (cSH2) of p85 can form 
contacts with the kinase domain of p110β, but not the p110α isoform.  All of these serve to 
obstruct domains required for p110 activity and thus inhibit the catalytic kinase activity of PI3K. 
Steady levels of  
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Figure 1.7: Intermolecular charge-charge interactions between p85 homodimers and p85-
p110 heterodimers. p85 dimerizes with another p85 subunit by forming direct interactions 
between the SH3 domain of one p85 subunit and the first proline rich domain of the other p85 
subunit. Contacts between the GAP domains are also necessary for homodimerization of p85. 
The nSH2 domain of p85 interacts with the p110 subunit of PI3K by making contacts with the 
C2, helical and kinase domain of p110. An additional regulatory contact is made between the 
iSH2 domain of p85 and the C2 domain of p110. p85 exerts its inhibitory effects on p110 
through these nSH2 and iSH2 contacts. The iSH2 domain of p85 also interacts with the ABD 
domain of p110, which is important for stabilizing p110. cSH2 (p85) – kinase domain (p110) 
interactions occur with heterodimers containing p110β, but not the p110α isoform. It should be 
noted that p85 in p85-p110 heterodimers does not interact with another p85 as illustrated in the 
diagram. SH3, Src homology 3 domain; Pro, proline rich domain; GAP, GTPase activating 
protein domain; nSH2, N terminal Src homology 2 domain; iSH2, inter-SH2 domain; cSH2, C 
terminal Src homology 2 domain; ABD, adaptor binding domain; RBD, ras binding domain; C2, 
calcium binding-homology domain.  
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the p110 protein are maintained by stabilizing interactions made between the iSH2 domain of 
p85 and the adaptor binding domain (ABD) domain of p110.  
The subcellular localization and specific function of p85 can be controlled by 
phosphorylation of serine and tyrosine residues (Mellor et al., 2012). A summary of residues that 
are phosphorylated and their respective associated biological outcomes can be seen in Table 1.2. 
p85 can also be modified by Casitas B-lineage Lymphoma (Cbl)-dependent ubiquitination (Bulut 
et al., 2013; Mellor et al., 2012). Cbl-b-dependent ubiquitination of p85 initiates the cascade of 
events that result in internalization and down-regulation of the erythropoietin receptor (EpoR) 
through endocytosis (Bulut et al., 2013), and can also prevent the formation of a complex 
between p85, CD28 and T-cell receptor that is essential for the PI3K-dependent activation of 
Vav-1, a GEF for Rac (Fang and Liu, 2001; Fang et al., 2001; Han et al., 1998; Ma et al., 1998). 
p85 is an important signalling node in numerous signal transduction pathways. It acts as a 
scaffolding protein to enhance crosstalk between signalling pathways and receptor endocytosis 
and trafficking (Mellor et al., 2012). During RTK-mediated PI3K signalling, p85 binds to the 
RTK (e.g. PDGFR) via its phosphotyrosine-dependent SH2 domain and this action relieves the 
inhibitory effects exerted by p85 on p110. p110 is then brought into proximity to its lipid 
substrates and fully activates the PI3K signalling pathway. Alternatively, the PI3K pathway can 
be activated through phosphorylation independent interactions between the proline rich domain 
of p85 and some intracellular signalling molecules including members of the Abl-Scr family 
(non-receptor/cytoplasmic tyrosine kinases) (Kapeller et al., 1994; Pleiman et al., 1994), Crk 
(adaptor protein that can bind E3 ubiquitin ligase Cbl) (Gelkop et al., 2001; Sattler et al., 1996) 
and Growth factor receptor-bound protein 2 (Grb2) (Wang et al., 1995; Weinger et al., 2008). 
The antagonist to PI3K signalling, PTEN, can be activated by binding of PTEN to the GAP 
domain of p85 (Anderson, 2010; Chagpar et al., 2010). This mechanism functions as a negative 
feedback loop that down-regulates signalling events initiated by PI3K (Mellor et al., 2012). A 
phosphotyrosine independent interaction between the SH2 domain of p85 and A-Raf 
(serine/threonine protein kinase) can also inhibit PI3K activity (Fang et al., 2002; King et al., 
2000). 
The regulatory p85 subunit can transiently or constitutively increase local concentrations 
of signalling molecules by sequestering intracellular proteins to locations where they are of the 
most importance. Specifically, the GAP domain of p85 interacts with Rab5 to enhance the 
	   21	  
Table 1.2:  p85 posttranslational modification and the effect on cellular signalling.  
(Mellor et al., 2012) 
 
Phosphorylation of p85 
Amino acid modified 
[Domain] 
Kinase involved Effects on signalling 
Ser 83 
[Pro rich region] 
Protein kinase A (PKA) (i) Serves as a binding site for the 
regulatory subunit of PKA in the 
cAMP/PKA pathway. 
(ii) Increases binding between 
PI3K and Ras resulting in PI3K 
activation, induced by the 
cAMP/PKA pathway. 
Ser 608 p110 Significant reduction in PI3K 
activity.  
Tyr 508 
[i-SH2] 
PDGFR 
Interleukin (IL)-8 
Granulocyte/Macrophage colony-
stimulating factor (GM-CSF) 
Not known. 
Tyr 688 
[c-SH2] 
Abl and Src family (i) Modifies the SH2 binding 
potential of p85, and relieves its 
inhibitory effect on p110, hence 
activating PI3K. 
(ii) Promotes de novo p85-p110 
heterdimerization. 
De-phosphorylation of p85 
Amino acid modified Phosphatase involved Effects on signalling 
Ser 608 Protein phosphatase 2C Leads to increased PI3K activity 
by reversing the action of p110. 
Tyr residues Src homology-2 domain containing 
phosphatase-1 (SHP-1) 
CD148 
Reverses phosphorylation 
induced by the Src family. 
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hydrolysis of GTP to GDP (Chamberlain et al., 2004). The p85 subunit of PI3K has RabGAP 
activity towards Rab5 and Rab4 (Chamberlain et al., 2004). Rab5 is important for the 
internalization of activated RTKs whereas Rab4 mediates events leading up to RTK recycling 
(reviewed in Section 1.4.1.3). p85 regulates the “on” GTP-bound and “off” GDP-bound states of 
Rab5 and Rab4, thereby, regulating intracellular receptor trafficking. Expression of a p85 protein 
in which a critical arginine is substituted for an alanine (R274A), which significantly abolishes 
its RabGAP activity, results in a prolonged activation of PDGF receptor and sustained 
downstream signalling especially in the MAPK/Erk pathway. This implies a role for p85α in 
receptor trafficking and down-regulation (Chamberlain et al., 2004).  
Expressing this RabGAP defective p85R274A mutant in cells results in the 
transformation of these cells (Chamberlain et al., 2008). These cells appear more rounded than 
control cells expressing wild type p85 and also spontaneously form foci on subconfluent plates 
(Chamberlain et al., 2008). The p85R274A-expressing cells form large colonies when cultured in 
a medium of soft agar (Chamberlain et al., 2008). These results suggest that disruption of the 
RabGAP activity of p85 in cells leads to a loss of contact inhibition and of anchorage 
dependence growth, which are characteristic of transformed cells. In order to investigate the 
tumorigenic properties of these transformed cells, p85R274A-expressing cells were injected 
subcutaneously into nude mice. By day 16, tumours had started developing and they continued to 
grow rapidly (Chamberlain et al., 2010). Further examination of the tissues revealed that the 
tumours were invasive and highly proliferative (Chamberlain et al., 2010). These results indicate 
that p85 plays essential roles in the regulation of PDGFR intracellular trafficking and signalling 
which is not limited to roles in PDGFR signalling. 
Other roles for p85 in receptor signalling and trafficking have been reported in the 
literature (Mellor et al., 2012). During β-integrin signalling, p85 binds Caspase 8 via a 
phosphotyrosine-dependent SH2 domain and Caspase 8 sequesters p85 to prevent its Rab5 
regulatory function (Torres et al., 2008). Signalling initiated by integrins leads to the association 
of the SH3 domain of p85 with focal adhesion kinase (FAK), which in turn interacts with Crk-
associated substrate, p130CAS to activate pathways culminating in a change in the adhesive 
properties of the cell (Guinebault et al., 1995). Furthermore, binding of the SH2 domain of p85 
to phosphorylated tyrosine residues on β-catenin is important for cell adhesion (Woodfield et al., 
2001). Interaction between the SH3 domain of p85 and p130CAS important for cell migration has 
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also been observed (Li et al., 2000a). During dynamin-dependent receptor endocytosis, the SH3 
domain of p85 binds to dynamin and this interaction has been shown to be important for the 
vesicle scission process, one of the early steps of endocytosis (Gout et al., 1993; Scaife et al., 
1994). A phosphotyrosine-independent association between the SH2 domain of p85 and Ankyrin 
3 has been reported to be involved in PDGFR trafficking and degradation via the endocytic 
pathway (Ignatiuk et al., 2006). The iSH2 domain of p85 also binds α/β-tubulins, proteins that 
function in microtubule-dependent vesicle trafficking to regulate budding or fusion of vesicles 
(Kapeller et al., 1995). 
 
1.3.2.3 PI3K signalling and cancer 
As discussed previously, the PI3K/Akt signalling pathway is activated in response to 
binding of a growth factor to its RTK. The PI3K/Akt signalling pathway can be down-regulated 
by PTEN as well as by endocytosis of the receptor ligand complex. Deregulation of these 
pathways has been associated with cancers. In several types of human cancers, including those of 
the breast, lung and brain, RTKs or components of the signal transduction pathways that they 
activate are either over-expressed or mutated (Bache et al., 2004; Blume-Jensen and Hunter, 
2001). Overexpression of RTKs resulting from gene amplification, increased gene expression, or 
defects in receptor trafficking and degradation can activate a given pathway, even in the absence 
of ligand (Bache et al., 2004; Blume-Jensen and Hunter, 2001). The RTK, PDGFRβ, has been 
reported to be overexpressed in glioblastomas and some skin cancers (Fleming et al., 1992; 
Hagerstrand et al., 2006; Shimizu et al., 1999; Sjoblom et al., 2001). Overexpression of another 
RTK, EGFR, has been implicated in a number of cancers including that of the breast (Arteaga, 
2003; Sebastian et al., 2006). RTKs or intracellular signalling molecules may also initiate 
tumorigenesis due to defects such as mutations, frame-shifts, deletions or chromosomal 
translocations (Bache et al., 2004; Blume-Jensen and Hunter, 2001). PDGFRβ chromosomal 
translocation generates a fusion-PDGFR kinase (e.g. TEL-PDGFR) and has been implicated in 
chronic myelomonocytic leukemias (Apperley et al., 2002; Baxter et al., 2003; Golub et al., 
1994; Hidalgo-Curtis et al., 2010; Rodrigues and Park, 1994; Steer and Cross, 2002). PTEN is 
mutated and inactivated in glioblastomas, for example, resulting in constitutive Akt signalling 
and thus, the formation of tumours (Li et al., 1997). Some cancers have been shown to develop 
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as a result of mutations in proteins involved in multivesicular body formation and sorting (e.g. 
Tsg101) (Bache et al., 2004; Jiang and Beaudet, 2004; Katzmann et al., 2002). 
Mutations within the p85 regulatory subunit and the p110 catalytic subunit of PI3K are of 
particular interest to this project. The most widely reported mutations have been those discovered 
in the p110α catalytic subunit. These mutations have been reported in a variety of cancers 
(Gabelli et al., 2010; Samuels and Waldman, 2010; Zhao and Vogt, 2008). The most frequent 
mutations in cancer include E542K and E545K in the helical domain of p110α, as well as 
H1047R in the kinase domain (Gabelli et al., 2010; Ikenoue et al., 2005; Miled et al., 2007; 
Samuels and Velculescu, 2004; Samuels et al., 2004). However, mutations can occur in all other 
domains of p110α except the Ras-binding domain. These mutations are gain-of-function 
mutations that result in constitutively active p110α and thus, enhanced Akt signalling in the 
absence of growth factor, cell survival and the development of tumours (Vogt et al., 2010). 
Mutation of glutamic acid 542 or 545 to lysine relieves the inhibitory effects exerted by the 
nSH2 domain of p85 (Huang et al., 2007a; Samuels and Velculescu, 2004). The histidine 1047 to 
arginine mutation causes a conformational change in p110α that enhances p110α’s ability to 
interact with the membrane and lipid substrates within the membrane (Huang et al., 2007a; 
Mandelker et al., 2009). 
Recently, mutations in p85α have been reported to lead to the development of 
glioblastomas, colorectal, urothelial, ovarian, colon, breast and pancreatic cancers (Ikenoue et 
al., 2005; Jaiswal et al., 2009; Ross et al., 2013). The most frequently mutated sites include 
Arg348, Gly376 and Leu380 in the nSH2 domain, and Lys459, Asp560, Asn564 and Arg574 in 
the iSH2 domain (Cancer Genome Atlas Research, 2008; Ikenoue et al., 2005; Jaiswal et al., 
2009). These mutations result in increased p110α activity due to a disruption of inhibitory 
contacts made between p85 and p110 (Ikenoue et al., 2005; Jaiswal et al., 2009; Samuels and 
Velculescu, 2004). A recent study, using urothelial cancers as a model, discovered novel 
mutations within the GAP (E137K, R262T, K288Q), nSH2 (N377K), iSH2 (R481W, R557P) 
and cSH2 (T645I) domains of p85α (Ross et al., 2013). It has been shown that GAP domain 
mutants do not alter p85α inhibition and stabilization of p110α, suggesting that the oncogenicity 
of these mutations is independent of p110 catalytic functions (Ross et al., 2013). The mechanism 
of cancer development in GAP domain mutants remains unknown.  
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1.4 Endocytosis 
Communication of vital signals as well as the import and export of essential molecules 
across membranes is facilitated by signal transduction pathways, transport channels within 
membranes and by endo- and exocytosis (Conner and Schmid, 2003). Endocytosis allows for the 
uptake of molecules in the extracellular environment or the internalization of molecules 
embedded in the membrane (Conner and Schmid, 2003; Marsh and McMahon, 1999; Mukherjee 
et al., 1997; Scita and Di Fiore, 2010). Exocytosis on the other hand is important for the 
secretion of molecules to the outside of the cell.  
Endocytosis can be grouped into two processes depending on the size and type of 
material that is internalized. In the first type, referred to as phagocytosis, large particles including 
bacteria and apoptotic bodies are completely engulfed by cells such as macrophages (Conner and 
Schmid, 2003; Mukherjee et al., 1997). The second process, termed pinocytosis, involves the 
uptake of extracellular fluid carrying smaller particles including solutes, proteins and nutrients 
(Conner and Schmid, 2003; Mukherjee et al., 1997). Pinocytosis is further classified into 
macropinocytosis, clathrin-mediated endocytosis, caveolin-mediated endocytosis, or 
clathrin/caveolin-independent endocytosis on the basis of the mechanism of vesicle formation as 
well as cargo specificity (Conner and Schmid, 2003; Le Roy and Wrana, 2005; Mayor and 
Pagano, 2007; Mukherjee et al., 1997). The first step in the endocytic pathway is the recognition 
and internalization of the particle of interest. This involves the invagination of plasma 
membrane, which leads to the scission of the membrane to form a vesicle within the cell. All 
types of endocytosis follow the same path irrespective of the molecules being internalized and 
the method of internalization. After internalization and vesicle formation, the cargo is trafficked 
within the cell and delivered to the lysosome, the endoplasmic reticulum, the trans-Golgi 
network, or to the plasma membrane (Sigismund et al., 2012). 
 
1.4.1 RTK-mediated Endocytosis 
 Signal transduction regulation is necessary for maintaining homeostasis of the cell. RTK 
signalling is regulated by clathrin-mediated endocytosis, caveolin-mediated endocytosis (also 
referred to as clathrin-independent endocytosis), or clathrin/caveolin-independent endocytosis 
(e.g. Flotillin-dependent endocytosis) (Aguilar and Wendland, 2005; Anderson, 1998; Conner 
and Schmid, 2003; Doherty and McMahon, 2009; Le Roy and Wrana, 2005; Mayor and Pagano, 
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2007; Sorkin and von Zastrow, 2009). Endocytosis is not only important for regulation of signal 
by reducing the pool of receptors available for signalling, but also for the turnover of RTKs and 
the maintenance of plasma membrane composition (Le Roy and Wrana, 2005; Sorkin and von 
Zastrow, 2009). 
 
1.4.1.1 Clathrin-mediated endocytosis 
 The mechanism of clathrin-mediated endocytosis has been studied more extensively than 
the other forms of endocytosis, which are consequently also less well understood. Clathrin is a 
protein lattice made up of triskelion (three clathrin heavy chains tightly bound to three clathrin 
light chains and all joined together to make a three-legged structure) that assembles into 
polyhexagonal cages (Brodsky et al., 2001; Edeling et al., 2006; Kirchhausen, 2000; McMahon 
and Boucrot, 2011). These polyhexagonal cages coat and support the curvature of the plasma 
membrane within invaginated pits. Clathrin-mediated endocytosis begins with the recruitment of 
clathrin, adapter proteins and accessory protein to the plasma membrane (Figure 1.8) (Brodsky et 
al., 2001; McMahon and Boucrot, 2011; Owen et al., 2004). RTKs contain internalization 
recognition motifs for adapter proteins that aid in their recruitment to the budding site (Sorkin, 
2004). Adaptor protein 2 (AP-2) is one such adapter protein (Traub, 2003). It is a 
heterotetrameric protein complex that binds to phosphatidylinositol-4,5-bisphosphate (PI4,5P2) 
within the plasma membrane and to the RTK (Mousavi et al., 2004; Sigismund et al., 2012; 
Takei and Haucke, 2001; Traub, 2003). Clathrin binds to AP-2 and assembles into the lattice. 
Other assembly or accessory proteins include EGFR pathway substrate clone 15 (Eps15) and 
epsin 1/2 in the case of EGFR endocytosis (McMahon and Boucrot, 2011). These proteins drive 
curvature of the membrane and promote invagination of plasma membrane (Ford et al., 2002; 
Ungewickell and Hinrichsen, 2007). Eps15 and epsin 1/2 bind to each other, to AP-2 and to 
clathrin. They can also associate with the receptor by binding to ubiquitin on the receptor via 
ubiquitin interaction motifs (UIM) or ubiquitin associated (UBA) domains in Eps15 and epsin 
1/2 (Chen and De Camilli, 2005; Polo et al., 2003; Polo et al., 2002). In some cases ubiquitin 
acts as an endocytic signal (Acconcia et al., 2009). Ubiquitination has been shown to be 
important for PDGFR internalization and degradation, whereas it is not required for EGFR 
internalization (Duan et al., 2003; Huang et al., 2007b; Mori et al., 1993; Stang et al., 2004).  
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Figure 1.8: Clathrin and Caveolin modes of RTK internalization. I) During internalization of 
activated RTK, the budding vesicle is coated with clathrin, AP-2 and accessory proteins in the 
case of clathrin-mediated endocytosis. The pits are coated with caveolin during caveolin-
mediated endocytosis. Dynamin facilitates the scission of the budding vesicles in both routes of 
internalization. II) The vesicles are coated with either clathrin or caveolin. III) Uncoating occurs 
as the vesicles move along the actin cytoskeleton to traffic the RTK within the cells. IV) The 
vesicle fuses with the early/sorting endosome and cargo is delivered to the early/sorting 
endosome or further intracellular trafficking events.  
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Ubiquitination is the conjugation of the 76 amino acid ubiquitin (Ub) polypeptide to a 
single lysine residue in a protein (monoubiquitination) or to multiple lysine residues within the 
protein (multiubiquitination) (Hershko and Ciechanover, 1998; Komander, 2009). A chain of 
ubiquitin molecules can also be conjugated to a single lysine residue and is denoted as 
polyubiquitination. Ubiquitin can be conjugated onto any one of the seven lysine residues within 
the ubiquitin molecule. Polyubiquitination can, therefore, be classified as Lys48-, 63-, 6-, 11-, 
27-, 29-, or 33-linked polyubiquitination (Komander, 2009). Some studies have demonstrated 
that ubiquitin can sometimes by conjugated onto a cysteine residue (Cadwell and Coscoy, 2005; 
Hensel et al., 2011; Okumoto et al., 2011). Lysine 48-polyubiquitination usually promotes the 
proteosomal degradation of proteins, while mono- and multiubiquitination ultimately result in 
lysosomal degradation of proteins (Di Fiore et al., 2003; Haglund et al., 2003a; Haglund et al., 
2003b; Hicke, 2001; Komander, 2009; Marmor and Yarden, 2004; Sigismund et al., 2004; 
Umebayashi, 2003). There are three steps in the ubiquitination process: (i) ATP-dependent 
conjugation of Ub to an E1 Ub activating enzyme; (ii) Transfer of Ub to an E2 Ub conjugating 
enzyme; and (iii) Transfer of Ub to an E3 Ub ligase and the subsequent conjugation of Ub onto 
the substrate (Figure 1.9) (Hershko and Ciechanover, 1998; Komander, 2009). There are two 
types of E3 Ub ligase; the “homologous to the E6-AP carboxy terminus” (HECT) and the “really 
interesting new gene” (RING) domain containing E3 ligases (Urbe, 2005). With HECT E3 
ligases including Nedd4, Ub is transferred from the E2 enzyme to the HECT E3 enzyme before it 
is conjugated onto the substrate (Komander, 2009; Urbe, 2005; Wang et al., 2007). RING E3 
ligases on the other hand act as adapter proteins by forming a bridge between the E2 enzyme and 
the substrate (Komander, 2009; Thien and Langdon, 2005; Urbe, 2005). In this case Ub is 
transferred directly from E2 to the substrate. An example of a RING E3 ligase is Cbl (d'Azzo et 
al., 2005; Fang et al., 2001; Komander, 2009; Thien and Langdon, 2005; Urbe, 2005). Cbl 
associates with PDGFR on the phosphorylated tyrosine at position 1021 within the receptor tail 
and monoubiquitinates the receptor (Miyake et al., 1998; Reddi et al., 2007; Thien and Langdon, 
2001, 2005; Tsygankov et al., 2001). Monoubiquitination serves as the signal for internalization 
of the PDGFR.  
Recruitment of AP-2, clathrin, Eps15, epsin 1/2 and Rab5 to the site of activated receptor 
triggers coat assembly, membrane invagination and ultimately scission of the vesicle. In order to  
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Figure 1.9: RTK Ubiquitination. The 3 steps involved in ubiquitination. ATP-dependent 
conjugation of Ub to an E1 Ub activating enzyme. Transfer of Ub to an E2 Ub conjugating 
enzyme. Transfer of Ub to an E3 Ub ligase and the subsequent conjugation of Ub onto the 
substrate. Conjugation with one ubiquitin moiety (monoubiquitylation), conjugation with 
multiple ubiquitin monomers (multiubiquitylation) or the formation of a ubiquitin chain 
branched at internal lysines within ubiquitin (polyubiquitylation). 
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facilitate scission of the vesicle, the large GTPase dynamin is loaded around the point of closure 
of the invaginating vesicle, the neck (Conner and Schmid, 2003; Mettlen et al., 2009; Pucadyil 
and Schmid, 2009; Sweitzer and Hinshaw, 1998). Dynamin interacts with PI4,5P2 in the 
membrane and organizes into polymers to form a helical ring or collar (Pucadyil and Schmid, 
2009; Ramachandran et al., 2009). The activity of dynamin is enhanced by its ability to 
hydrolyse GTP (Pucadyil and Schmid, 2009; Song and Schmid, 2003). The action of dynamin 
and other proteins, including actin and myosin, result in constriction of the neck and detachment 
of the vesicle from the membrane into the cytosol. The budded vesicle travels along the actin 
cytoskeleton and fuses with the early/sorting endosome, disassembling its coat in the process. 
 
1.4.1.2 Caveolin-mediated endocytosis 
Caveolin is a hairpin-shaped protein that embeds into the membrane lipid bilayer 
(Anderson, 1998; Doherty and McMahon, 2009; Miaczynska and Zerial, 2002). Caveolin-
mediated endocytosis involves the assembly of caveolin at specific locations within the plasma 
membrane referred to as the caveolar raft (Figure 1.8) (Lajoie and Nabi, 2010; Mayor and 
Pagano, 2007; Nabi and Le, 2003; Parton and Richards, 2003). These rafts are analogous to lipid 
rafts (Nabi and Le, 2003; Parton and Richards, 2003). Lipid rafts are highly ordered, tightly 
packed microdomains within the plasma membrane that are concentrated with proteins, 
cholesterol and glycosphingolipids (Lajoie and Nabi, 2010; Nabi and Le, 2003; Parton and 
Richards, 2003). Lipid rafts are central to signal transduction as they serve as hubs for all the 
essential players important for any given pathway (Anderson, 2006; Lajoie and Nabi, 2010; Nabi 
and Le, 2003; Parton and Richards, 2003; Simons and Toomre, 2000). They also play essential 
roles in receptor trafficking (Anderson, 2006; Lajoie and Nabi, 2010). Insertion of caveolin into 
the membrane as well as oligomerization of caveolin molecules into a spiral-like coat may 
contribute to membrane curvature and invagination of pits during caveolin-mediated endocytosis 
(Anderson, 1998). As with clathrin-mediated endocytosis, dynamin causes the scission of the 
budding vesicle coated with caveolin. The budded vesicle uncoats and fuses with the 
early/sorting endosome. Caveolin-mediated endocytosis plays a dual role of allowing for the 
uptake of lipid molecules and secondly, the regulation of signalling events (Anderson, 1998; 
Simons and Toomre, 2000). 
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It has been reported that RTKs, e.g. EGFR, can follow different routes for internalization 
of activated receptor complexes depending on factors such as ligand availability, cholesterol and 
ubiquitination state (Sigismund et al., 2008; Sigismund et al., 2005). Under limited EGF 
conditions, EGFR is internalized via the clathrin-dependent pathway (Sigismund et al., 2005). 
Conversely, EGFR is internalized using both clathrin-dependent and clathrin-independent 
pathways when EGF is abundant (Sigismund et al., 2005). The internalization route taken 
contributes to differential signalling effects (Sigismund et al., 2008; Sorkin and von Zastrow, 
2009). For instance, when cells expressing the transforming growth factor β receptor (TGFβR) 
utilize the clathrin-dependent pathway it results in a continued activation of downstream 
signalling events (Di Guglielmo et al., 2003). However, TGFβR is ubiquitinated and degraded 
when cells use the caveolin-mediated pathway (Di Guglielmo et al., 2003). The ubiquitination 
state of the receptor may also play a role in determining the route taken, though ubiquitin-
dependent internalization appears to be caveolin specific (Huang et al., 2006; Sigismund et al., 
2005; Umebayashi, 2003). 
 
1.4.1.3 RTK intracellular trafficking 
Signal transduction continues to occur from activated receptor complexes internalized 
into the early endosome and early/sorting endosome (Burke et al., 2001; Cavalli et al., 2001; 
Wang et al., 2004). The early/sorting endosome is so named because from this compartment the 
receptor is either deactivated and recycled to the plasma membrane for further signal 
transduction, or ubiquitinated and sorted into a lysosomal degradation pathway (Figure 1.10) 
(Lemmon and Traub, 2000; Rosenfeld et al., 1984). There are different schools of thought on the 
issue of how different endosomes form and mature. It is postulated that one endosome matures 
into another simply by disassembly of marker proteins of the previous endosome due to a change 
in the lipid composition of the membrane, which allows a new set of proteins specific to the 
‘new’ endosome to accumulate on the membrane (Christoforidis et al., 1999a; De Camilli et al., 
1996; Poteryaev et al., 2010; Rink et al., 2005). Another theory is that the early/sorting 
endosome is pre-existing and vesicles from the plasma membrane fuse with it. Then, vesicles 
that become recycling endosomes or late endosomes bud off from the early/sorting endosome 
(Vonderheit and Helenius, 2005). 
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Figure 1.10: Rab GTPase proteins regulate vesicle trafficking events. Rab5 mediates the 
transfer of receptor-ligand cargo to the early/sorting endosome. Most of the receptor complexes 
are recycled either by a slow Rab4- and Rab11-mediated pathway or a fast Rab4-mediated 
pathway. A small fraction of the receptor-ligand complexes are internalized into multivesicular 
bodies within late endosomes and finally degraded in the lysosome via a Rab7-dependent 
pathway.  
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Internalized vesicles are loaded with the small GTPase, Rab5, which mediates homotypic 
vesicle fusion events between the internalized vesicle and the early sorting endosome (Figures 
1.10 and 1.11) (Bucci et al., 1994; Gorvel et al., 1991; Wickner, 2010). A discussion of Rab 
proteins can be found in Section 1.4.1.5. Rab5 binds to the p85 regulatory subunit of PI3K on the 
activated receptor complex (Figure 1.11) (Chamberlain et al., 2004; Christoforidis et al., 1999a). 
The activated receptor complex binds and recruits Rin1, a Rab5 guanine nucleotide exchange  
factor (GEF) responsible for generating active Rab5 (Rab5-GTP) (Figure 1.11) (Barbieri et al., 
2004; Barbieri et al., 2003; Kong et al., 2007). p85 acts as a GTPase activating protein (GAP) for 
Rab5-GTP that enhances GTP to GDP hydrolysis, resulting in the inactivation of Rab5 
(Chamberlain et al., 2004). However, another Rab5 GAP, RN-Tre – that negatively regulates the 
endocytosis of EGFR –  is recruited to the plasma membrane by the presence of Rab5 bound to 
p85 (Lanzetti et al., 2000; Martinu et al., 2002). During vesicle fusion and tethering, Rab5 
recruits effector molecules such as the early endosomal auto-antigen 1 (EEA1) and Rabenosyn-5 
to the site of membrane fusion (Figures 1.11 and 1.13) (Callaghan et al., 1999a; Christoforidis et 
al., 1999a; Mills et al., 1998; Nielsen et al., 2000; Rubino et al., 2000; Shin et al., 2005; 
Simonsen et al., 1998). Parallel coiled-coil homodimers of EEA1 bind to both Rab5 and PI3P on 
different endosomes to form the tether (Figures 1.11 and 1.13) (Callaghan et al., 1999b). EEA1 
interacts with the membrane of one endosome via its C-terminal FYVE domain and with Rab5 
on the other endosome through its N-terminal zinc finger (Mishra et al., 2010). FYVE domain 
containing proteins specifically bind to PI3P, a lipid product of the class III p150–Vps34-PI3Ks. 
Much like EEA1, Rabenosyn-5 is a FYVE zinc finger protein (Nielsen et al., 2000).  Other 
effector molecules recruited by Rab5 to the site of membrane fusion include the lipid 
phosphatases, PI-4-phosphatase and PI-5-phosphatase, that use PI3,4,5P3 as a substrate to 
generate PI3P on the early endosome (Shin et al., 2005). Tethering of two endosomes by EEA1 
allows for the formation of a soluble NSF (N-ethylmaleimide-sensitive factor)-attachment 
protein receptor (SNARE) complex (McBride et al., 1999; Wickner, 2010). SNAREs are a group 
of membrane-anchored proteins that organize into a complex to facilitate membrane fusion and 
endocytic trafficking of RTKs (Figure 1.11) (Woodman, 2000; Xu et al., 2013). SNARE 
complex formation is not specific to the fusion of membranes between the early endosome and 
the early/sorting endosome. It is a requirement for membrane fusion at different steps within the 
endocytic trafficking pathway. 
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Figure 1.11: Model for receptor-associated proteins in the regulation of Rab5-mediated 
processes. RTKs activated by growth factor binding become tyrosine phosphorylated and recruit 
Rin1 (a Rab5 guanine nucleotide exchange factor (GEF)) and p85α–p110β (a possible Rab5 
GDI-displacement factor (GDF) and a Rab5 GTPase activating protein (GAP)). RTK complexes 
are internalized into early endosomal vesicles by clathrin-dependent and clathrin-independent 
processes, which involve dynamin-dependent scission from the plasma membrane and the 
subsequent uncoating steps (not shown). The ability of p85 to bind Rab5-GDP suggests that 
RTK-associated p85 could act as a GDF to identify the appropriate vesicle membranes for Rab5 
recruitment. The RTK-associated Rin1 is a Rab5 GEF that generates active Rab5-GTP suitable 
for interactions with many effector proteins. One effector protein is EEA1, which forms a tether 
between two early endosomes by binding to Rab5-GTP on one endosome and PI3P lipids on a 
second endosome, to facilitate SNARE-mediated vesicle fusion. Rab5-GTP is no longer required 
within the larger early/sorting endosome. We propose that p85α–p110β dissociates from the 
RTK, up-regulating its GAP activity towards Rab5-GTP to promote the formation of inactive 
Rab5-GDP, and allowing for GDI binding and membrane release. (Reproduced from (Mellor et 
al., 2012)). A general discussion of Rab protein regulation can be found in section 1.4.1.5. 
 
 
As discussed above, receptor complexes can be delivered from the early/sorting 
endosome to either a recycling endosome to be transported back to the plasma membrane, or can 
be delivered to a late endosome as part of a lysosomal degradation pathway (Figure 1.10). Most 
receptor complexes are recycled either by a slow Rab4- and Rab11-mediated pathway or a fast 
Rab4-mediated pathway (Sheff et al., 1999; Stenmark, 2009; Takahashi et al., 2012). A small 
fraction of the receptor-ligand complexes are internalized into multivesicular bodies (MVBs) 
within late endosomes and finally degraded in the lysosome via a Rab7-dependent pathway. It 
has been postulated that ‘new’ endosomes may form from the budding off of specific domain 
within the early/sorting endosome. In support of this hypothesis, Rab microdomains have been 
reported to exist within early/sorting endosomes for Rab5, Rab4, and Rab11 (Miaczynska, 2013; 
Miaczynska and Zerial, 2002; Zerial and McBride, 2001).  The specific Rab proteins, together 
with the appropriate endosome markers, are loaded onto the early/sorting and those sections bud 
off to generate recycling endosomes. The balance between recycling and degradation is regulated 
by the ubiquitination status of the RTK, other sorting signal proteins, or the level of RTK 
phosphorylation (Miaczynska, 2013). Specifically, loss of the T-cell protein tyrosine phosphatase 
(TC-PTP) leads to an increase in PDGFRβ, but not PDGFRα, phosphorylation resulting in a shift 
towards rapid recycling rather than degradation (Miaczynska, 2013). 
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1.4.1.4 Late endosomal sorting 
Activated RTKs can transduce a signal during the initial phases of endocytosis and can 
continue to do so until the receptors are either dephosphorylated and recycled or sequestered into 
multivesicular bodies within the late endosome (Cavalli et al., 2001; Miaczynska, 2013).  A 
small fraction of the receptor-ligand complexes are targeted for degradation in the lysosome via a 
Rab7-dependent pathway. One of the theories of endosome formation argues for the disassembly 
of marker proteins of the early/sorting endosome, for instance, and the assembly of recycling 
endosome markers that converts an early/sorting endosome into a recycling endosome 
(Poteryaev et al., 2010; Spang, 2009). Early/sorting endosomes are converted into late 
endosomes by the assembly of Rab7 into a microdomain within the membrane of the 
early/sorting endosome (Cavalli et al., 2001). Mon1 regulates the conversion of early to late 
endosomes by displacing Rabex-5 and the recruitment of the homotypic fusion and vacuole 
protein sorting (HOPS) complex (Poteryaev et al., 2010; Spang, 2009). Rabex-5 is a Rab5 GEF 
(Lippe et al., 2001). Displacement of this protein results in less activation of Rab5. The HOPS 
complex contains Vps39, a GEF for Rab7, which is crucial for Rab7 activation (Rink et al., 
2005). A Rab5 GAP is thought to be recruited to deactivate Rab5 and promote guanine 
nucleotide dissociation inhibitor (GDI)-mediated membrane extraction of Rab5 to convert the 
vesicle from a Rab5-positive early endosome into a Rab7-positive late endosome (Rink et al., 
2005). 
Markers of the late endosome include the presence of PI3P in the membrane, 
lysobisphosphatidic acid, hydrolytic enzymes within its lumen and a decrease in pH to 5-6 
(Marmor and Yarden, 2004; Teis and Huber, 2003). Receptor complexes on the membrane of the 
late endosome are completely engulfed into the luminal space where there are sequestered into 
multivesicular bodies (MVBs). As mentioned earlier, RTKs such as the PDGFR that are 
degraded as part of receptor down-regulation associate with the Cbl E3 ubiquitin ligase 
(Levkowitz et al., 1998; Miyake et al., 1998; Thien and Langdon, 2001; Tsygankov et al., 2001). 
Monoubiquitination is an absolute requirement for sorting of RTKs into the MVBs of the late 
endosomes (Haglund et al., 2003a; Haglund et al., 2003b; Hicke, 2001; Ravid et al., 2004). 
MVB biogenesis takes place through interactions between ubiquitin on mono- or 
multiubiquitinated receptors and the ubiquitin interacting motif (UIM) or the ubiquitin-
conjugating enzyme E2 variant (UEV) domain or the ubiquitin-associated (UBA) domain of 
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members of the Endosomal Sorting Complex Required for Transport (ESCRT) protein 
complexes (Hicke and Dunn, 2003; Polo et al., 2002; Raiborg and Stenmark, 2009).  
The ESCRT machinery consists of four complexes; ESCRT 0, ESCRT I, ESCRT II and 
ESCRT III (Figure 1.12) (Hurley and Emr, 2006; Katzmann et al., 2002; Raiborg and Stenmark, 
2009). The ESCRT machinery operates on the basis of a ‘hand off’ model of MVB biogenesis. 
ESCRT 0 is a heterodimer of the hepatocyte growth factor-regulated tyrosine kinase substrate 
(Hrs) and the signal-transducer adapter molecule (STAM) (Raiborg and Stenmark, 2009). It 
associates with the membrane of the late endosome by binding to PI3P through the FYVE 
domain of Hrs (Hanson et al., 2009; Henne et al., 2011; Raiborg and Stenmark, 2009). ESCRT 0 
localizes to microdomains on the membrane that are characterized by flat clathrin coats (Raiborg 
et al., 2006). MVB formation starts with the recognition and binding of ubiquitin on the receptor 
by the UIMs of Hrs (Bache et al., 2003; Henne et al., 2011; Hirano et al., 2006; Katzmann et al., 
2003). Hrs then recruits ESCRT I via interactions between ESCRT I and the four amino acid 
motif of Hrs; the PSAP motif (Clague and Urbe, 2003). ESCRT I is a heterotetramer consisting 
of Tsg101.  
Tsg101 is thought to be the main subunit required for the function of ESCRT I as knock-
down studies show a dysregulation of degradation of EGFR (Babst et al., 2000). Studies on the 
other subunits are lacking. The UEV domain of Tsg101 binds to ubiquitinated receptor. ESCRT I 
recruits ESCRT II to the site of MVB biogenesis. Both ESCRT I and ESCRT II are important for 
sorting of the receptor. ESCRT II interacts with ubiquitin through its GRAM-like ubiquitin 
binding in EAP45 (GLUE) domain (Henne et al., 2011; Slagsvold et al., 2005).  
Finally, ESCRT II recruits ESCRT III, which is a filament-like oligomer responsible for 
membrane invagination, scission of budding MVBs and disassembly of the ESCRT complex 
(Hanson et al., 2009; Raiborg and Stenmark, 2009; Saksena et al., 2009). Deubiquitination 
precedes inclusion of receptor within the MVBs. ESCRT III recruits the deubiquitinating enzyme 
Doa4, which catalyzes the removal of ubiquitin on all cargo associated with the budding MVB 
(Amerik et al., 2000; Henne et al., 2011). ESCRT III constricts the area of the MVB to be 
enclosed and pinches it off in an ATP-dependent manner (Hanson et al., 2009; Saksena et al., 
2009). All the components of the ESCRT complex are dissociated and MVB biogenesis is 
complete. The late endosome containing MVBs fuse with the lysosome. Cargo is transferred and 
completely degraded.  
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Figure 1.12: Late endosomal sorting of ubiquitnated RTK into multivesicular bodies 
(MVB) via the ESCRT machinery. 1) ESCRT 0 recognizes and binds to ubiquitin (Ub) on 
activated RTK complexes. ESCRT 0 interacts with ESCRT I, recruiting it to the site of 
ubiquitinated protein. 2) ESCRT I binds to Ub and recruits ESCRT II. ESCRT I and II function 
as cargo sorters. 3) ESCRT II recruits ESCRT III. ESCRT III deubiquitinates the RTK and 
initiates the invagination and scission of vesicles. ESCRT III is also responsible for disassembly 
of ESCRT complexes. 
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1.4.1.5 Rab Proteins and their regulation 
Rab GTPase proteins belong to the Ras superfamily of GTPases (Pereira-Leal and 
Seabra, 2000). They regulate intracellular vesicle trafficking events from the plasma membrane 
to target organelles such as endosomes, lysosome, trans-Golgi network or endoplasmic reticulum 
(Brighouse et al., 2010; Hutagalung and Novick, 2011; Mitra et al., 2011; Stenmark, 2009; 
Zerial and McBride, 2001). Over 60 Rab proteins have been identified (Brighouse et al., 2010). 
Some Rab proteins, such as Rab4 and Rab5, are ubiquitously expressed while others, such as 
Rab3 (neurons) and Rab27 (platelets), are tissue specific (Stenmark and Olkkonen, 2001). Rab 
proteins are targeted to specific membrane locations possibly through the hypervariable region in 
the C-terminus (Pfeffer and Aivazian, 2004). 
Rab proteins are regulated by their subcellular localization and their guanine nucleotide 
bound state, through interactions with a number of different proteins (Nottingham and Pfeffer, 
2009). These proteins are GDP-bound and cytosolic when inactive, and GTP-bound with an 
insertion into a membrane when activated by their GEF (Bos et al., 2007; Nottingham and 
Pfeffer, 2009). The inactive Rab proteins are characteristically bound to a GDI protein that 
masks a C-terminal lipid prenylation site (Pfeffer et al., 1995). Rab proteins contain two 
geranylgeranyl motifs (20 carbon polyisoprenoid groups on two cysteine residues: C-C, C-X-C, 
C-C-X-X, C-C-X-X-X OR X-X-C-C; where X is any amino acid) at the C-terminus that can be 
prenylated by Rab geranylgeranyl transferases (Leung et al., 2006; Pfeffer and Aivazian, 2004; 
Seabra et al., 1992; Tuvim et al., 2001). In order to activate Rab proteins the GDI is removed, 
upon growth factor stimulation and receptor endocytosis, by a GDF (Figure 1.13) (Pfeffer and 
Aivazian, 2004; Seabra and Wasmeier, 2004; Stenmark and Olkkonen, 2001).  
Displacement of the GDI exposes the lipid prenylation site, which can be inserted into the 
target membrane. GDP bound to the Rab protein is then exchanged for the more abundant GTP 
by the action of a GEF (Bos et al., 2007; Nottingham and Pfeffer, 2009; Stenmark and Olkkonen, 
2001; Vetter and Wittinghofer, 2001). This leads to full activation of the Rab protein. Rab 
proteins contain two flexible switch regions, switch I and switch II, which are important for 
interaction with GEFs and GTPase activating proteins (GAP) (Bos et al., 2007; Fidyk and 
Cerione, 2002; Nottingham and Pfeffer, 2009; Scheffzek et al., 1998b; Tuvim et al., 2001). 
Binding of GTP to the Rab protein induces a conformational change within these two regions.  
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Figure 1.13: Regulation of Rab5 at the interface of endosome membrane fusion. A) The C-
terminal prenylation site masked by a GDI (guanine nucleotide dissociation inhibitor) protein is 
removed by a GDF (GDI displacement factor) protein exposing the lipid site and allowing for 
membrane insertion. B) The GEF (guanine nucleotide exchange factor) protein stimulates the 
exchange of GDP for GTP, thus activating Rab5. C) Rab5-GTP recruits EEA1 (early endosomal 
auto-antigen 1) to the membrane that forms a tether between the two endosomes by binding to 
Rab5-GTP and PI3P. D) The GTPase activating protein (GAP) stimulates the weak intrinsic 
GTPase activity of Rab5. This returns Rab5 to an inactive state. 
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The conformational change creates a pocket that allows effector molecules to bind to active Rab 
proteins.  
Rab proteins have a weak intrinsic ability to hydrolyse the bound GTP to GDP that is 
enhanced 100-1000 fold by GAPs (Bos et al., 2007; Scheffzek et al., 1998b; Vetter and 
Wittinghofer, 2001). The inactivated Rab protein is dislodged from the membrane, allowing for 
interaction between the lipid prenylyation site and the GDI to return Rab to its cytosolic GDP-
bound state (Figure 1.13) (Pfeffer and Aivazian, 2004). GAPs serve two functions: (i) They 
provide a catalytic arginine residue (the arginine finger) that is involved in hydrogen bonding 
with a glutamic acid residue in the switch II region of the Rab protein, thereby positioning it 
within the nucleotide binding pocket and facilitating a hydrogen bond formation with the 
attacking nucleophilic water molecule (Clabecq et al., 2000; Li and Zhang, 2004; Vetter and 
Wittinghofer, 2001). The arginine finger is also involved in hydrogen bonding with the 
phosphate of GTP to stabilize the transition state (Li and Zhang, 2004; Sprang, 1997a). This is 
achieved by hydrogen bonding between the guanidine functional group of arginine and the α and 
γ phosphate oxygen atoms of GTP. The presence of Mg2+ within the nucleotide binding pocket is 
also important for stabilizing the switch region by interacting with oxygen atoms. These steps 
come together to promote the nucleophilic attack of water upon the γ phosphate of GTP to 
produce GDP and inorganic phosphate (Li and Zhang, 2004). Also, insertion of the arginine 
finger into the nucleotide binding pocket displaces water molecules and reduces the entropy of 
the reaction (Kotting et al., 2007); and (ii) They stabilize the switch regions of the Rab protein 
(Bos et al., 2007; Fidyk and Cerione, 2002; Li and Zhang, 2004; Scheffzek et al., 1998b; 
Seewald et al., 2002; Sprang, 1997b; Vetter and Wittinghofer, 2001). Interactions between the 
GAP and the Rab protein within the switch II region maintain the switch regions in an ordered 
state during the hydrolysis reaction. 
A single protein can typically perform both functions (i.e. provide an arginine finger and 
stabilize the switch region), however, there also have been reports indicating that two proteins 
can work in concert to provide both functions (Szafer et al., 2000b). The ADP-ribosylation factor 
(Arf) GAP requires a coatomer to boost its GAP activity (Goldberg, 1999; Szafer et al., 2000b). 
A single Rab protein can be regulated by more than one GAP. Rab5 GAPs include p85, Tuberin, 
RN-Tre and TBC1D3/PRC17 (Chamberlain et al., 2004; Lanzetti et al., 2000; Pei et al., 2002; 
Xiao et al., 1997). Studies in our laboratory have demonstrated that arginine 274 in the BH 
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domain of p85α is the critical residue that serves as the arginine finger to enhance the GTPase 
activity of Rab5 (Chamberlain et al., 2004). The choice of Rab GAP may be dependent on 
differential GAP expression, subcellular localization of Rab protein or differential Rab protein 
target in response to specific stimuli (Frasa et al., 2012).  
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2.0 RATIONALE AND OBJECTIVES  
The rationale for this thesis project stems from several inter-related experimental 
observations as follows. It has been documented in the literature that GAP proteins perform their 
function by stabilising the switch regions (which are crucial for interactions with GAPs and 
GEFs) in GTP-bound forms of Rab proteins. GAP proteins also provide a catalytic arginine 
required for the hydrolysis. A single GAP protein may perform both functions or two different 
proteins perform the separate functions (Bos et al., 2007; Fidyk and Cerione, 2002; Goldberg, 
1999; Seewald et al., 2002; Seewald et al., 2003; Szafer et al., 2000a; Szafer et al., 2001). Our 
laboratory has shown, through mutational analysis, that arginine 274 in the BH domain of p85α 
serves as the arginine finger (Chamberlain et al., 2004). It was observed that p85 has a relatively 
low RabGAP activity and is able to bind both Rab5-GDP and Rab5-GTP, unlike most GAP 
proteins that bind selectively to the GTP forms (Chamberlain et al., 2004). One report found that 
p110β can bind selectively to Rab5-GTP (Christoforidis et al., 1999b) suggesting that it binds 
the conformation-specific switch regions and, thus, may work together with p85 to provide GAP 
functions. There are other reports indicating that PI3K has functions independent of its catalytic 
activity. Experiments performed with PI3K inhibitors show decreased PI3K activity and enlarged 
early endosomes that could not be restored by the addition of PI3K signalling products (Chen 
and Wang, 2001a, b). This observation is similar to observations made in cells expressing a 
constitutively active Rab5, Rab5-Q79L (Houle and Marceau, 2003). Expression of a 
constitutively inactive Rab5, Rab5-S34N, partially inhibited the effects of the PI3K inhibitor 
(Houle and Marceau, 2003). These results suggest that the PI3K complex may need to exist as a 
heterodimer of p85 and p110 in order to regulate Rab5. Furthermore, knock-out of p110β results 
in altered intracellular trafficking of EGFR and transferrin that can be restored by expression of a 
kinase dead p110β mutant (Ciraolo et al., 2008; Jia et al., 2008). This finding recapitulates the 
importance of both p85 and p110 in the regulation of endocytic events. 
Further, since p85 binds to Rab5-GDP as well as Rab5-GTP, it may help recruit Rab5 to 
vesicle membranes containing activated PDGFR signalling complexes and thereby regulate 
PDGFR signalling events (Chamberlain et al., 2004). Taken together these results suggest the 
involvement of p110, and possibly the PDGFR, in enhancing (p110) or localizing (PDGFR) the 
RabGAP activity of p85. 
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The p85 protein regulates PI3K function and downstream signalling cascades, and also 
has a role in regulating Rab function (Chagpar et al., 2010; Chamberlain et al., 2004; 
Rabinovsky et al., 2009; Yu et al., 1998a; Yu et al., 1998b; Zhang et al., 2011). Defects in the 
ability of p85 to regulate Rab function are oncogenic (Chamberlain et al., 2008). As such, this 
thesis project was designed to examine how directed mutations in p85 known to affect its GAP 
activity as well as its ability to interact with p110 or PDGFR could influence the phenotype of 
NIH 3T3 mouse fibroblasts, an established model cell system for evaluating oncogenic 
transformation. 
 
 
2.1 Hypothesis  
We postulate that p85 acts in concert with p110 and/or PDGFR in order to enhance 
and/or localize its GAP activity near Rab proteins. 
 
2.2 Objectives 
1) To determine the effects of expressing a p85 mutant unable to bind to p110 or a RabGAP 
defective p85 mutant, unable to bind p110 on the  
a. Activation of PDGFR in response to PDGF 
b. Degradation of PDGFR in response to PDGF 
c. Activation of downstream effector molecules in response to PDGF 
d. Tumorigenicity of cells 
2) To determine the effects of expressing a p85 mutant unable to bind to PDGFR or a 
RabGAP defective p85 mutant, unable to bind PDGFR on the  
a. Activation of PDGFR in response to PDGF 
b. Degradation of PDGFR in response to PDGF 
c. Activation of downstream effector molecules in response to PDGF 
d. Tumorigenicity of cells 
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3.0 MATERIALS AND METHODS 
3.1 Materials 
3.1.1 Reagents  
All chemicals and reagents used were of molecular biological or analytical grade or 
higher. The majority of the chemicals and reagents used were procured from Sigma-Aldrich, 
VWR or BD Biosciences, unless otherwise specified. 
 
3.1.2 Mammalian cells 
NIH 3T3 mouse embryonic fibroblast cells and COS-1 African green monkey SV40 
transformed kidney fibroblast-like cells were obtained from American Type Culture Collection 
(ATCC CRL1658 and ATCC CRL1650, respectively). Cell lines were maintained at 37 ºC in a 
5% CO2 humidified air environment. 
 
3.1.3 Bacterial Strain 
Replication of plasmid DNA was performed in the following Escherichia coli (E. coli) 
strain: TOP10 chemically competent E. coli [Genotype: F- mcrA Δ(mrr-hsdRMS-mcrBC) 
Φ80lacZΔM15 Δ lacX74 deoR recA1 ara∆139 Δ(ara, leu)7697 galU galK λ- rpsL (StrR) endA1 
nupG] (Invitrogen, C4040-03).  
 
3.1.4 Vectors and Plasmids  
3.1.4.1 Vectors  
Vectors used in this study include pFLAG3 and pMyc3, both of which carry both the 
ampicillin and geneticin resistance genes and allow for selection in bacterial transformation and 
stable expression of protein of interest in mammalian cell lines, respectively. 
 
3.1.4.1.1 pFLAG3 vector 
The pFLAG3 vector was modified from the pHA3 vector as described previously 
(Chamberlain et al., 2004). It encodes three copies of the FLAG-epitope (DYKDDDDK). The 
triple HA tag flanked by the HindIII and the BglII restriction sites and upstream of the multiple 
cloning site in the pHA3 vector (Figure 3.1) was replaced by the following sequence to generate 
the new pFLAG3 vector: 5ʹ′-AA GCT TCC ACC ATG GAC TAC AAG GAC GAC GAT GAC 
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AAG GCT AGT GAC TAC AAG GAC GAC GAC GAT AAA GCG GCC GCT GAT TAC 
AAG GAC GAC GAC GAT AAA GCT AGC AGA TCT-3ʹ′ (Figure 3.2) (Chamberlain et al., 
2004). The pFLAG3 vector was used to express p85 wild type and p85 mutant fusion proteins 
with the FLAG-epitope at the N-terminus of the protein. 
 
 
 
 
upstream coding sequences and MCS of pHA3 vector: 
 
                  1st HA tag_ 
           Hind III Kozak  M+1 I   F   Y   P   Y   D                                      
T7 of pRC/CMV GGGAGACCGGAAGCTT CCACC ATG ATC TTT TAC CCA TAC GAT  
(Invitrogen) CCCTCTGGCCTTCGAA GGTGG TAC TAG AAA ATG GGT ATG CTA 
 
 
           not unique 
___________________    ________2ND HA tag__________________ Bam HI 
 V   P   D   Y   A   G   Y   P   Y   D   V   P   D   Y   A   G_ 
GTT CCT GAC TAT GCG GGC TAT CCC TAT GAC GTC CCG GAC TAT GCA GGA  
CAA GGA CTG ATA CGC CCG ATA GGG ATA CTG CAG GGC CTG ATA CGT CCT 
           5’HAseq 
 
             
 __________3rd HA tag_______________       lost Not I   Bgl II  
 S   Y   P   Y   D   V   P   D   Y   A   A   Q   C   S   R   R_ 
TCC TAT CCA TAT GAC GTT CCA GAT TAC GCT GCT CAG TGC AGC CGC AGA  
AGG ATA GGT ATA CTG CAA GGT CTA ATG CGA CGA GTC ACG TCG GCG TCT 
 
 
 
 Xba I   HpaI      EcoRI       Apa I 
 S   R   V   N   S   N   S   E   G  pRC/CMV 
TCT AGA GTT AAC TCG AAT TCT GAG GGC CCTATTCTATAGTGTCACCTAAA 
AGA TCT CAA TTG AGC TTA AGA CTC CCG CCATAAGATATCACAGTGGATTT 
 
Figure 3.1: Multiple cloning site of pHA3 vector showing the location of the HA epitopes. 
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upstream coding sequences and MCS of pFLAG3 vector: 
 
 
          _______  1st FLAG tag__ 
           Hind III Kozak  M+1 D   Y   K   D   D   D                                      
T7 of pRC/CMV GGGAGACCGGAAGCTT CCACC ATG GAC TAC AAG GAC GAC GAT   
(Invitrogen) CCCTCTGGCCTTCGAA GGTGG TAC CTG ATG TTC CTG CTG CTA 
      5’seqFLAGeuk 
 
          unique 
_______          _________2nd FLAG tag _________     Not I   ___ 
 D   K (no NheI) D   Y   K   D   D   D   D   K   A   A   A   D 
GAC AAG GCT AGT GAC TAC AAG GAC GAC GAC GAT AAA GCG GCC GCT GAT  
CTG TTC CGA TCA CTG ATG TTC CTG CTG CTG CTA TTT CGC CGG CGA CTA 
  5’FLAG3seq 
 
 
_____3rd FLAG tag___________ Nhe I   Bgl II Xba I Hpa I   Eco RI       
 Y   K   D   D   D   D   K   A   S   R   S   R   V   N   S   N    
TAC AAG GAC GAC GAC GAT AAA GCT AGC AGA TCT AGA GTT AAC TCG AAT  
ATG TTC CTG CTG CTG CTA TTT CGA TCG TCT AGA TCT CAA TTG AGC TTA 
 
 
    Apa I 
 S   E   G   P   I    pRC/CMV 
TCT GAG GGC CCT ATT CTATAGTGTCACCTAAA 
AGA TCT CCG GGA TAA GATATCACAGTGGATTT 
 
Figure 3.2: Multiple cloning site of pFLAG3 vector showing the location of the FLAG 
epitopes. 
 
3.1.4.1.2 pMyc3 vector 
The pMyc3 vector was generated by modifying the pFLAG3 vector. It encodes three 
copies of the Myc-epitope (EQKLISEEDL) upstream of the multiple cloning site (MCS). The 
fragment flanked by the HindIII and the NheI restriction sites encoding the three copies of 
FLAG-epitope (Figure 3.2) was replaced by the following sequence in the new pMyc3 vector: 5ʹ′-
AA GCT TCC ACC ATG GAA CAG AAA CTG ATC AGC GAA GAG GAT CTG CTG AGC 
GAG CAG AAA CTG ATC AGC GAG GAA GAA CTG GCC GCG GAA CAG AAA CTG 
ATC AGC GAA GAG GAT CTG GCT AGC-3ʹ′ (Chamberlain et al., 2004). This FLAG-
modified vector was then digested with EcoRI and ApaI. A pair of oligonucleotides (5ʹ′-AAT 
TCG CGG CCG CGG GCC-3’ and 5’-CGC GGC CGC G-3ʹ′) were ligated into the EcoRI-ApaI-
restriction enzyme digested FLAG-modified vector, so as to introduce a unique NotI restriction 
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site within the multiple cloning site and between EcoRI and ApaI restriction sites (Figure 3.3) 
(Chamberlain et al., 2004).  The pMyc3 vector was used to express p110α fusion protein with the 
triple Myc-epitope tag at the N-terminus of the protein. 
 
upstream coding sequences and MCS of pMyc3 vector: 
 
 
           .           1st Myc tag  
           Hind III Kozak  M+1 E   Q   K   L   I   S                                      
T7 of pRC/CMV GGGAGACCGGAAAGCTT CCACC ATG GAA CAG AAA CTG ATC AGC  
(Invitrogen) CCCTCTGGCCTTTCGAA GGTGG TAC CTT GTC TTT GAC TAG TCG 
      
              
Unique 
              .         .            2nd Myc tag             .  SacII  
 E  E   D   L   L   S   E   Q   K   L   I   S   E   E   E   L   A 
GAA GAG GAT CTG CTG AGC GAG CAG AAA CTG ATC AGC GAG GAA GAA CTG GCC 
CTT CTC CTA GAC GAC TCG CAC GTC TTT GAC TAG TCG CTC CTT CTT GAC CGG 
   
 
    .            3RD Myc tag              .  Nhe I   Bgl II 
A   E   Q   K   L   I   S   E   E   D   L   A   S   R   S   R   V 
GCG GAA CAG AAA CTG ATC AGC GAA GAG GAT CTG GCT AGC AGA TCT AGA GTT  
CGC CTT GTC TTT GAC TAG TCG CTT CTC CTA GAC CGA TCG TCT AGA TCT CAA 
 
   Unique 
   EcoRI     Not I  
 N   S   N   S   R  P   R   A   L   F   pRC/CMV 
AAC TCG AAT TCG CGG CCG CGG GCC CTA TTC TATAGTGTCACCTAAA 
TTG AGC TTA AGC GCC GGC GCC CGG GAT AAG ATATCACAGTGGATTT 
 
Figure 3.3: Multiple cloning site of pMyc3 vector showing the location of the Myc epitopes. 
 
3.1.4.2 Plasmids 
Table 3.1 gives a summary of plasmids used for different investigations. 
 
3.1.4.2.1 pFLAG3-p85 wild type and mutants 
In order to generate plasmids encoding wild type p85, cDNA encoding full-length wild 
type p85 was subcloned into BglII and EcoRI sites of the MCS of the pFLAG3 vector 
(Chamberlain et al., 2004). Plasmids encoding pFLAG3-p85R274A, pFLAG3-p85Δ110 and 
pFLAG3-p85ΔR were generated by Quikchange mutagenesis method (Stratagene) (Chamberlain 
et al., 2004).  
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Table 3.1: List of Plasmids used in this thesis. 
Protein Species Amino Acids Vector 
backbone 
Expression 
system 
Selection 
p85  Bovine 1 – 724, full-length pFLAG3 Mammalian Geneticin 
p85R274A Bovine 1 – 724 (R274 mutated to 
A) 
pFLAG3 Mammalian Geneticin 
p85Δ110 Bovine 1 – 477 & 514 – 724 
(deletion of amino acids 
478-513, prevents p85 
from binding to p110) 
pFLAG3 Mammalian Geneticin 
p85Δ110+R274A Bovine 1 – 477 & 514 – 724 
(deletion of amino acids 
478-513 plus R274 
mutated to A) 
pFLAG3 Mammalian Geneticin 
p85ΔR Bovine 1 – 724 (2 amino acid 
substitutions: R358 to A 
and R649 to A, prevents 
binding to tyrosine 
phosphorylated PDGFR) 
pFLAG3 Mammalian Geneticin 
p85ΔR+R274A Bovine 1 – 724 (3 amino acid 
substitutions of R to A, at 
positions 358, 649 and 
274) 
pFLAG3 Mammalian Geneticin 
p110α Mouse  1 – 1068, full-length pMyc3 Mammalian Geneticin 
 
 
3.1.4.2.2 pMyc3-p110α 
cDNA encoding full-length wild type mouse p110α was amplified by PCR from the 
pCMV-p110myc plasmid (a gift from Dr. L.T. Williams, University of California San Francisco, 
CA). The pCMV-p110myc plasmid was digested with BamHI and NotI. The pMyc3 vector was 
digested with BglII and NotI. The p110α insert DNA was subcloned into the BglII-NotI-digested 
pMyc3 vector to generate a plasmid encoding pMyc3-p110α (Chamberlain et al., 2004). 
Restriction enzyme digestion with BamHI or BglII results in sequences that have compatible 
overhanging cleavage sites that can be ligated. However, once ligated both the BamHI and BglII 
restriction recognition sites are lost. 
 
3.1.5 Primers 
All primers were ordered from Invitrogen, Gibco BRL, or the University of Alberta. 
Table 3.2 lists the primers used for site-directed mutagenesis and sequencing reactions. 
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Table 3.2: List of Primers used for Site-directed Mutagenesis and Sequencing 
Primer Name Sequence (5' to 3' notation) 
Mutagenesis Primers 
5' p85R274A GCC CTC TGC TTT TCG CAT TCC CAG CAG C 
3' p85R274A GCT GCT GGG AAT GCG AAA AGC AGA GGG C 
Sequencing Primers 
3' 85 SEQ 157 (DAN31) GTA ACT CGG CTG GGT 
3' 85 SEQ 226 GGG CGA CCT AAT GAG 
3' 85 SEQ 352 CAA AAA GGT CCC GTC 
3' 85 SEQ 549 CCG CCT GCT TCT TCA 
3' 85 SEQ 666 (DAN27) GCA GTG CTT GAC CTC 
5' p85R649A (DAN26) TTC TTG TCG CGG AAA GC 
SEQ 3' HA3 CAG CGA GCT CTA GCA 
 
 
3.1.6 Antibodies 
Antibodies were purchased from Santa Cruz Biotechnology (Dallas, Texas, USA), 
Sigma-Aldrich (St. Louis, Missouri, USA), Cell Signalling Technology (Danvers, 
Massachusetts, USA), EMD Millipore (Billerica, Massachusetts, USA), Ambion® Life 
Technologies Invitrogen (Carlsbad, California, USA), or BD Biosciences (Franklin Lakes, New 
Jersey, USA). Antibodies used for immunoprecipitation and Western blotting experiments are 
described in Table 3.3.  
 
3.2 Methods 
3.2.1 Generation of pFLAG3-p85∆110+R274A and pFLAG3-p85∆R+R274A encoding 
plasmids 
3.2.1.1 Site-directed mutagenesis  
Plasmids encoding pFLAG3-p85∆110+R274A (deletion of amino acids 478-513 plus 
amino acid substitution of alanine for arginine at position 274) or pFLAG3-p85∆R+R274A 
(three amino acid substitutions of alanine for arginine, at positions 358, 649 and 274) were 
generated using the Quikchange Site-Directed Mutagenesis method by Stratagene. The 
mutagenic PCR reaction mixture contained 1x Pfu buffer with MgSO4, template DNA (30 ng for 
pFLAG3-p85∆110 and 60 ng for pFLAG3-p85∆R), 125 ng of each sense/antisense mutagenic 
primer (5' p85R274A and 3' p85R274A), 0.05 mM dNTPs and 2.5 units of Pfu DNA polymerase  
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Table 3.3: List of Antibodies and the Dilution or Concentration used for Western Blotting (WB) 
and Immunoprecipitation (IP) Analysis. 
Antibody Company, Catalogue Number 
Host 
Species 
Dilution or 
Concentration 
used 
Application Figure (s) 
Akt Cell Signalling Technology, 9272 Rabbit 1:500 WB 4.8, 4.20 
Phospho-Akt 
(Ser473) (pAkt) 
Cell Signalling 
Technology, 9271 Rabbit 1:500 WB 4.8, 4.20 
Erk1 (MAPK) BD Biosciences, 610030 Mouse 1:500 WB 4.7, 4.19 
Phospho-p44/42 
MAPK (Erk1/2) 
(Thr202/Tyr204) 
(pMAPK) 
 
Cell Signalling 
Technology, 9101 
Rabbit 1:500 WB 4.7, 4.19 
FLAG-M2 Sigma-Aldrich, F3165 Mouse 
4.9 µg/mL WB 
4.2, 4.3, 
4.4, 4.5, 
4.14, 4.15, 
4.16, 4.17  
4 µg IP 4.2 
GAPDH Ambion, AM4300 Mouse 0.5 µg/mL WB 
4.3, 4.4, 
4.6, 4.16, 
4.18  
c-Myc (A-14) 
Santa Cruz 
Biotechnology, sc-
789 
Rabbit 1 µg/mL WB 4.2 
Normal mouse 
IgG-AC 
Santa Cruz 
Biotechnology, sc-
2343 
Mouse 4, 5 or 10 µg IP 4.2 
Normal rabbit 
IgG-AC 
Santa Cruz 
Biotechnology, sc-
2345 
Rabbit 4, 5 or 10 µg IP 4.3 
p85 (BH) 
Anderson, affinity 
purified (amino 
acids: 78-332) 
Rabbit 1 µg/mL WB 4.4 
PDGFR-β (958) 
Santa Cruz 
Biotechnology, 
sc432 
Rabbit 1 µg/mL WB 
4.3, 4.6, 
4.15, 4.16, 
4.18 
5 µg IP 4.3, 4.15 
Phospho-Tyr 
(pY20) 
Santa Cruz 
Biotechnology, sc-
508 
Mouse 2 µg/mL WB 4.6, 4.18 
PI3K p85 N-SH2 EMD Millipore, 05-
217 
Mouse 1:100 WB 4.3, 4.15, 
4.16 
PI3K p85 N-SH3 EMD Millipore, 05-212 Mouse 1:100  WB 4.4 
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Table 3.4: List of Secondary Antibodies and the Concentration used for Western Blotting (WB) 
Analysis. 
Antibody Company, Catalogue Number Host Species Concentration used 
IRDye 680 Goat anti-
Mouse IgG [now IRDye® 
680RD Goat anti-Mouse 
IgG, 926-68070] 
LI-COR, 926-32220 Goat 0.067 or 0.2 or 0.5 ng/mL 
IRDye 680 Goat anti-
Rabbit IgG [now IRDye® 
680RD Goat anti-Rabbit 
IgG, 926-68071] 
LI-COR, 926-32221 Goat 0.067 or 0.2 or 0.5 ng/mL 
IRDye 800CW Goat anti-
Mouse IgG LI-COR, 926-32210 Goat 0.067 or 0.2 or 0.5 ng/mL 
IRDye 800CW Goat anti-
Rabbit IgG LI-COR, 926-32211 Goat 0.067 or 0.2 or 0.5 ng/mL 
 
 
(Thermo Scientific/Fermentas, EP0502) in a 50 µL reaction volume. The thermocycler (Applied 
Biosystems, 2720 or Veriti Thermal Cycler) was programmed as follows: (i) initial melting:  95 
ºC for 1 minute, (ii) 16 cycles of 95 ºC for 30 seconds (melting), 55 ºC for 1 minute (annealing) 
and 68 ºC for 16 minutes (extension), with (iii) a final extension at 68 ºC for 7 minutes. The 
amplification reaction products were digested with 20 units of DpnI (New England Biolabs, 
R0176) for 1 hour at 37 ºC. The entire DpnI digested mutagenesis amplification reaction was 
transformed into TOP10 chemically competent E. coli as described in Section 3.2.1.3.  
 
3.2.1.2 Preparation of competent cells 
Five mL of Luria-Bertani Broth Miller (LB, Novagen, 71753-6) [1% (w/v) bacto-
tryptone, 0.5% (w/v) bacto-yeast extract and 1% (w/v) sodium chloride (NaCl) pH 7.0 per litre] 
was inoculated with TOP10 chemically competent E. coli cells from a glycerol stock. Cells were 
incubated overnight at 37 °C with agitation. The entire 5 mL overnight culture was used to 
inoculate 100 mL of LB and was incubated at 37 °C with agitation until an optical density (O.D.) 
at 550 nm of 0.4 was attained. The culture was transferred to pre-chilled sterile 50 mL falcon 
centrifuge tubes and incubated on ice for 15 minutes. Cells were pelleted at 805×g for 15 
minutes at 4 °C. The supernatant was removed and the bacterial cell pellets were resuspended in 
30 mL of ice cold RF1 buffer [100 mM RbCl, 50 mM MnCl2, 30 mM KOAc pH 7.5, 10 mM 
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CaCl2, 15% (w/v) glycerol]. The cell suspension was incubated for 15 minutes on ice. Cells were 
pelleted at 805×g for 15 minutes at 4 °C. The supernatant was discarded and the pellet was 
resuspended in 7.2 mL of ice cold RF2 buffer [10 mM MOPS pH 6.8, 10 mM RbCl, 75 mM 
CaCl2, 15% (w/v) glycerol]. Cells were incubated on ice for 15 minutes. Cells were distributed 
into 200 µL aliquots, flash frozen in liquid nitrogen and stored at -80 °C. 
 
3.2.1.3 Transformation of competent cells with DNA 
After site-directed mutagenesis, TOP10 chemically competent E. coli cells (described in 
Section 3.2.1.2) were transformed with DNA. The reaction mixture was transferred to 200 µL of 
competent TOP10 cells and incubated on ice for 30 minutes. Cells were heat shocked at 42 ºC 
for 90 seconds and then placed on ice for 5 minutes after which 800 µL of liquid LB was added 
to each tube. Cells were incubated at 37 ºC for 30 minutes to allow for expression of the 
ampicillin resistant gene product. Cells were pelleted at 2,320×g and 4 °C for 1 minute. The 
supernatant was discarded and the cells were resuspended in 50 µL of LB. The cell suspension 
was spread on the surface of LB-agar plates [1% (w/v) bacto-tryptone, 0.5% (w/v) bacto-yeast 
extract and 1% (w/v) sodium chloride (NaCl) pH 7.0, 1.5% (w/v) agar (Sigma-Aldrich, A7002) 
per litre] supplemented with 100 µg/mL ampicillin (LBA agar plates) and incubated at 37 °C 
overnight. Ten distinct colonies were picked into 5 mL of LB supplemented with 100 µg/mL 
ampicillin and grown overnight at 37 °C with shaking (250 rpm). Plasmid DNA was isolated 
with a QIAprep Spin Miniprep Kit (Qiagen, 27106) according to the manufacturer’s instructions. 
Samples were sequenced by the DNA Technologies Laboratory, National Research Council of 
Canada Plant Biotechnology Institute, University of Saskatchewan to confirm the mutation and 
verify the integrity of the entire inserted cDNA sequence. 
 
3.2.2 Protein Analysis 
3.2.2.1 Cell Lysate Preparation 
Cells are harvested in either sodium dodecyl sulfate (SDS) sample buffer  [62.5 mM Tris-
HCl pH 6.8, 10% (v/v) Glycerol, 5% (v/v) β–mercaptoethanol, 2.3% (w/v) SDS, 0.1% (w/v) 
bromophenol blue] or phospholipase C (PLC) lysis buffer [50 mM HEPES pH 7.5, 150 mM 
NaCl, 10% (v/v) Glycerol, 1% (v/v) Triton X-100, 1.5 mM MgCl2, 1 mM EGTA, 10 mM NaPPi, 
100 mM NaF] depending on the study. SDS sample buffer was used when the sole purpose of the 
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lysate was for SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and Western blot analysis. 
Cell lysates used for immunoprecipitation experiments were prepared with PLC lysis buffer plus 
protease and phosphatase inhibitors [10 µg/mL aprotinin, 10 µg/mL leupeptin, 1 mM AESBF, 1 
mM sodium orthovanadate (Na3VO4)].   
For lysates prepared with SDS sample buffer, cells were washed with cold phosphate 
buffered saline (PBS) and SDS sample buffer heated to 100 ºC was added directly to the tissue 
culture dish. Cells were scraped off the dish and collected into a tube. The cell lysates were 
sonicated for 10 to 20 seconds on the output setting of 1.5 with a Sonifier (Branson Sonifier 450 
UltraSonic Processor Homogenizer Disruptor Sonicator) in order to shear the DNA (reduces the 
viscosity due to genomic DNA). Cell lysates were sometimes passed through a 25 G needle 
several times in order to shear the DNA. Lysates were then boiled at 100 ºC for 5 minutes. The 
protein concentration was determined using a Lowry assay (see below), and samples were loaded 
on an SDS-PAGE gel immediately or stored at -80 ºC for further analysis.  
In order to harvest cells for immunoprecipitation experiments, tissue culture dishes were 
placed on ice, cells were washed with cold PBS and then lysed with cold PLC lysis buffer plus 
protease and phosphatase inhibitors. Cells were scraped off the dish and collected into a tube. 
Cell lysates were centrifuged at 16,100×g for 10 minutes at 4 ºC to pellet the insoluble cellular 
material. The supernatant was transferred to another tube and these pre-cleared lysates were used 
for immunoprecipitation experiments immediately or stored at -80 ºC. A protein concentration 
determination was performed by Lowry protein assay using the Total Protein Kit, Micro Lowry, 
Peterson’s Modification (Sigma-Aldrich, TP0300) according to the manufacturer’s instructions 
before cell lysates were used for different assays. 
 
3.2.2.2 SDS-polyacrylamide gel electrophoresis (SDS-PAGE) 
Lysates were prepared as described in Section 3.2.2.1 and proteins were resolved by 
SDS-PAGE for visualization by Western blot analysis. This discontinuous gel system consists of 
a lower resolving (or separating gel) and an upper stacking gel sandwiched between two glass 
plates separated by 1 mm or 1.5 mm using precision spacers. SDS-PAGE experiments were 
performed using ether the Mini-PROTEAN II Electrophoresis Cell or the Mini-PROTEAN Tetra 
Cell electrophoresis system (Bio-Rad). Depending on the molecular weight of the proteins to be 
resolved, the resolving gels contained between 7.5% to 12% acrylamide solution [29.2:0.8 
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acrylamide: bisacrylamide], 375 mM Tris-HCl pH 8.8 and 0.1% (w/v) SDS. The lower 
percentage of acrylamide allowed for resolution of larger molecular weight proteins and vice 
versa. Polymerization was initiated by the addition of 0.16% (w/v) ammonium persulfate (APS, 
Sigma-Aldrich, 248614) and 0.1% (v/v) N,N,N’,N’-Tetra-methylethylenediamine (TEMED, 
Sigma-Aldrich, T22500). The stacking gel contained 4.5% acrylamide solution, 125 mM Tris-
HCl pH 6.8 and 0.1% (w/v) SDS. Polymerization of the stacking gel was initiated by the addition 
of 0.24% (w/v) APS and 0.2% (v/v) TEMED. Lysates containing equal amounts of total protein 
(determined by the Lowry assay above) were prepared in SDS sample buffer and the protein 
content denatured by heating to 100 °C for 5 minutes. Samples and prestained molecular weight 
markers (Fermentas, SM0671 or Fisher Scientific, BP3603-500) were loaded onto the gel and 
proteins were resolved at a constant voltage of 180 V in running buffer [25 mM Tris, 192 mM 
glycine, 0.1% (w/v) SDS] until the bromophenol blue tracking dye ran off the bottom of the gel 
(Laemmli, 1970). The resolved proteins were visualized by Western blot analysis as described in 
Section 3.2.2.3. The size of each individual resolved proteins was compared to prestained 
molecular weight markers.  
 
3.2.2.3 Western blot analysis   
For Western blot analysis, proteins resolved by SDS-PAGE were transferred to a 
nitrocellulose membrane using a Panther semi-dry Electroblotter Owl Separation System (VWR, 
27372-374 or Fisher Scientific, FB-SDB-2020) or a Trans-Blot Turbo Transfer System (Bio-
Rad, 170-4155). Following protein separation by electrophoresis (Section 3.2.2.2), the SDS-
PAGE gel was equilibrated in transfer buffer [48 mM Tris, 39 mM glycine, 0.038% (w/v) SDS, 
20% (v/v) methanol] for 10 minutes. Components of the transfer system were prepared as 
follows for each gel: six pieces of 3MM filter paper (Whatman, 3030 700) were soaked in 
transfer buffer and one piece of nitrocellulose membrane (Whatman, 10401196) was rehydrated 
in distilled water. In order to transfer the proteins from the gel to the nitrocellulose membrane, a 
blotting sandwich consisting of three pieces of 3MM filter paper, the SDS-PAGE gel, the 
nitrocellulose membrane and three more pieces of 3MM filter paper was assembled and placed in 
the transfer apparatus with the membrane side closer to the anode ⊕. Air bubbles were removed 
from the layers by rolling a flat tube over the stack. Protein transfer was facilitated by applying a 
constant current of 400 mA (15 minutes per gel being transferred) to the Panther semi-dry 
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Electroblotter Owl Separation System or by applying a constant current of 1 A and a voltage of 
25 V to the Trans-Blot Turbo Transfer System for 15 – 30 minutes. 
After the transfer step, the membrane was incubated in blocking buffer. Fat-free milk is 
usually used as a blocking agent; however, certain antibodies can bind to the casein in milk-
based blocking buffers. In those instances, BSA-based blocking buffers are used. Therefore, two 
different blocking buffers were used depending on the antibody: (i) 5% (w/v) Carnation fat-free 
instant skim milk powder in PBS [137 mM NaCl, 2.7 mM KCl, 4.3 mM Na2HPO4(7H2O) or 
Na2HPO4, 1.4 mM KH2PO4, pH 7.3], or (ii) 1% (w/v) BSA fraction V (Sigma-Aldrich, A9418) 
in PBS. Membranes were blocked for 1 hour at room temperature with gentle rocking or 
overnight at 4 °C. The membrane was then incubated with primary antibody made up in blocking 
buffer, plus 0.05% (v/v) Tween-20, overnight at 4 °C with nutation (see Table 3.3 for primary 
antibodies and their working concentrations). Following primary antibody incubation, the 
membrane was washed three times in PBST [PBS plus 0.05% (v/v) Tween-20] for 10 minutes 
per wash. The membrane was then incubated with a secondary antibody conjugated to an 
infrared-labelled dye (IRDye680 or IRDye800 for LI-COR Odyssey infrared imaging) made up 
in 5% (w/v) Carnation fat free instant skim milk powder in PBST for 1 hour at room temperature 
with nutation (see Table 3.4 for secondary antibodies and their working concentrations) and 
washed as described above.  
For detection of proteins using infrared-labeled dyes, the membrane was washed three 
times in PBST and twice in PBS to remove Tween-20 (the presence of Tween-20 on the infrared 
scanner increases the amount of background on the membrane). The membrane was scanned 
using the Mandel LI-COR Odyssey Classic Infrared Imager (LI-COR, ODY-1079) and analyzed 
with the Odyssey V3.0 software.  
It should be noted that, for Western blot analysis of samples that were compared with 
each other, multiple gels containing the samples were resolved together, transferred, probed and 
scanned side-by-side to ensure that they were treated as similar as possible. 
 
3.2.3 Cell Culture Techniques 
3.2.3.1 Mammalian Cell lines 
NIH 3T3 cells were maintained in Dulbecco’s Modified Eagle Medium (DMEM, Gibco, 
12100-061) supplemented with 10% fetal bovine serum (FBS, Gibco, 16250-078) and grown at 
	   57	  
37 °C in a 5% CO2 humidified air environment. NIH 3T3 cells stably transfected with pFLAG3 
vector as well as pFLAG3 plasmids containing p85wt, p85R274A, p85∆110, p85∆110+R274A, 
p85∆R or p85∆R+R274A cDNA were grown in selection medium containing DMEM 
supplemented with 10% FBS and 400 µg/mL Geneticin (G418 Sulfate, Gibco 11811-031) at 37 
°C in a 5% CO2 humidified air environment. Geneticin disrupts protein synthesis by inhibiting 
the elongation step (Bar-Nun et al., 1983). COS-1 cells were transiently transfected with 
pFLAG3 plasmids containing p85wt, p85R274A, p85∆110, p85∆110+R274A, p85∆R or 
p85∆R+R274A cDNA and/or pMyc3-p110 and grown in DMEM supplemented with 10% FBS 
at 37 °C in a 5% CO2 humidified air environment. Cells were fed every 3 to 4 days. Cells were 
passaged at 80 to 90% confluency by detaching with 0.05% Trypsin-EDTA (Gibco, 15400-054). 
 
3.2.3.2 Transient Transfection 
COS-1 cells as well as NIH 3T3 cells were transiently transfected with the empty 
pFLAG3 plasmid vector or pFLAG3 plasmids containing p85wt, p85R274A (substitution 
mutation that abolishes p85 RabGAP activity), p85∆110 (deletion mutation that prevents p85 
from binding to p110), p85∆110+R274A (deletion and substitution mutations that prevents p85 
from binding to p110 and abolishes p85 RabGAP activity), p85∆R (substitution mutations that 
prevent binding to tyrosine phosphorylated PDGFR) or p85∆R+R274A (substitution mutations 
that prevent binding to tyrosine phosphorylated PDGFR and abolishes p85 RabGAP activity) 
cDNA (Chamberlain et al., 2004; King et al., 2000). One million (1 x 106) cells were seeded 
onto a 10 cm tissue culture dish and cultured at 37 °C in a 5% CO2 humidified air environment 
for 24 hours. For each 10 cm dish to be transfected the following solutions were prepared: 
solution A [6 µg plasmid DNA, 600 µL Opti-MEM reduced serum medium (Gibco, 31985-070)] 
and solution B [600 µL Opti-MEM reduced serum medium, 18 µL Lipofectamine Transfection 
Reagent (Invitrogen, 18324-020)]. Solutions A and B were combined and incubated for 15 
minutes at room temperature after which 4.8 mL serum-free DMEM was added to the mixture.  
The transfection mixture was added to cells that had been previously washed with serum-free 
DMEM. The cells were incubated for 5 hours at 37 °C. Six (6) mL of DMEM supplemented with 
20% FBS was added to the transfection medium and the cells were incubated overnight at 37 °C. 
The medium was then changed to DMEM supplemented with 10% FBS and cells were left to 
grow for 24 to 72 hours. Cells were used for growth factor stimulation studies (Section 3.2.3.4), 
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adhesion assay (Section 3.2.3.8), or harvested for immunoprecipitation experiments (Section 
3.2.3.5) or Western blot analysis (Section 3.2.2.3). 
 
3.2.3.3 Stable transfection 
Three hundred and fifty thousand (3.5 x 105) NIH 3T3 cells were seeded onto a 6 cm 
tissue culture dish and cultured at 37 °C for 24 hours. Plasmids encoding the pFLAG3 vector or 
pFLAG3-p85∆110+R274A or pFLAG3-p85∆R+R274A were transfected into NIH 3T3 cells. 
For each 6 cm dish to be transfected the following solutions were prepared: solution A [0.6 µg 
plasmid DNA, 300 µL Opti-MEM reduced serum medium] and solution B [300 µL Opti-MEM 
reduced serum medium, 10 µL Lipofectamine Transfection Reagent]. Solutions A and B were 
combined and incubated for 15 minutes at room temperature after which 2.4 mL serum-free 
DMEM was added to the mixture.  The transfection mixture was added to cells that had been 
previously washed with serum-free DMEM. The cells were incubated for 5 hours at 37 °C. Three 
(3) mL of DMEM supplemented with 20% FBS was added to the transfection medium and the 
cells were incubated overnight at 37 °C. The medium was then changed to DMEM supplemented 
with 10% FBS and cells were left to grow until 90% confluency was observed.  
Cells were trypsinized and resuspended in selection medium containing DMEM 
supplemented with 10% FBS and 400 µg/mL Geneticin. Cells were seeded onto 10 × 10 cm 
tissue culture dishes per 6 cm dish transfected and cultured in selection medium for up to 10 days 
until distinct colonies of drug resistant cells were seen. Twenty four (24) distinct colonies were 
picked from the 10 cm tissue culture dishes and transferred to 2 × 12-well tissue culture dishes. 
The rest of the colonies left on the 10 × 10 cm tissue culture dishes were pooled together, 
cultured on 10 cm dishes and referred to as the mixed population. Cells were cultured in 
selection medium until they were about 80% confluent. Each clonal isolate was trypsinized, 
resuspended in selection medium and seeded onto a 6-well tissue culture dish (to be lysed and 
analyzed for protein expression using a Western blot analysis) and a 12-well tissue culture dish 
(maintained as a stock plate).  
Cells in the 6-well dishes were cultured in selection medium until they were about 90% 
confluent. Cells were lysed in sodium dodecyl sulfate (SDS) sample buffer as described in 
Section 3.2.2.1. Protein concentration was determined using the Total Protein Kit, Micro Lowry, 
Peterson’s Modification (Sigma-Aldrich, TP0300) according to the manufacturer’s instructions. 
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Proteins were resolved by SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and Western 
blot analysis as described in Section 3.2.2.3.  
Clonal isolates expressing different amounts of the overexpressed protein were 
transferred from the 12-well stock dish onto a 6 cm dish and maintained in selection medium 
until they were about 90% confluent. Cells were then trypsinized, resuspended in selection 
medium and seeded onto 2 × 10 cm tissue culture dishes. Cells were further expanded, frozen 
down as stocks and used for the desired experiments. 
 
3.2.3.4 Growth Factor Stimulation 
In order to measure the rate of degradation of the PDGFR and activation of downstream 
signalling pathways events in response to PDGF treatment, a time-course experiment involving 
growth factor stimulation was performed using NIH 3T3 cells either transiently expressing p85 
wild type or p85 mutants or NIH 3T3 cells stably expressing p85 wild type or p85 mutants. Cells 
were grown as described in Section 3.2.3.1 to 80% confluency. The cells were serum deprived 
for 12 to 18 hours in DMEM containing 0.5% FBS. The cells were then treated with 50 ng/mL of 
rhPDGF-BB (R&D Systems, 220-BB) for 0, 10, 30, 60, 120 or 240 minutes at 37 °C. Cells were 
harvested by placing tissue culture dishes on ice, washing with cold phosphate buffered saline 
(PBS) and lysing with SDS sample buffer or PLC lysis buffer as described in Section 3.2.2.1.  
 
3.2.3.5 Immunoprecipitation 
3.2.3.5.1 Anti-FLAG immunoprecipitation 
COS-1 cells were transiently co-transfected with plasmids expressing the different p85 
mutants and Myc-p110 as described in Section 3.2.3.2. Lysates were collected three days after 
transfection in cold PLC lysis buffer containing protease and phosphatase inhibitors. The protein 
concentrations of lysates were determined by the Lowry assay. An anti-FLAG 
immunoprecipitation was carried out using 125 µg of total cell protein. The volume of lysate 
equivalent to 125 µg of total protein was pre-cleared with 4 µg of normal mouse IgG-agarose 
conjugate (Santa Cruz Biotechnology, sc-2343) and 30 µL of a 50% slurry of protein G-agarose 
beads (Sigma-Aldrich, P7700) for 1 hour at 4 °C with nutation. This removed any proteins that 
interacted non-specifically with the mouse antibody. The agarose beads were pelleted at 
18,188×g and 4 °C for 10 minutes. The pre-cleared supernatant was transferred to a new tube 
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and the pre-clear step was repeated as before. The resulting pre-cleared supernatant was 
transferred to a new tube and proteins of interest were immunoprecipitated with 4 µg of anti-
FLAG M2 antibody (Sigma-Aldrich, F3165) and 30 µL of a 50% slurry of protein G-agarose 
beads. Another set of samples were incubated with 4 µg of normal mouse IgG-agarose conjugate 
and 30 µL of a 50% slurry of protein G-agarose beads. These samples served to demonstrate that 
any non-specific immunoprecipitation/interaction with antibody or agarose beads had been 
mitigated. All samples were incubated for 90 minutes at 4 °C with nutation. Beads were then 
pelleted at 2,320×g and 4 °C for 2 minutes. The supernatant was discarded and samples were 
washed in 1 mL HNTG buffer (20 mM HEPES pH 7.5, 150, mM NaCl, 0.1% Triton X-100, 10% 
glycerol and 1 mM Na3VO4) and centrifuged at 2320×g and 4 °C for 2 minutes. The washes and 
centrifugation were repeated three times to remove residual supernatant. The samples were either 
assayed for PI3K activity (Section 3.2.5.3) or used for Western blot analysis (Section 3.2.4.3). 
For Western blot analysis, the supernatant was completely removed from the beads and 20 µL of 
2× SDS sample buffer was added to the pelleted beads. The samples were boiled for 5 minutes 
(to denature and dissociate the proteins from the beads) and centrifuged at 18,188×g and 4 °C for 
1 minute (to pellet the dissociated agarose beads). The supernatant was loaded immediately on 
SDS-PAGE gels or stored at -20 °C for later analysis.  
 
3.2.3.5.2 Anti-PDGFR immunoprecipitation 
To determine whether p85 wild type or p85 mutants associate with the PDGFR and to 
measure the duration of any such association an anti-PDGFR immunoprecipitation was 
performed. NIH 3T3 cells stably expressing either p85 wild type or the individual p85 mutants 
were treated with growth factor (PDGF) for 0, 10, 30, 60, 120 or 240 minutes (Section 3.2.3.4) 
and lysed in PLC lysis buffer containing protease and phosphatase inhibitors. The protein 
concentrations of lysates were determined by the Lowry assay. An anti-PDGFR 
immunoprecipitation was carried out using 125 µg of protein. The volume of lysate equivalent to 
125 µg of total protein was pre-cleared with 5 µg of normal rabbit IgG-agarose conjugate (Santa 
Cruz Biotechnology, sc-2345) and 30 µL of a 50% slurry of protein G-Sepharose 4B Fast Flow 
beads (Sigma-Aldrich, P3296) for 30 minutes at 4 °C with nutation. The beads were pelleted at 
18,188×g and 4 °C for 10 minutes. The supernatant was transferred to a new tube and the pre-
clear step was repeated as before. The supernatant was transferred to a new tube and proteins 
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were immunoprecipitated with 5 µg of anti-PDGFR-β (958) antibody (Santa Cruz 
Biotechnology, sc-432) and 30 µL of a 50% slurry of protein G-Sepharose 4B Fast Flow beads. 
A parallel set of samples was incubated with 5 µg of normal rabbit IgG-agarose conjugate and 30 
µL of a 50% slurry of protein G-Sepharose 4B Fast Flow beads. These samples served as a 
control used to demonstrate specificity of the immunoprecipitation in the anti-PDFGR set of 
immunoprecipitated samples. All samples were incubated for 90 minutes at 4 °C with nutation. 
Beads were then pelleted at 2,320×g and 4 °C for 2 minutes. The supernatant was discarded and 
samples were washed in 1 mL HNTG buffer and centrifuged at 2,320×g and 4 °C for 2 minutes. 
The washes and centrifugation were repeated three times. The supernatant was completely 
removed from the beads and 20 µL of 2× SDS sample buffer was added. The samples were 
boiled for 5 minutes, centrifuged at 18,188×g (4 °C for 1 minute) and the supernatant loaded 
immediately on SDS-PAGE gels or stored at -20 °C until needed.  
 
3.2.3.5.3 Anti-Rab5-GTP IP 
To determine the levels of Rab5-GTP in NIH 3T3 cells stably expressing p85 wild type 
or the individual p85 mutants, an immunoprecipitation experiment was carried out using 
activation-specific Rab5 antibodies based on the manufacturer’s protocol. The Rab5 activation 
assay from New East Biosciences required a preliminary optimization. For this, NIH 3T3 cells 
were treated with PDGF (Section 3.2.6.4) for 2 or 30 minutes and lysed in Rab5 activation assay 
Assay/Lysis buffer [50 mM Tris-HCl pH 8, 150 mM NaCl, 10 mM MgCl2, 1 mM EDTA, 1% 
Triton X-100]. The lysates collected were used immediately for the assay since the activation of 
Rab5 is a transient event. Either 1 mg total protein of NIH 3T3 cell lysate, or 1 or 5 µg of 
purified Rab5 wild type was used for the assay. Samples equivalent to the appropriate amount of 
protein were dispensed into tubes and Assay/Lysis buffer was added to a total volume of 500 µL.  
The negative and positive controls were set up as follows: the negative control tube had GDP 
(Sigma-Aldrich, G-7127) added to it while the positive control tube contained GTPγS (Sigma-
Aldrich, G-8634).  
In order to strip Rab5 of nucleotides, EDTA was added to the negative and positive 
control samples to a final concentration of 20 mM. The nucleotides were loaded onto Rab5 by 
adding GDP to the negative control tube to a final concentration of 1 mM and GTPγS to the 
positive control tube to a final concentration of 100 µM. Samples were incubated at 30 °C for 30 
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minutes with agitation. The nucleotide loading reaction was terminated by placing tubes on ice 
and adding MgCl2 to a final concentration of 60 mM. From here on, the control samples as well 
as the lysates and purified proteins were subjected to the same procedure. The volume of the 
samples was adjusted to 1 mL with Assay/Lysis buffer. One (1) µg of anti-Active Rab5 mouse 
monoclonal antibody (New East Biosciences, 26911) and 20 µL of a 50% slurry of protein G-
agarose beads was added to all samples. Samples were incubated at 4 °C for 1 hour with 
nutation. Beads were pelleted at 2,320×g and 4 °C for 2 minutes. The supernatant was discarded 
and the beads were washed three times with 1 mL of Assay/Lysis buffer. The supernatant was 
completely removed from the beads and 20 µL of 2× SDS sample buffer was added. The samples 
were boiled for 5 minutes, centrifuged at 18,188×g (4 °C for 1 minute) and the supernatant 
loaded immediately on SDS-PAGE gels or stored at -20 °C. It can be observed from the 
optimization results depicted in Figure 3.4 that the anti-Active Rab5 antibody that was supposed 
to specifically immunoprecipitate Rab5-GTP is also immunoprecipitating GDP loaded Rab5. 
Therefore, the Rab5 activation assay from New East Biosciences could not be used to measure 
the levels of Rab5-GTP in NIH 3T3 cells stably expressing p85 wild type or p85 mutants. 
 
3.2.3.6 Foci formation assay 
Proliferating normal cells are inhibited by contact with neighbouring cells, ensuring 
controlled regulation of cellular processes. However, transformed (oncogenic) cells are not 
inhibited and continue to grow, often piling on top of each other to form clumps or foci. To 
assess whether the stable expression of wild type p85 or the different p85 mutants could affect 
contact inhibition, a foci formation assay was carried out. The stable NIH 3T3 clones were 
seeded at a density of 1×105 cells/10 cm dish and maintained in normal medium for two weeks at 
37°C. The medium was changed every three to four days. After two weeks, the medium was 
removed and the cells were fixed in situ in –20 °C methanol for at least 1 hour and allowed to air 
dry. Cells were stained with Giemsa stain (Sigma-Aldrich, GS1L) overnight with gentle rocking. 
Giemsa stains the nuclei blue/violet by binding to DNA (Horobin, 2011). Cells were washed 
with water until the excess unbound stain was completely removed. Photographs of each entire 
plate were taken with a Nikon D3100 digital camera (Nikon). The results shown were obtained 
from three independent experiments (i.e. three separate series of plated cells) with each 
independent experiment being performed in duplicate. 
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Figure 3.4: Optimization of Rab5GTP antibody. A) Different amounts of purified Rab5 wild 
type (1 µg, 5 µg) were loaded with either GDP or GTP. One (1) µg of RabGTP antibody was 
used to immunoprecipitate Rab5 for 1 hour at 4 °C. Samples were resolved and immunoblotted 
with an anti-Rab5 antibody. B) Cells were serum starved (DMEM supplemented with 0.5% FBS) 
for 48 hours and then left unstimulated or stimulated with 50 ng/mL PDGF-BB for 0, 2 and 30 
minutes. One (1) µg of RabGTP antibody was used to immunoprecipitate Rab5 for 1 hour at 4 
°C. Samples were resolved and immunoblotted with an anti-Rab5 antibody. This figure is a 
representation of data obtained from four independent experiments.  
 
 
 
3.2.3.7 Colony formation in soft agar assay 
The soft agar colony formation assay is a method routinely used to monitor anchorage-
independent growth (a feature of transformed cells). To measure anchorage independent growth, 
a colony formation assay was performed in which cells stably expressing wild type p85 or the 
individual p85 mutants were grown in soft agar. Fifty thousand (5×104) cells/ 6 cm dish were 
cultured in a suspension of top agar (DMEM, 10% FBS, 3.75x MEM vitamin solution (Gibco 
Invitrogen, 11120-052), 0.36% agar (Sigma-Aldrich, A-7002)) above of a layer of bottom agar 
(DMEM, 10% FBS, 5x MEM vitamin solution, 0.61% agar). Cells were left to grow for a total of 
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20 days at 37°C. Cells were fed every four days by adding 2 mL of top agar to the plate. Colony 
formation was determined by the ability of individual cells to divide and ultimately form colony 
over time. Colonies often had uneven edges with smaller satellite colonies growing around their 
circumference. Photographs of colonies formed were captured either under phase contrast using 
a Nikon D3100 digital camera attached to a Nikon Eclipse TE300 microscope; or an Olympus 
IX51 microscope with the Infinity 3 software. Colonies that were greater than 17 µm in diameter, 
as measured using a grid and the Infinity 3 software, were considered true colonies and were 
counted. This value was determined by the size of colonies measured in control NIH 3T3 cells 
and cells expressing the FLAG empty vector plasmid. The results shown were obtained from two 
independent experiments with duplicate measurements per experiment.  
 
3.2.3.8 Adhesion assay 
Attachment to extracellular matrix is required for the survival and proliferation of normal 
cells. However, this can change in transformed cells and can often contribute to their ability to 
invade and grow in other tissues. Changes in adhesion often reflect changes in “anchorage 
independent” growth as tested in Section 3.2.3.7 above. An adhesion assay was performed to 
quantify the ability of cells to attach to different extracellular matrix proteins. Ninety-six (96)-
well tissue-culture-treated microtiter plates were either left uncoated or coated with 50 ng/mL of 
either Fibronectin, human plasma (Calbiochem, 341635) or Collagen I, rat tail (Gibco Invitrogen, 
A10483-01) for 1 hour at 37°C. Each well was washed twice with 100 µL washing buffer 
(DMEM, 10% FBS, 0.1% BSA fraction V (Sigma-Aldrich, A9418)) and then blocked with 100 
µL blocking buffer (DMEM, 10% FBS, 0.5% BSA fraction V) per well for 1 hour at 37°C. NIH 
3T3 cells stably expressing wild type p85 or different p85 mutants were detached with 0.05% 
trypsin/EDTA/PBS (Gibco Invitrogen, 15400-054) for as short a time as possible to prevent 
digestion of proteins involved in the cell adhesion process and resuspended in DMEM 
supplemented with 10% FBS.  
After the blocking step, wells were washed once with 100 µL washing buffer. Twenty 
thousand (2×104) cells were seeded per well and incubated for 30 minutes at 37°C to allow cells 
to attach. Wells were washed three times with 100 µL washing buffer to remove any cells that 
had not attached. Attached cells were then fixed with 100 µL 4% paraformaldehyde/PBS at room 
temperature for 15 minutes. Cells were washed once with 100 µL washing buffer and stained 
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with 100 µL crystal violet (5 mg/mL in 2% ethanol) (Sigma-Aldrich, C3886) for 10 minutes. 
Cells were washed 8 times with distilled water and the plate was left to air dry for at least 1 hour. 
Cells were lysed with 100 µL 2% SDS for 30 minutes with agitation to solubilize stain and mix 
evenly. Absorbance readings were measured at 550 nm on a microplate reader (Molecular 
Devices, SpectraMax M5 Multi-Mode Microplate Reader) as an indication of the cells’ ability to 
adhere. The absorbance varied as a function of the amount of stain (i.e. the number of cells) that 
had remained attached to the surfaces coated with fibronectin or collagen. The results shown 
were obtained from two independent experiments with triplicate measurements per experiment. 
 
3.2.3.9 Migration assay 
In order to study the cells’ ability to migrate towards a chemoattractant stimulus, a 
migration assay was carried out. The assay was based on a modification of the Boyden chamber, 
which consists of two chambers separated by a membrane with pores to allow for the passage of 
cells. The cells migrate from one chamber to another in response to a chemoattractant stimulus, 
e.g. along a concentration gradient (Boyden, 1962; Chen, 2005). The membrane was a 
transparent, polyethylene terephthalate (PET) membrane insert with a pore size of 8 µm (Falcon, 
353097) supported by a 24-well cell culture insert companion plate (Falcon, 353504).  
Cells were resuspended in DMEM supplemented with 0.1% FBS and 1×105 cells were 
added to the upper chamber of the membrane inserts. The lower compartment was filled with 1 
mL of either DMEM supplemented with 0.1% FBS as control or DMEM supplemented with 
10% FBS (the chemoattractant stimulus). Air bubbles were removed when the inserts were 
placed in the 24-well companion plate, as air bubbles at the interface between the upper and 
lower chambers can block the pores and prevent cell migration towards the chemoattractant 
stimulus. Cells were incubated at 37 °C for 24 hours. After cells had migrated for 24 hours, the 
media was removed from both chambers and the upper surface of the membrane was gently 
wiped with cotton swab dipped in serum-free DMEM to remove non-migratory cells. Cells that 
had migrated to the lower surface of the membrane were fixed in methanol at – 20 ºC overnight.  
The membrane inserts were washed once in distilled water and the cells were stained with 
hematoxylin for 10 minutes. The membrane inserts were then immersed in tap water for 10 
minutes. Membranes were dehydrated through increasing ethanol concentrations of 50%, 75%, 
90% and 100% for 1 minute each. The membrane inserts were air dried for 1 hour. The 
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membrane was removed from the housing by cutting it out with a No.11 surgical scalpel blade. 
The membrane was immediately mounted on a microscope slide using a dibutylphthalate xylene 
(DPX) synthetic resin mountant. The number of cells that migrated to the lower chamber was 
quantified by counting eight random fields of view using the Stereo Investigator software (MBF 
Bioscience) at a magnification of 20X. The results shown were obtained from duplicate wells 
(each with an individual NIH 3T3 clone). 
 
 
 
 
 
 
 
Figure 3.5: Picture of membrane insert with migrated cells viewed under an optical 
microscope. Cells that migrated to the lower chamber were fixed and stained. The Stereo 
Investigator software (MBF Bioscience) was used to quantify migrated cells. The photograph 
represents a typical field of view. Purple diamonds (a marker provided by the software) can be 
seen within the nuclei of cells that had fully migrated and identify those cells that were used for 
quantification. 
 
 
3.2.4 PI3K activity assay 
In order to determine whether the disruption of p85-p110 binding or p85-PDGFR 
interaction affected PI3K catalytic activity, a PI3K assay was carried out. COS-1 cells were 
transiently co-transfected with plasmids expressing the different FLAG-p85 mutants and Myc-
p110 as described in Section 3.2.3.2. Lysates were collected three days after transfection in PLC 
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lysis buffer. The protein concentrations of lysates were determined by the Lowry assay. An anti-
FLAG immunoprecipitation was carried out using 125 µg of protein as described in Section 
3.2.3.5.1, after which samples were assayed for PI3K activity using 2.5 µg phosphatidylinositol 
(PI) as a lipid substrate and 10 µCi [γ-32P]ATP (Perkin-Elmer, BLU502A). Reaction products 
were spotted onto a thin layer chromatography plate, developed in a chromatography chamber, 
and exposed to a phosphorimager screen as described below (Chamberlain et al., 2004). Anti-
FLAG immunoprecipitates were washed twice with each of the following: wash 1 (phosphate 
buffered saline), wash 2 (100 mM Tris-HCl pH 7.4, 50 mM LiCl), and wash 3 (10 mM Tris-HCl 
pH 7.4, 100 mM NaCl, 1 mM EDTA). Excess liquid was completely aspirated from the 
immunoprecipitate samples.  
Lipid micelles were generated by sonicating phosphatidylserine (PS) and 
phosphatidylinositol (PI) in PI3K assay buffer (25 mM HEPES pH 7.4, 10 mM MgCl2) in a 
sonicating water bath for 20 minutes. Each sample was incubated with lipid micelles (5 µg 
phosphatidylserine + 2.5 µg phosphatidylinositol) in PI3K assay buffer and 10 µCi [γ-32P]ATP in 
a total volume of 50 µL for 15 minutes at 20°C with gentle agitation. The reaction was 
terminated by acidification with HCl (to a final concentration of 1.7 M). Lipids were extracted 
with chloroform:methanol (1:1) and washed with methanol:1 N HCl (1:1). The reaction products 
were dried down, resuspended in chloroform:methanol (1:1) and spotted onto a 20 x 20 cm Silica 
Gel 60Å TLC plate (VWR Canlab-BDH, Whatman 4865-821). Samples were developed in 1-
propanol:water:acetic acid (17.4:7.9:1) in a chromatography chamber for four hours, dried and 
exposed to a phosphorimager screen. Results were visualized using a phosphorimager 
(Molecular Imager FX Pro Plus, Bio-Rad) and quantified using Quantity One software (Bio-
Rad), and the statistical analysis was performed using Prism software (GraphPad Software, Inc.). 
 
3.2.5 Statistical Analysis 
Data were analyzed and graphed with Prism software (GraphPad Software, Inc.). Unless 
otherwise noted, data was analyzed by Analysis of Variance (ANOVA) and significance was set 
at p < 0.05. Post hoc statistical analysis between experimental groups relied on Bonferroni’s 
multiple comparison test. Data are presented as mean ± standard error of the mean (SEM).  
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4.0 RESULTS 
4.1 Functional analysis of expression plasmids coding for p85 mutants tagged with a triple 
FLAG epitope 
In order to examine how altering the RabGAP activity of p85, and/or its ability to bind 
either the p110 subunit or PDGFR, affects receptor signalling and trafficking events as well as 
cell behaviour (e.g. cell proliferation and survival), plasmids encoding different mutant forms of 
p85α were generated. The plasmid constructs were based on the pFLAG3 vector. The empty 
pFLAG3 was used as the vector control. The various p85α cDNA include (Figure 4.1): 
• pFLAG3 (vector control) 
• pFLAG3-p85 wild type  
• pFLAG3-p85R274A (amino acid substitution of alanine for arginine, at position 274; 
lacks GAP activity towards Rab5 and Rab4 involved in receptor trafficking) 
• pFLAG3-p85∆110 (deletion of amino acids 478-513; prevents p85 from binding to p110)  
• pFLAG3-p85∆110+R274A (deletion of amino acids 478-513 plus amino acid 
substitution of alanine for arginine at position 274; lacks GAP activity and is unable to 
bind to p110)  
• pFLAG3-p85∆R (2 amino acid substitutions of alanine for arginine, at positions 358 and 
649; prevents binding to tyrosine phosphorylated PDGFR) 
• pFLAG3-p85∆R+R274A (3 amino acid substitutions of alanine for arginine, at positions 
358, 649 and 274; lacks GAP activity and is unable to bind to tyrosine phosphorylated 
PDGFR) 
The p85α cDNA highlighted in bold above were generated during this project. All others 
were previously generated. In addition to the p85 constructs a triple Myc-tagged p110α plasmid 
was previously generated. Due to a lack of good quality p110 antibodies, the Myc tag was 
necessary for monitoring the interactions between the p85 proteins and p110. All plasmids were 
verified by sequencing and tested for protein expression by transient co-transfections into COS-1 
cells and Western blot analysis using anti-Myc (exogenous Myc-p110) and anti-FLAG 
(exogenous FLAG-p85) antibodies (Figure 4.2A). COS-1 cells were used for these experiments 
since they are easy to transfect and are therefore an appropriate cell line to test if plasmids 
encoding proteins of interest are being expressed. Cells were co-transfected with plasmids  
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Figure 4.1: Schematic representation of the pFLAG3 plasmids expressing the different p85 
mutants. The different domains of p85 are represented by different shapes and colours and 
labelled accordingly. p85 binds to phosphotyrosine (pTyr) residues on the PDGFR via the SH2 
domains. The black stars indicate the site of the amino acid substitution of alanine (A) for 
arginine (R).  The two new plasmids that were generated for this project are indicated. The 
shorter purple iSH2 domain represents the truncated iSH2 domain (i.e. deletion of aa478-513). 
The remaining plasmids and stable cell lines expressing them were previously described 
(Chagpar et al., 2010; Chamberlain et al., 2004).  
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Figure 4.2: p85∆110 and p85∆110+R274A are unable to bind to p110 and when 
immunoprecipitated do not contain PI3K activity. A) COS-1 cells were transiently co-
transfected with the indicated plasmids. Lysates were collected 3 days after transfection in SDS 
sample buffer for whole cell lysates. Proteins (25 µg) were resolved by SDS-PAGE. 
Untransfected COS-1 and NIH 3T3 whole cell lysates were used as negative controls. Proteins 
were resolved on an SDS-PAGE gel and probed with anti-Myc and anti-FLAG antibodies. B) 
Anti-FLAG immunoprecipitation (IP): COS-1 cells were transiently co-transfected with the 
indicated plasmids. Lysates were collected 3 days after transfection in PLC lysis buffer. An anti-
FLAG immunoprecipitation was carried out using 125 µg of protein, after which proteins were 
resolved on an SDS-PAGE gel and probed with anti-Myc and anti-FLAG antibodies. A lack of 
co-immunoprecipitation with normal mouse IgG antibody confirms the specificity of the anti-
FLAG IP. C) PI3K assay: Samples obtained after an anti-FLAG IP were assayed for PI3K 
activity using PI as a lipid substrate and [γ-32P]ATP. The TLC plate was exposed to the 
phosphorimager screen for 20 min. Similar results were obtained in three independent 
experiments. 
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encoding either FLAG-p85 wild type (wt) or FLAG-p85 mutants and Myc-p110. Figure 4.2A 
indicates that the proteins are being expressed at the expected molecular weights and are 
immunoreactive. p85∆110 and p85∆110+R274A have a slightly lower molecular weight due to 
the deletion of 35 amino acids (478 to 513). In all replicates of the transient transfections 
performed, there was very low expression of Myc-p110 in cells expressing Myc-p110 alone or 
cells expressing Myc-p110 co-transfected with p85∆110 or p85∆110+R274A. This could be due 
to the fact that interaction between p85 and p110 is necessary for protecting p110 from 
degradation. 
 
4.1.1 p85∆110 and p85∆110+R274A do not bind p110 
The p85Δ110 proteins were tested for their ability to bind p110. COS-1 cells were transiently 
co-transfected with plasmids encoding either FLAG-p85wt or the different FLAG-p85 mutants 
and Myc-p110. Lysates were collected three days after transfection in PLC lysis buffer. The 
protein concentrations of lysates were determined after which an anti-FLAG 
immunoprecipitation was carried out using 125 µg of protein. The immunoprecipitates were 
resolved by SDS-PAGE followed by Western blot analysis using anti-Myc (exogenous p110) 
and anti-FLAG (exogenous p85) antibodies (Figure 4.2B). Consistent with the hypothesis, cells 
expressing p85∆110 and p85∆110+R274A were unable to bind p110, whereas the rest of the p85 
mutants could bind p110 (Figure 4.2B). A parallel series of lysates were immunoprecipitated 
with normal mouse IgG antibody. The lack of any detectable p110 demonstrated the specificity 
of the anti-FLAG immunoprecipitation. 
 
4.1.2 p85∆110 and p85∆110+R274A do not associate with PI3K activity 
In order to determine whether disruption of p85-p110 binding or p85-PDGFR interaction 
affected PI3K activity, a PI3K assay was carried out. COS-1 cells were transiently co-transfected 
with plasmids encoding FLAG-p85wt or the different FLAG-p85 mutants and Myc-p110. An 
anti-FLAG IP was carried out as described in Section 4.1.1, after which samples were assayed 
for PI3K activity using 2.5 µg phosphatidylinositol (PI) as lipid substrate and 10 µCi [γ-32P]ATP. 
Reaction products were resolved on a thin layer chromatography plate and exposed to a 
phosphorimager screen (Figure 4.2C). The results of the PI3K assay confirm that the p85∆110 or 
p85∆110+R274A proteins are devoid of any p85-associated PI3K activity (given that they are 
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unable to bind p110), whereas the other forms of p85 are associated with PI3K activity (given 
that their ability to co-immunoprecipitate with p110 is not affected) (Figure 4.2C). 
 
4.1.3 p85∆R and p85∆R+R274A do not interact with PDGFR in response to growth factor 
treatment 
To confirm that p85∆R and p85∆R+R274A are unable to bind activated receptor, NIH 
3T3 cells were transiently transfected with FLAG-p85wt or the different FLAG-p85 mutants. 
NIH 3T3 cells were used in these experiments because they express PDGFR, in contrast with 
COS-1 cells that do not express endogenous PDGFR. Cells were serum starved (0.5% FBS) for 
24 hours and then were stimulated with 50 ng/mL PDGF-BB for 10, 30, 60, 120 and 240 
minutes. Control cells were left unstimulated. Proteins (125 µg) were immunoprecipitated using 
an anti-PDGFR antibody and a rabbit IgG as control. Immunoprecipitates were resolved by SDS-
PAGE followed by Western blot analysis using anti-FLAG (exogenous FLAG-p85) and anti-p85 
(both endogenous and exogenous p85) antibodies (Figure 4.3C). Figure 4.3A shows that similar 
amounts of the FLAG-tagged p85wt and mutants were expressed in NIH 3T3 cells. It can be 
observed from Figure 4.3B that there was an absence of non-specific immunoprecipitation of 
non-target proteins. Consistent with the hypothesis, no PDGFR-associated FLAG-tagged p85 
was observed in cells expressing either p85∆R or p85∆R+R274A in response to growth factor 
treatment (Figure 4.3C). In cells expressing p85wt, both endogenous and exogenous p85 bound 
to the PDGFR after 10 minutes of growth factor treatment and stayed bound to the receptor for 
up to 2 hours when the receptor is normally dephosphorylated and inactivated. However, the 
amount of exogenous p85 that interacted with PDGFR at the 2 hour time point is higher than the 
endogenous p85. In cells expressing p85R274A, p85∆110 or p85∆110+R274A there appears to 
be a small amount of p85-PDGFR association in unstimulated cells (0 min time point) suggesting 
that there may be some abnormal binding of these p85 mutants to PDGFR in the absence of 
growth in these cells (Figure 4.3C).  In these three cell types, the mutant form of p85 does not 
completely dissociate from the receptor even at 4 hours, though the levels start to decrease after 
the 2 hour treatment. 
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Figure 4.3: Association and dissociation pattern between p85 and PDGFR in response to 
growth factor stimulation. A) NIH 3T3 cells were transiently transfected with the indicated p85 
wild type (wt) or the indicated mutants. Proteins (25 µg) were resolved by SDS-PAGE followed 
by Western blot analysis using anti-FLAG and anti-GAPDH antibodies. B) and C) NIH 3T3 cells 
were transiently transfected with the indicated p85 wt or mutants. Cells were serum starved 
(DMEM supplemented with 0.5% FBS) for 24 hours and then left unstimulated or stimulated 
with 50 ng/mL PDGF-BB for 10, 30, 60, 120 and 240 minutes. An anti-PDGFR 
immunoprecipitation (IP) was carried out using 125 µg of protein. IP products were resolved by 
SDS-PAGE and then probed with anti-PDGFR, anti-FLAG and anti-p85 antibodies. An IgG 
control experiment was performed to show the absence of non-specific interaction (B). Blue 
ovals for both FLAG and p85 blots identify exogenous pFLAG3-p85 (wt, R274A, Δ110 and 
Δ110+R274A). Red diamonds for p85 blots identify endogenous p85. This figure represents data 
obtained from one experiment.  
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4.2 Stable expression of pFLAG3-p85 wild type and p85 mutants 
NIH 3T3 cells stably expressing pFLAG3-p85 wild type, pFLAG3-p85R274A, pFLAG3-
p85∆110 and pFLAG3-p85∆R have been previously generated in the Anderson laboratory 
((Chagpar et al., 2010; Chamberlain et al., 2004) and unpublished results). At least two clones 
per p85 construct were characterized in order to verify that effects observed were due to the p85 
mutation and not an artefact of random integration into the genome (Figure 4.4 and Table 4.1). 
Clones expressing similar levels of FLAG-p85 were selected for the study and are indicated by 
the red asterisks in Figure 4.4. Clones selected from p85∆110+R274A-expressing cells tend to 
lose FLAG-p85 expression after a few passages so three sets of stable transfections had to be 
performed to increase the probability of having enough clones for subsequent experiments. Cells 
were kept in culture for only a few passages and new batches of cells were thawed in order to 
continue the experiments with cells that still expressed FLAG-p85. Some clonal isolates lose 
gene expression with time possibly because the overexpression of gene of interest, or even the 
site of integration within the genome, could be toxic to the cells and they slowly die off leaving 
behind cells that have become resistant to the selective antibiotic but lack the gene of interest. 
 
4.3 Properties of NIH 3T3 cells expressing pFLAG3-p85Δ110+R274A (a RabGAP defective 
p85 that is unable to bind the p110 subunit) 
One of the main objectives of this thesis was to determine if the catalytic subunit of 
PI3K, i.e. p110, contributed a portion of the GAP function through its association with p85. The 
p110β subunit can bind selectively to Rab5-GTP (Christoforidis et al., 1999b) suggesting that it 
may bind the conformation-specific switch regions of Rab5 and thus work together with p85 to 
provide the switch stabilization GAP function. In this manner, p110β would enhance the GAP 
activity over and above that of p85 alone. In order to test this hypothesis, the rate of PDGFR 
degradation in cells expressing a RabGAP defective p85 that is unable to bind the p110 subunit 
was measured in comparison to cells expressing wild type p85, a RabGAP defective p85 or p85 
unable to bind p110. The levels and duration of activated PDGFR as well as its effect on 
downstream signalling events were also measured in these cell lines.   
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Figure 4.4: Relative expression of the different p85 mutants. NIH 3T3 cells were stably 
transfected with the indicated plasmids and selected in G418 (Geneticin). Individual clones from 
each FLAG-p85 wt or mutant were expanded and a fraction of each clone made into lysates in 
SDS sample buffer for analysis. Proteins (200 µg) were resolved by SDS-PAGE and probed with 
anti-FLAG, anti-p85 (p85NSH3 and p85BH antibodies recognise the N-SH3 and BH domains of 
p85 respectively) and anti-GAPDH antibodies. Western blots were visualised using the LICOR 
scanner. EXO: Transfected FLAG tagged p85. ENDO: Endogenously expressed p85. Blue 
diamond: non-specific band. Red asterisks: clones selected for subsequent experiments. A) 
p85Δ110 clones. B) p85ΔR clones.   
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Table 4.1: List of p85wt and mutant clonal isolates used for experiments in this thesis.  
Cell type Clonal isolate Referred to as 
pFLAG3-p85 wild type 
Clone 16 
Clone 23 
C1 
C2 
pFLAG3-p85R274A 
Clone 18 
Clone 20 
C1 
C2 
pFLAG3-p85∆110 
Clone 16 
Clone 20 
C1 
C2 
pFLAG3-p85∆110+R274A 
Set 1 Clone 18 
Set 2 Clone 8 
Set 3 Clone 6 
Mixed population 
C1 
C2 
C3 
C4 
pFLAG3-p85∆R 
Clone 6 
Clone 12 
C1 
C2 
pFLAG3-p85∆R+R274A 
Clone 8 
Clone 11 
Clone 18 
Mixed population 
C1 
C2 
C3 
C4 
 
 
 
4.3.1 PDGFR degradation rates and signalling kinetics of downstream effectors within 
stable cell lines expressing pFLAG3-p85Δ110+R274A compared to controls (pFLAG3-p85 
wild type, pFLAG3-p85R274A and pFLAG3-p85Δ110) 
In order to examine the response of p85Δ110+R274A to growth factor stimulation and 
activation of downstream signal transduction pathways, cells were serum starved for 24 hours 
and then were stimulated with 50 ng/mL PDGF-BB for 10, 30, 60, 120 and 240 minutes. 
Unstimulated cells served as controls. Proteins were resolved by SDS-PAGE followed by 
Western blot analysis using anti-PDGFR, anti-pTyr, anti-pMAPK/Erk, anti-MAPK/Erk, anti-
pAkt and anti-Akt, antibodies to measure downstream signalling events in these cells. If p110 
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contributes to the GAP activity (possibly through switch stabilization), then in cells expressing 
p85∆110+R274A, where p110 is not localized to Rab5, an even more sustained signalling 
(pMAPK/Erk), a slower rate of PDGFR degradation (i.e. sustained levels of PDGFR) and 
PDGFR that is highly activated (tyrosine phosphorylated) would be expected in comparison to 
cells expressing p85R274A (where p110 would still associate with p85 and be localized to 
Rab5).  
 
4.3.1.1 Effect of ∆110 or ∆110+R274A mutation on PDGFR activation and degradation 
In Figure 4.6, cells were stimulated with PDGF for increasing lengths of time and 
corresponding lysates were resolved and immunoblotted with anti-pTyr antibodies to determine 
the levels of tyrosine phosphorylated PDGFR, which is an indication of activated PDGFR. 
Figure 4.5 shows the levels of FLAG-tagged p85 wild type and mutants used in these 
experiments. The pTyr blots in Figure 4.6 reveal that in control cell lines (NIH 3T3, pFLAG3 
and p85wt) the PDGFR is fully activated by 10 minutes of growth factor treatment and that the 
receptor begins to deactivate 30 minutes after treatment with growth factor. A similar pattern of 
receptor activation (i.e. change in pTyr status) is observed in p85∆110-expressing cells (clone 2). 
On the other hand, clone 1 of p85∆110-expressing cells shows a slight increase in the duration of 
receptor activation as seen by a marginally denser band in the 60 minute sample (Figure 4.6). As 
reported previously, cells expressing p85R274A have a more prolonged activation of PDGFR as 
shown by the high levels of tyrosine phosphorylated PDGFR at two hours of growth factor 
treatment (Figure 4.6 and (Chamberlain et al., 2004)). The pTyr blots also reveal that cells 
expressing p85∆110+R274A have a more prolonged activation of PDGFR, indicated by higher 
levels of phosphorylated tyrosine residues, when compared to cells expressing p85R274A as 
well as control cell lines. It should be noted that clone 3 of p85∆110+R274A-expressing cells 
does not show a dramatic increase in the duration of PDGFR activation, possibly due to the fact 
that these cells expressed lower amounts of FLAG-tagged p85 at the time the experiments were 
performed. As mentioned previously, the majority of clonal isolates expressing FLAG-tagged 
p85∆110+R274A tend to lose FLAG expression over time. In all cell lines tested, the absence of 
a band in the 0 minute lane for the pTyr blots suggests that in these cells lines the PDGFR is only 
fully activated in response to growth factor stimulation. 
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Figure 4.5: Relative expression of the different p85 Δ110 and R274A mutants. NIH 3T3 
cells stably expressing the indicated plasmids were harvested in SDS sample buffer for whole 
cell lysates. Proteins (200 µg) were resolved by SDS-PAGE and probed with anti-FLAG 
antibodies. Western blots were visualised using the LICOR scanner. Blue diamond: non-specific 
band.  
 
 
In order to measure the rate of receptor degradation, the same cell lysates obtained from 
the PDGF stimulation described above were Western blotted with anti-PDGFR antibodies 
(Figure 4.6). In control cell lines (NIH 3T3, pFLAG3 and p85wt) it can be seen that the total 
levels of PDGFR decrease after 30 minutes of growth factor stimulation. The PDGFR usually 
appears as two bands; a higher thicker band and a lower thinner band. The PDGFR undergoes 
glycosylation in order to yield a fully mature receptor that migrates at approximately 180 kDa in 
size (the higher band). The immature non-glycosylated receptor is about 170 kDa in size (the 
lower band). p85∆110-expressing cells (clone 1) show a slight decrease in the rate of receptor 
degradation as can be observed by the presence of a stronger signal in the 60, 120 and 240 
minute samples when compared to control cell lines. Cells expressing p85R274A show a 
significant decrease in the rate of receptor degradation as compared to control cell lines (Figure 
4.6), thus confirming previous results (Chamberlain et al., 2004). However, p85∆110+R274A-
expressing cells have an even slower rate of receptor degradation when compared to cells 
expressing p85R274A. Since p85Δ110-expressing cells show intermediate effects between those 
of NIH 3T3/pFLAG3/p85wt and that of p85R274A/p85∆110+R274A, it suggests that the p110 
localized to receptors via p85 binding contributes to the altered PDGFR degradation kinetics in 
particular. 
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Figure 4.6: Prolonged PDGFR receptor activation and decreased receptor degradation in 
cells expressing p85R274A or p85∆110+R274A. The cells indicated were serum starved 
(DMEM supplemented with 0.5% FBS) for 24 hours and then left unstimulated or stimulated 
with 50 ng/mL PDGF-BB for 10, 30, 60, 120 and 240 minutes. Proteins were resolved by SDS-
PAGE followed by Western blot analysis using anti-pTyr, anti-PDGFR and anti-GAPDH 
antibodies. Similar results were obtained in three independent experiments. 
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4.3.1.2 The ∆110 or ∆110+R274A mutations in p85 affects downstream signalling in 
response to PDGF 
The prolonged receptor activation and reduced rate of receptor degradation observed in 
p85∆110+R274A-expressing cells (Figure 4.6) could alter signalling from the MAPK/Erk 
pathway or the PI3K/Akt pathway, both of which have been associated with the PDGFR 
signalling (Alvarez et al., 2006; Cross et al., 2000; Fruman et al., 1998; McKay and Morrison, 
2007). Downstream effectors of the PDGFR signalling pathway were examined by Western blot 
analysis using the same lysates obtained from the growth factor stimulation experiments 
described in Section 4.3.1. Activation of the MAPK/Erk pathway was measured by Western blot 
analysis with antibodies targeting phospho-MAPK/Erk (pMAPK/Erk) (Figure 4.7). The total 
MAPK/Erk levels were also measured. MAPK/Erk can be seen as a doublet of 44 and 42 kDa. 
The 44 kDa protein represents the MAPK1/Erk1 isoform that is phosphorylated on both Thr202 
and Tyr204 to activate it. On the other hand, the 42 kDa protein is the MAPK2/Erk2 isoform that 
is phosphorylated on Thr185 and Tyr187 for full activation. The pMAPK/Erk blots in Figure 4.7 
show that in control cells (NIH 3T3, pFLAG3 and p85wt) phosphorylation of MAPK/Erk was 
induced from 10 minutes to 60 minutes, with minimal levels of pMAPK/Erk at the 2 hour and 4 
hour time points. In cells expressing p85∆110, there was slightly more phosphorylated 
MAPK/Erk present at the 2 hour and 4 hour time points. Expression of p85R274A leads to an 
enhanced activation of the MAPK/Erk pathway (Figure 4.7 and (Chamberlain et al., 2004)). In 
these cells, phosphorylation of MAPK/Erk can be observed even after 4 hours of growth factor 
treatment. Similar to p85R274A-expressing cells, phosphorylation of MAPK/Erk in 
p85∆110+R274A-expressing cells is induced from 10 minutes to 4 hours. In both p85R274A- 
and p85∆110+R274A-expressing cells there are very low amounts of pMAPK/Erk present before 
growth factor stimulation indicating that the presence of p85R274A and p85∆110+R274A 
proteins in these cells in may interfere with the mechanism(s) that would inhibit MAPK/Erk 
signalling (e.g. any one of the 11 dual specificity MAPK/Erk phosphatases) (Boutros et al., 
2008). The MAPK/Erk blots in Figure 4.7 show the total levels of the MAPK/Erk. All cell lines 
tested express similar levels of MAPK/Erk. 
Activation of the PI3K/Akt pathway was also examined by Western blotting with 
phospho-specific antibodies for Akt (Figure 4.8). The total levels of Akt across the different 
clones show that the cells express similar levels of Akt. In all cell lines tested, Akt was 
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Figure 4.7: MAPK signalling following PDGFR stimulation is sustained by the expression 
of R274A. Cells were serum starved (DMEM supplemented with 0.5% FBS) for 24 hours and 
then left unstimulated or stimulated with 50 ng/mL PDGF-BB for 10, 30, 60, 120 and 240 
minutes. Proteins were resolved by SDS-PAGE followed by Western blot analysis using anti-
pMAPK/Erk and anti-MAPK/Erk antibodies. Similar results were obtained in three independent 
experiments. 
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phosphorylated on Ser473 within 10 minutes of beginning growth factor treatment and the 
phosphorylation was sustained over the time course. There was no difference in the activation of 
the Akt pathway between control cells and cells expressing p85∆110, p85R274A or 
p85∆110+R274A. Taken together, the data suggests that expression of p85R274A or 
p85∆110+R274A results in sustained activation of the MAPK/Erk pathway (but not the 
PI3K/Akt pathway). The lack of any detectable effect in cells expressing p85∆110 suggests that 
the sustained activation of the MAPK/Erk pathway is primarily due to the R274A substitution in 
p85. 
 
4.3.2 Oncogenic properties of cells expressing pFLAG3-p85Δ110+R274A compared to 
controls 
It has been reported by our laboratory that cells expressing the RabGAP defective 
p85R274A are transformed indicating that the RabGAP function of p85 plays an essential role in 
the regulation of cell survival and proliferation (Chamberlain et al., 2008). The hallmarks of 
some transformed cells include loss of cell-cell and cell-basement membrane contact inhibition, 
loss of anchorage dependence for cell survival and proliferation, and the ability to degrade and 
detach from the extracellular matrix (ECM) and migrate to secondary sites. Since the expression 
of p85Δ110+R274A resulted in enhanced PDGFR signalling much like p85R274A-expresssing 
cells, similar cell based assays were used to determine the oncogenicity of the p85Δ110+R274A 
mutation as had been used previously (Chamberlain et al., 2008).  
 
4.3.2.1 Loss of contact inhibition (Foci formation assay) 
Proliferation of normal cells in tissue culture is inhibited by contact with other cells 
ensuring that they grow in a monolayer. Transformed cells, however, continue to grow and pile 
on top of each other to form clumps, eventually forming foci. The foci formation assay is used to 
determine whether an adherent cell is transformed or not, however, it should be noted that not all 
cells that are transformed can form foci. Cells expressing p85wt or the different mutants of p85 
were seeded at a density of 100 000 cells/10 cm dish and maintained in normal medium for two 
weeks, with routine medium changes, till they were well past 100% confluency. Cells were 
stained with Giemsa stain and the entire 10 cm dish was photographed to show macroscopic foci  
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Figure 4.8: Akt signalling following PDGFR stimulation is not affected by the expression of 
either the ∆110 or the R274A variant of p85.  Cells were serum starved (DMEM supplemented 
with 0.5% FBS) for 24 hours and then left unstimulated or stimulated with 50 ng/mL PDGF-BB 
for 10, 30, 60, 120 and 240 minutes. Proteins were resolved by SDS-PAGE followed by Western 
blot analysis using anti-pAkt and anti-Akt antibodies. Similar results were obtained in three 
independent experiments. 
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(Figure 4.9). Parental NIH 3T3 cells and cells stably expressing p85wt, p85Δ110 or 
p85Δ110+R274A remained as a monolayer for the duration of the experiment and started to lift 
off along the circumference of the 10 cm dish when the cells were just past confluency. In some 
experiments the cells lifted completely off the dish in an intact monolayer. No foci were 
observed with cells expressing p85wt, p85Δ110 or p85Δ110+R274A (Figure 4.9). Cells 
expressing p85R274A formed foci seen as black spots on the C1 and C2 dishes (Figure 4.9). 
Expression of p85Δ110 or p85Δ110+R274A does not lead to the formation of foci, which 
suggests that cells expressing these mutants are not transformed. This result is contrary to what 
was expected as cells expressing p85R274A or p85Δ110+R274A both had enhanced PDGFR 
signalling (pMAPK/Erk), which would contribute to cell proliferation and survival, and would 
usually result in transformation and oncogenic cell properties. The formation of foci in cells 
expressing p85R274A confirms a role for this RabGAP defective p85 in cellular transformation, 
as observed previously (Chamberlain et al., 2008). However, any condition that might interfere 
with the ability of a RabGAP defective p85 to bind to p110 would appear to inhibit this aspect of 
cellular transformation and strongly suggests that p85 needs to exist as the PI3K heterodimer for 
full transformation of cells to occur via the PI3K signalling pathway. 
 
4.3.2.2 Anchorage independent growth (Colony formation in soft agar) 
To further analyse the transformation ability of the p85Δ110 or p85Δ110+R274A 
mutation another transformation assay was used; the colony formation in soft agar assay 
(anchorage-independent growth assay). In normal tissue, cells adhere both to one another and to 
the protein mesh filling the intercellular space. The intricate network of proteins occupying the 
space is referred to as the extracellular matrix (ECM). In contrast with normal cells that require 
proper cell-cell and cell-matrix interactions for maintaining cellular functions, transformed cells 
can continue to survive and proliferate without being attached to a surface or communicating 
through cell-cell interactions. The colony formation in soft agar assay is used to demonstrate a 
cell’s capacity for anchorage-dependent versus -independent growth. Cells were seeded in a 
suspension of top agar above of a layer of bottom agar and cultured for 20 days. Colonies formed 
were visualized under a microscope with a 10X objective lens and photographed (Figure 4.10). 
Colonies formed from cells expressing the pFLAG3 vector or those expressing p85wt had an 
average diameter 28 µm. Therefore, only colonies that were 28 µm or larger in diameter were 
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Figure 4.9: Cells expressing p85R274A form foci in a contact inhibition assay, but cells 
expressing p85∆110 and p85∆110+R274A do not. Cells were seeded at a density of 100 000 
cells/10 cm dish and maintained in normal medium for two weeks. Cells were fixed in -20 °C 
methanol, stained with Giemsa stain and photographed. Images show the entire surface of a 10 
cm dish and each image is representative of four different experiments (except for 
p85∆110+R274A clone 4 where only two experiments were performed). C: clone number. Red 
arrows point to foci. 
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counted. p85∆110-expressing cells developed colonies that were marginally wider than vector 
control and p85wt (Figure 4.10). These colonies ranged in diameter from 28 to 39 µm. Cells 
expressing p85R274A formed numerous colonies that ranged in diameter from 28 to 180 µm 
(Figure 4.10). The observations that these cells were able to grow on soft agar (anchorage-
independent) (Figure 10) and also lost any contact inhibition (Figure 4.9) further supports the 
report that they are transformed (Chamberlain et al., 2008). p85∆110+R274A clones 1 and the 
mixed population, referred to as clone 4, formed colonies that ranged in size from 28 to 39 µm in 
diameter. Both p85∆110- and p85∆110+R274A-expressing cells formed similar sized colonies 
and similar number of colonies (Figures 4.10 and 4.11). Taken together, the data suggests that 
expression of a p85 mutant unable to bind to the p110 subunit or a RabGAP defective p85 that is 
unable to bind p110 does not lead to cellular transformation. 
 
4.3.2.3 Attachment to fibronectin and collagen (Adhesion assay) 
Cell adhesion is important for the maintenance of cell-cell communication as well as for 
the maintenance of cellular structure via the connections made with the extracellular matrix 
(ECM) and the cytoskeleton. One of the early steps involved in cancer cell metastasis is the 
transformed cells’ ability to degrade components of the ECM, thereby diminishing their 
adherence and increasing their potential for escaping from the primary tumour site. The ECM 
contains connective tissue proteins such as collagen and fibronectin. To examine the cells’ ability 
to interact with the ECM, 96-well microtiter plates were coated with either of two common 
connective tissue proteins, e.g. fibronectin or collagen type I. Twenty thousand (20 000) cells 
were then seeded onto the coated plates and allowed to adhere to the plates for 30 minutes. They 
were then washed, fixed, stained with crystal violet and solubilised. Absorbance readings were 
taken at 550 nm, with the absorbance reflecting the cell’s ability to adhere (Figure 4.12). Cells 
expressing p85wt or p85∆110 adhered to collagen I to the same extent. It can be seen from 
Figure 4.12 that cells expressing p85R274A were less adherent to collagen I than cells 
expressing p85wt. Two cell lines expressing p85∆110+R274A (clones 2 and 3) were less 
adherent to collagen I when compared to cells expressing p85wt, whereas clone 1 appeared to be 
more adherent. Adhesion to fibronectin, however, was similar for all FLAG-tagged p85 
expressing cell lines tested. This suggests that expression of p85R274A or p85∆110+R274A 
changes the adherent properties of cells by making them less adherent to collagen I. 
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Figure 4.10: Cells expressing p85R274A form colonies in soft agar, but cells expressing 
p85∆110 or p85∆110+R274A do not. Fifty thousand cells/6 cm dish were cultured in a 
suspension of top agar (3.75X MEM vitamins, 0.36% agar) above of a layer of bottom agar (5X 
MEM vitamins, 0.61% agar). Cells were left to grow for a total of 20 days. Images are 
representative of the colonies formed by the individual cells expressing the different p85 mutants 
in four different experiments (except for p85∆110+R274A clone 4 where two experiments were 
performed). C: clone number. Colonies are spots that are 28 µm or larger in diameter. 
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Figure 4.11: Cells expressing p85R274A form numerous colonies in soft agar. The graph 
depicts the number of colonies formed per 50 000 cells plated that are expressing different p85 
mutants (see Figure 4.10). Each value represents the mean (± SD) of four independent 
experiments, each based on three separate viewing fields. Bonferroni’s multiple comparison test 
indicates ***, p<0.001 as compared to the vector control or either of the p85wt clones. C: clone 
number. 
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4.3.2.4 Migratory properties (Boyden chamber assay) 
Cell migration is used as a measure of cells’ ability to detach from the primary location 
and move. Most migration assays are a modification of the Boyden chamber, which is simply 
two chambers separated by a membrane with pores to allow cells to migrate from one chamber to 
the other along a chemical gradient, e.g. towards a chemoattractant such as a growth factor or 
ECM substrates (Boyden, 1962; Chen, 2005). In order to study the cells’ ability to migrate 
towards a stimulus, cells were resuspended in DMEM supplemented with 0.1% FBS and 1x105 
cells were added to the top chamber. The bottom chamber was filled with either DMEM 
supplemented with 0.1% FBS as control or DMEM supplemented with 10% FBS. Samples were 
incubated at 37 °C for 24 hours. The cells that migrated to the lower chamber were stained with 
hematoxylin. The results were expressed as the number of cells that migrated towards 10% FBS 
minus the number of cells that migrated towards 0.1% FBS (Figure 4.13). All cells migrated to 
the same extent towards 0.1% FBS except for p85∆110+R274A clones 1 and 3 that migrated 
more and p85∆110+R274A clone 2 that migrated much less. Cells expressing p85wt clone 2 
migrated to a greater extent towards 10% FBS than cells expressing p85wt clone 1. Statistical 
analyses were therefore performed in relation to p85wt clones 1 and 2 separately. There was no 
difference between the number of cells expressing p85wt or p85∆110 that migrated towards 10% 
FBS. Cells expressing p85R274A clone 2 migrated significantly more than both p85wt- and 
p85∆110-expressing cells. Cells expressing p85∆110+R274A clones 2 and 4 migrated more 
towards 10% FBS in comparison to both p85wt- and p85∆110-expressing cells. Cells expressing 
p85∆110+R274A clone 2 had an even higher rate of migration than p85R274A-expressing cells. 
The data indicate that expression of p85R274A or p85∆110+R274A could result in an increase 
in the migratory properties of cells. However, this increase appears to be clone specific. 
 
4.3.3 Analysis of PDGFR and p85 association in cells expressing pFLAG3-p85∆110+R274A 
It was previously observed in the Anderson laboratory that a significant amount of p85 is 
still bound to the PDGFR in cells expressing pFLAG3-p85∆110 even after 2 hours of growth 
factor stimulation (when the PDGFR is usually dephosphorylated and inactivated) (Figure 4.14). 
This suggests that the p110 subunit facilitates dissociation of the PI3K complex from the 
PDGFR, and without it, p85 stays bound to PDGFR. In order to better understand this signalling  
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Figure 4.12: The inability of p85 to bind to p110 affects the adhesion properties of the 
R274A mutation in p85. Cells were seeded on 96-well plates coated with either collagen (A) or 
fibronectin (B) and incubated for 30 minutes. Cells were then fixed, stained with crystal violet 
and solubilised. Relative fluorescent units were quantified at 550 nm and represented relative to 
cells expressing the vector control (pFLAG3) from two independent experiments with triplicate 
measurements for each experiment. ANOVA for overall groups indicates p value = 0.014 for 
collagen (A) and p value = 0.015 for fibronectin (B). Post hoc analysis using the stringent 
Bonferroni’s adjustment for multiple comparisons, however, showed no statistical significance. 
	   91	  
 
 
 
 
 
Figure 4.13: p85R274A and p85∆110+R274A mutations induce more migration of cells in a 
clone specific manner. Cells were seeded into the top section of a Boyden chamber and left to 
migrate towards either 0.1% FBS or 10% FBS at 37 °C for 24 hours. Cells that had migrated to 
the bottom side of the Boyden chamber were then fixed and stained with hematoxylin. Cells 
observed in 8 fields of view at a magnification of 20X were quantified using the Stereo 
Investigator software (MBF Bioscience). The results represent cells that migrated towards 10% 
FBS minus cells that migrated towards 0.1% FBS from one experiment with duplicate 
measurements. Bonferroni’s multiple comparison test indicates ** p<0.01, *** p<0.001 as 
compared to p85wt C1 and # p<0.05, ## p<0.01, ### p<0.001 as compared to p85wt C2.   
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event, the association and dissociation pattern between p85 and PDGFR in response to PDGF 
stimulation in cells expressing pFLAG3-p85∆110 or pFLAG3-p85∆110+R274A was studied. 
Cells were first serum deprived (0.5% FBS) for 24 hours and then left unstimulated or 
stimulated with 50 ng/mL PDGF-BB for 10, 30, 60, 120 and 240 minutes. An anti-PDGFR 
immunoprecipitation was carried out and samples resolved by SDS-PAGE were probed using 
anti-FLAG (exogenous p85) and anti-p85 (both endogenous and exogenous p85) antibodies 
(Figure 4.15). Based on the results from the previous study shown in Figure 4.14, the levels of 
PDGFR-associated FLAG-tagged p85, in response to growth factor treatment, were expected to 
increase after the 0 minute time point and slowly decline to almost undetectable levels by the 60 
minute time point in control cells (NIH 3T3, pFLAG3 and p85wt). It can be observed from 
Figure 4.15 that cells expressing p85wt (clone 2), p85∆110 and p85∆110+R274A (clone 2) have 
PDGFR-associated FLAG-tagged p85 up until the 240 minute time point. All the other cell lines 
tested did not show any co-immunoprecipitation of FLAG-p85 protein and activated PDGFR. 
This could be due to the fact that most of these cell lines had lost expression of the FLAG-p85 
protein or had very low expression by the time this work was carried out (p85wt clone 1, both 
clones expressing p85R274A and p85∆110+R274A clones 1, 3 and 4) (Figure 4.16). As can be 
seen from Figure 4.16, cells expressing p85wt (clone 2), p85∆110 and p85∆110+R274A (clone 
2) expressed the highest level of FLAG-tagged p85 when compared to the other clones with that 
same mutation. This may suggest that the sustained levels of FLAG-tagged p85 observed at the 
240 minute time point that was previously observed (Figure 4.14) may just be a consequence of 
over-expression; in that, clones with higher expression will stay associated to receptor longer 
since there is an abundance of p85 and those with lower expression will show the same 
association and dissociation pattern as endogenous p85.  
The data also indicates that p85 does not require being part of a p85-p110 heterodimer to 
associate with the PDGFR. 
 
4.4 Properties of NIH 3T3 cells expressing pFLAG3-p85ΔR+R274A (a RabGAP defective 
p85 that is unable to bind PDGFR) 
The second major objective of this thesis was to determine whether p85 needed to 
associate with PDGFR in order to exert its GAP activity on Rab5 and Rab4. Since p85 binds to 
Rab5-GDP as well as Rab5-GTP, it may help recruit Rab5 to vesicle membranes containing 
	   93	  
activated PDGFR signalling complexes and thereby regulate PDGFR signalling and/or 
trafficking events (Chamberlain et al., 2004). We postulate that PDGFR may help localize the 
RabGAP activity of p85. 
 
 
 
 
 
  
Figure 4.14: p85∆110 stays bound to activated PDGFR. Cells were serum starved (DMEM 
supplemented with 0.5% FBS) for 24 hours and then left unstimulated or stimulated with 50 
ng/mL PDGF-BB for 10, 30, 60, 120 and 240 minutes. An anti-PDGFR IP was carried out after 
which IP products were resolved by SDS-PAGE followed by Western blot analysis using anti-
FLAG and anti-p85 antibodies. Experiments were performed by Jonathan Hanson. 
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Figure 4.15: Association and dissociation pattern between p85∆110 or p85∆110+R274A and 
PDGFR in response to growth factor stimulation. Cells were serum starved (DMEM 
supplemented with 0.5% FBS) for 24 hours and then left unstimulated or stimulated with 50 
ng/mL PDGF-BB for 10, 30, 60, 120 and 240 minutes. An anti-PDGFR IP was carried out using 
125 µg of protein. IP products were resolved by SDS-PAGE followed by Western blot analysis 
using anti-PDGFR, anti-FLAG and anti-p85 antibodies. Blue ovals for both FLAG and p85 blots 
identify exogenous pFLAG3-p85 (wt, R274A, Δ110 and Δ110+R274A). Red diamonds for p85 
blots identify endogenous p85. This figure represents data obtained from three independent 
experiments. 
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Figure 4.16: Input amount of pFLAG3-tagged p85 used for the anti-PDGFR IP. Cells stably 
expressing p85 wt or the different mutants were serum starved for 24 hours and then left 
unstimulated or stimulated with 50 ng/mL PDGF-BB for the indicated time course. Cells were 
lysed in PLC lysis and cleared of cellular debris by centrifugation. A fraction of the lysates were 
used for the anti-PDGFR IP described in Figure 4.15. Proteins (50 µg) were denatured with SDS 
sample buffer and resolved by SDS-PAGE followed by Western blot analysis using anti-FLAG, 
anti-p85, anti-PDGFR and anti-GAPDH antibodies. Similar results were obtained from three 
independent experiments. Solid arrows for both FLAG and p85 blots: exogenous pFLAG3-
tagged p85. Broken arrow for p85 blots: endogenous p85. Red asterisks: non-specific bands.   
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4.4.1 PDGFR degradation rates and signalling kinetics of downstream effectors within 
stable cell lines expressing pFLAG3-p85ΔR+R274A compared to controls (pFLAG3-p85 
wild type, pFLAG3-p85R274A and pFLAG3-p85ΔR) 
p85 regulates PDGFR trafficking events and, therefore, signal transduction initiated by 
PDGFR (Chamberlain et al., 2008; Chamberlain et al., 2010). The consequence of disrupting 
p85-PDGFR interaction was examined by measuring receptor activation and degradation rates as 
well as the activation of downstream signalling molecules. 
 
4.4.1.1 Effect of the ∆R or ∆R+R274A mutations in p85 on PDGFR activation and 
degradation 
To test the impact of disrupting binding between p85 and PDGFR on signalling initiated 
by PDGF, NIH 3T3 cells stably expressing FLAG-p85wt or FLAG-p85 mutants (Figure 4.17) 
were stimulated with PDGF for increasing intervals of time. Cell lysates were probed for levels 
of activated receptor and the expression levels of PDGFR (Figure 4.18). As described earlier, in 
control cell lines (NIH 3T3, pFLAG3 and p85wt) the phosphorylation of PDGFR is induced 
within 10 minutes of growth factor stimulation and sustained for 30 minutes (Figure 4.18). The 
same pattern was observed in p85∆R-expressing cells. Cells expressing p85R274A have a more 
sustained activation of PDGFR as shown by the high levels of tyrosine phosphorylated PDGFR 
at 2 hours of growth factor stimulation (Figure 4.18) and confirms a previous report 
(Chamberlain et al., 2004)). Cells expressing p85∆R+R274A mimic receptor activation patterns 
of cells expressing p85R274A. In all clones expressing p85∆R+R274A, it can be seen that there 
is an increase in the duration of receptor activation (pTyr blots) in comparison to control cells.  
The rate of receptor degradation was measured by stimulating cells with PDGF for the 
indicated times and Western blotting with anti-PDGFR antibodies (Figure 4.18). Again, it can be 
seen that the total levels of PDGFR decrease after 30 to 60 minutes of growth factor stimulation 
in control cell lines (NIH 3T3, pFLAG3 and p85wt). Cells expressing p85∆R are comparable to 
control cells with regards to the rate of PDGFR degradation. As previously reported, cells 
expressing p85R274A show a significant reduction in the rate of receptor degradation as 
compared to control cell lines (Figure 4.18 and (Chamberlain et al., 2004)). Similarly, a reduced 
rate of degradation of the receptor was also observed in cells expressing p85∆R+R274A.  These 
observations suggest that disrupting the interaction between p85 and PDGFR has no effect on the 
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p85 RabGAP-mediated signalling, since both p85R274A- and p85∆R+R274A-expressing cells 
show the same response to PDGF stimulation. Regulation of PDGFR activation by the RabGAP 
function of p85 is independent of p85-PDGFR association. 
 
 
 
 
Figure 4.17: Relative expression of the different p85 mutants. NIH 3T3 cells stably 
expressing the indicated plasmids were harvested in SDS sample buffer for whole cell lysates. 
Proteins (200 µg) were resolved by SDS-PAGE and probed with anti-FLAG antibodies. Western 
blots were visualised using the LICOR scanner. Blue diamond: non-specific band.  
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Figure 4.18: Prolonged PDGFR receptor activation and decreased receptor degradation in 
cells expressing p85R274A or p85∆R+R274A. The cells indicated were serum starved (DMEM 
supplemented with 0.5% FBS) for 24 hours and then left unstimulated or stimulated with 50 
ng/mL PDGF-BB for 10, 30, 60, 120 and 240 minutes. Proteins were resolved by SDS-PAGE 
followed by Western blot analysis using anti-pTyr, anti-PDGFR and anti-GAPDH antibodies. 
Similar results were obtained in three independent experiments. 
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4.4.1.2 Effect of ∆R or ∆R+R274A mutation on downstream signalling in response to PDGF 
PDGFR signalling cascade induces downstream signalling through cascades such as the 
MAPK/Erk pathway or the PI3K/Akt pathway. Having observed that the PDGFR is highly 
activated in p85∆R+R274A-expressing cells, the impact of this prolonged activation on 
downstream signalling was examined. In control cells (NIH 3T3, pFLAG3 and p85wt) as well as 
cells expressing p85∆R, MAPK/Erk was activated 10 minutes after growth factor stimulation 
and levels of activated MAPK/Erk started to decline 60 to 120 minutes after growth factor 
stimulation. p85R274A-expressing cells showed an enhanced activation of the MAPK/Erk 
pathway (Figure 4.19 and (Chamberlain et al., 2004)). Expression of p85∆R+R274A resulted in 
an induction of MAPK/Erk phosphorylation from 10 minutes to 4 hours after growth factor 
stimulation. In both p85R274A- and p85∆R+R274A-expressing cells there are very low amounts 
of pMAPK/Erk present before growth factor stimulation indicating that in these cells the 
MAPK/Erk pathway may be constitutively (although only modestly) active.  
The effect of the ∆R+R274A mutation on the PI3K/Akt pathway was also measured by 
Western blotting with phospho-specific antibodies for Akt (Figure 4.20). In all cell lines tested, 
Akt phosphorylation was induced from 10 minutes to 4 hours. There was no significant 
difference in the activation of the Akt pathway between control cells and cells expressing 
p85∆R, p85R274A or p85∆R+R274A.  
We hypothesized that p85-PDGFR interaction is necessary to localize the RabGAP 
function of p85. We would therefore expect cells expressing p85∆R and p85∆R+R274A-
expressing cells to have similar phenotypes. However, it was observed that cells expressing 
∆R+R274A have similar responses to PDGF in comparison to p85R274A-expressing cells, with 
regards to activation of PDGFR and of its downstream effectors. The results obtained so far 
suggest that p85 does not need to be associated with activated PDGFR to exert its RabGAP 
regulatory effects on PDGFR activation and signalling. 
 
4.4.2 Oncogenic properties of cells expressing pFLAG3-p85ΔR+R274A (a RabGAP 
defective p85 that is unable to bind PDGFR) 
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Figure 4.19: Sustained MAPK signalling downstream of PDGFR in cells expressing 
p85R274A or p85∆R+R274A.  Cells were serum starved (DMEM supplemented with 0.5% 
FBS) for 24 hours and then left unstimulated or stimulated with 50 ng/mL PDGF-BB for 10, 30, 
60, 120 and 240 minutes. Proteins were resolved by SDS-PAGE followed by Western blot 
analysis using anti-pMAPK/Erk and anti-MAPK/Erk antibodies. Similar results were obtained in 
three independent experiments. 
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Figure 4.20: Akt signalling is unaffected by the expression of any p85 variant in cells 
stimulated with PDGF.  Cells were serum starved (DMEM supplemented with 0.5% FBS) for 
24 hours and then left unstimulated or stimulated with 50 ng/mL PDGF-BB for 10, 30, 60, 120 
and 240 minutes. Proteins were resolved by SDS-PAGE followed by Western blot analysis using 
anti-pAkt and anti-Akt antibodies. Similar results were obtained in three independent 
experiments.  
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It was shown in the previous section that cells expressing p85ΔR+R274A have a 
sustained activation of signalling in response to PDGF. A disruption in the ‘brakes’ and 
‘checkpoints’ required to halt cellular proliferation can lead to transformation of cells. The 
oncogenicity of these cell lines was therefore characterized. 
 
4.4.2.1 Loss of contact inhibition (Foci formation assay) 
The foci formation assay described in Section 4.3.2.1 was used to determine whether 
cells expressing p85ΔR+R274A were transformed. Cells expressing p85wt or p85ΔR did not 
form foci (Figure 4.21). Furthermore, cells expressing p85ΔR+R274A clone 1 failed to form any 
foci. However, p85R274A- and p85Δ110+R274A-expressing cells (clones 2, 4, and to some 
extent 3) formed foci indicating that these cells are transformed. Expression of p85ΔR+R274A 
results in the formation of foci and based on this assay, cells expressing this mutant could be 
considered transformed, just as are cells expressing p85R274A. These results further support the 
observations made with the response to PDGF experiments and suggest that p85-PDGFR 
association is not critical for the regulation of PDGFR signalling by the RabGAP function of 
p85.  
 
4.4.2.2 Anchorage independent growth (Colony formation in soft agar) 
The colony formation in soft agar assay described in Section 4.3.2.2 was also used to test 
whether p85∆R+R274A-expressing cells are transformed. Colonies of cells expressing either 
pFLAG3 vector or p85wt had an average diameter of 17 µm. Colonies that were 17 µm and 
above in diameter were counted and reported (Figure 4.23). Cells expressing p85∆R developed 
colonies that were at most twice the diameter of colonies produced by cells expressing the vector 
or p85wt (Figure 4.22). These colonies ranged in size from 17 to 33 µm in diameter. Cells 
expressing p85∆R appeared to form more colonies per cells seeded than vector and p85wt 
control, however the apparent increase in number of colonies especially in clone number 2 was 
not statistically significant  (Figure 4.23).  
Cells expressing p85R274A or p85∆R+R274A formed numerous colonies (Figure 4.22). 
These cells have lost their response to contact inhibition as well as their anchorage dependence 
and are therefore transformed. As shown before, p85R274A-expressing cells formed colonies in 
soft agar that typically ranged in size from 17 to 150 µm in diameter, with a few colonies getting  
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Figure 4.21: Cells expressing p85R274A and p85∆R+R274A form foci in a contact 
inhibition assay. Cells were seeded at a density of 100 000 cells/10 cm dish and maintained in 
normal medium for 2 weeks. Cells were fixed in -20 °C methanol, stained with Giemsa stain and 
photographed. Images are representative of the entire 10 cm dish from four different 
experiments. C: clone number. Red arrows point to foci. 
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Figure 4.22: Cells expressing p85R274A and p85∆R+R274A form colonies in soft agar. 
Fifty thousand cells/ 6 cm dish were cultured in a suspension of top agar (3.75X MEM vitamins, 
0.36% agar) above of a layer of bottom agar (5X MEM vitamins, 0.61% agar). Cells were left to 
grow for a total of 20 days. Images are representative of the colonies formed by the individual 
cells expressing the different p85 mutants in four different experiments. Colonies are spots that 
are 17 µm or larger in diameter. 
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Figure 4.23: Cells expressing p85R274A and p85∆R+R274A form numerous colonies in soft 
agar. The graph depicts the number of colonies formed per 50 000 cells plated that are 
expressing different p85 mutants (see Figure 4.22). Each value represents the mean (± SD) of 
four independent experiments, each based on three separate viewing fields. Bonferroni’s multiple 
comparison test indicates ***, p<0.001 as compared to the vector control or either of the p85wt 
clones. 
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as big as 300 µm in diameter. Clones 1 and 2 of p85∆R+R274A-expressing cells developed 
colonies that were between 17 to 73 µm in diameter. On the other hand, clone 3 and the mixed 
population referred to as clone 4 formed colonies that ranged in size from 17 to 39 µm in 
diameter. The data suggests that expression of a RabGAP defective p85 (p85R274A) results in a 
loss of anchorage dependence. Expression of a p85 mutant unable to bind to the receptor results 
in a marginal loss in anchorage dependence as shown in cells expressing p85∆R or in two clones 
of cells expressing p85∆R+R274A (clones 3 and 4), which is not statistically significant. The 
data also showed a statistically significant increase in the loss of anchorage dependence of cells 
expressing p85∆R+R274A in clones 1 and 2. 
 
4.4.2.3 Attachment to fibronectin and collagen (Adhesion assay) 
As mentioned earlier, cell adhesion to ECM is vital to the normal function of the cell. The 
adherent properties of cells expressing p85∆R and p85∆R+R274A were investigated by 
examining the ability of these cells to attach to fibronectin and collagen I coated surfaces. 
Adherence to fibronectin was not altered by expression of p85∆R, p85R274A or p85∆R+R274A. 
When compared to cells expressing p85wt, three out of the four clonal isolates of p85∆R+R274A 
are less adherent to collagen I, as are p85R274A-expressing cells. Clone 1 of p85∆R+R274A-
expressing cells shows a significant increase in attachment to collagen I. This suggests that 
expression of p85R274A or p85∆R+R274A can result in cells adhering less to collagen I. 
Transformed cells can become more or less adherent to components of the ECM (Junker and 
Heine, 1987). 
 
4.4.2.4 Migratory properties  (Boyden chamber assay) 
The Boyden chamber was again used to determine whether cells expressing p85∆R or 
p85∆R+R274A are able to migrate. All cells migrated to the same extent towards 0.1% FBS. 
Cells expressing p85wt clone 2 were migrated more towards the chemoattractant than cells 
expressing p85wt clone 1. Statistical analyses were performed in relation to p85wt clones 1 and 2 
separately. Cells expressing p85∆R migrated towards 10% FBS much less than p85wt control 
cells (Figure 4.25). Whereas cells expressing p85R274A clone 2 are significantly more migratory 
than both p85wt- and p85∆R-expressing cells. Cells expressing p85∆R+R274A clones 3 and 4 
migrated more readily towards 10% FBS in comparison to both p85wt- and p85∆R-expressing  
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Figure 4.24: Cells expressing p85R274A and p85∆R+R274A are less adherent to collagen 
coated surfaces. Cells were seeded on 96-well plates coated with either collagen (A) or 
fibronectin (B) and incubated for 30 minutes. Cells were then washed, fixed, stained with crystal 
violet and solubilised. Relative fluorescent units were quantified at 550 nm and represented 
relative to cells expressing the vector control (pFLAG3) from two independent experiments with 
triplicate measurements for each experiment. Bonferroni’s multiple comparison test indicates * 
p<0.05, ** p<0.01 as compared to p85wt.   
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Figure 4.25: p85R274A and p85∆R+R274A mutations induce more migration of cells, 
whereas the p85∆R mutation induces less migration. Cells were seeded into the top section of 
a Boyden chamber and left to migrate towards either 0.1% FBS or 10% FBS at 37 °C for 24 
hours. Cells that had migrated to the bottom side of the Boyden chamber were then fixed and 
stained with hematoxylin. Cells observed in 8 fields of view at a magnification of 20X were 
quantified using the Stereo Investigator software (MBF Bioscience). The results represent cells 
that migrated towards 10% FBS minus cells that migrated towards 0.1% FBS from one 
experiment with duplicate measurements. Bonferroni’s multiple comparison test indicates ** 
p<0.01, *** p<0.001 as compared to p85wt C1 and # p<0.05, ## p<0.01, ### p<0.001 as 
compared to p85wt C2.   
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cells (Figure 4.25). Cells expressing p85∆R+R274A clone 4 had an even higher rate of migration 
than p85R274A-expressing cells. The data indicate that expression of p85R274A or 
p85∆R+R274A results in an increase in the migratory properties of cells.  
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5.0 DISCUSSION 
The p85 protein plays several different roles in regulating signalling by, as well as the 
trafficking of, activated growth factor receptors such as the PDGFR (Mellor et al., 2012). Our 
laboratory previously reported on a role for p85 in regulating the Rab GTPases, Rab5 and Rab4, 
which in turn regulate PDGFR intracellular trafficking and degradation (Chamberlain et al., 
2004; Chamberlain et al., 2010). Expression of a RabGAP defective mutant of p85, e.g. 
p85R274A, acts as a dominant negative mutant and blocks degradation of activated PDGFR, 
alters receptor trafficking and transforms cells (Chamberlain et al., 2004; Chamberlain et al., 
2008; Chamberlain et al., 2010). These observations suggest that the RabGAP activity of p85 is 
associated with PDGFR down-regulation. The main objective of this research was to determine 
whether p85R274A needs to associate physically with either the p110β catalytic subunit of PI3K 
and/or with the PDGFR in order to elicit its effects on receptor signalling, trafficking and 
transformation of cells.  
 
5.1 Role of p85-p110β binding in the RabGAP function of p85 
5.1.1 p110β as the switch stabilization effector protein of the p85-p110β GAP protein 
complex 
The selective interaction between p110β and Rab5-GTP (Christoforidis et al., 1999b) 
suggests binding within the conformation-specific switch regions. This interaction may be 
important for a number of different functions including switch region stabilization by p85-p110β 
during Rab5 effector functions that require Rab5GTP and the generation of lipid substrates 
required for tethering and fusion of endocytic vesicles. It should also be noted that p85 is unable 
to stabilize the switch regions of Rab5 and would therefore require a binding partner in order to 
perform the full function as a GAP protein (Scheffzek et al., 1998a; Terzyan et al., 2004).  
 It was hypothesized that if p110β contributes to the GAP activity (possibly through 
switch stabilization), then cells expressing p85∆110+R274A would be expected to have 
phenotypes even more pronounced than p85R274A-expressing cells. Expression of 
p85∆110+R274A led to an even more prolonged activation of PDGFR, reduced rates of 
degradation and a more sustained MAPK/Erk signalling than was previously described for 
p85R274A-expressing cells (Chamberlain et al., 2004). The enhanced signalling observed in 
p85R274A-expressing cells resulted in transformation of cells (Chamberlain et al., 2004; 
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Chamberlain et al., 2008). Yet, contrary to the cellular transformation seen for p85R274A-
expressing cells, expression of p85∆110+R274A did not lead to cellular transformation. This 
was clear from the lack of foci formation on over-confluent plates and colony formation in a 
semi-solid environment (soft agar). Even though the cells expressing p85∆110+R274A neither 
formed foci nor colonies in soft agar, half of the clones tested (clones 2, 3) were less adherent to 
collagen I, similar to p85R274A-expressing cells. However, the other two clones expressing 
p85∆110+R274A (clones 1, 4) adhered to collagen I to the same extent as cells expressing p85wt 
further suggesting that these cells are not transformed. The differences in adhesion to collagen I 
in clonal isolates of p85∆110+R274A-expressing cells could be due to the levels of FLAG-
tagged p85 expressed by the individual clones. Cells expressing p85∆110+R274A clones 2 or 3 
expressed similar levels of FLAG-tagged p85 in comparison to cells expressing p85R274A clone 
2 and may account for the similar pattern of adhesion that was observed.  It should be noted that 
clone 4 of p85∆110+R274A-expressing cells also expressed similar levels of FLAG-tagged p85 
when compared to cells expressing p85R274A clone 2. 
Cell adhesion to the extracellular matrix (ECM) can be used as a marker of cellular 
transformation. Transformed cells may change the properties of adhesion to the different proteins 
found on other cells or found within the ECM. For example, collagen (type IV) serves as a 
scaffold for laminin as well as other components of the basement membrane (Yurchenco et al., 
1986). A loss of collagen due to an increase in collagenase activity promotes invasion and 
metastasis (Junker and Heine, 1987). Fibronectin is important for mesenchymal cell attachment, 
cell proliferation and cell migration (Bitterman et al., 1983; Couchman et al., 1982; Hynes and 
Yamada, 1982). It is often reduced and/or absent from the surface of transformed cells (Junker 
and Heine, 1987). During the initial stages of metastasis, transformed cells can degrade and 
invade the ECM allowing these cells to migrate to secondary locations. The MAPK/Erk 
signalling pathway is a regulator of cell migration and invasion. In terms of the migratory 
properties of cells expressing p85∆110+R274A, two of the clones tested (clones 2, 4) appeared 
to migrate better than p85wt-expressing cells, as had already been observed with p85R274A-
expressing cells. The other two clones tested (clones 1, 3) migrated to the same extent as p85wt-
expressing cells.  
Even though 15 – 20% expression of p85R274A (compared to endogenous p85 levels) is 
sufficient to disrupt receptor signalling and trafficking events (Chamberlain et al., 2004; 
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Chamberlain et al., 2008), it is possible that this same level of expression is not enough to 
observe the RabGAP effects of p110β on receptor signalling and trafficking. It should be noted 
that all the cell lines used in this thesis express endogenous levels of p85 and the effects of p85 
mutations may be reduced by normal signalling from endogenous p85. Alternatively, the 
different functions of the PI3K complex, i.e. p85-mediated GAP activity (arginine finger), 
p110β-mediated GAP activity (switch stabilization) and lipid generation, may yield different 
phenotypes, and the assays used to test cell transformation in this thesis simply indicated the sum 
of an individual change within the p85 protein on any one or all three of these functions. It has 
already been shown that Rab5-GTP, and not Rab5-GDP, Rab4 or Rab11, can bind to p110β 
(Christoforidis et al., 1999b). This implies that p110β exerts its effects only on Rab5 and 
therefore only at the internalization step, whereas p85 has effects on both internalization and 
recycling during endocytosis since it serves as a GAP for both Rab5 and Rab4 (Chamberlain et 
al., 2004). Phosphatidylinositol-3,4,5-trisphosphate (PI3,4,5P3) generated by p110β can also 
supply Rab5-associated phosphatases with the substrate required to produce 
phosphatidylinositol-3-phosphate (PI3P), which is important for tether formation between the 
vesicle budded off from the plasma membrane and the early-sorting endosome (again, the 
internalization step). Indeed, it has recently been reported that in response to growth factor 
limitation, p110β can bind to Rab5-GTP and enhance the interaction between Rab5 and Vps34 
(Dou et al., 2013). Vps34 is a class III PI3K catalytic subunit that converts phosphatidylinositol 
(PI) to PI3P. The study conducted by Dou and colleagues also revealed that p110β is important 
for Rab5 activation, although they also show that binding of p110β to Rab5 antagonizes the 
Rab5GAP activity of p85 (Dou et al., 2013). The non-canonical functions of p110β therefore 
include switch stabilization of Rab5, regulation of Rab5 activation as well as regulation of 
internalization of receptor complexes and fusion to the early sorting endosome. 
 
5.1.2 Model for cells expressing p85Δ110 or p85Δ110+R274A 
Based on the hypothesis that p110β provides the switch stabilization function, it was 
further hypothesized that p110β needed to be bound to p85 for full GAP activity. As mentioned 
above, the different functions of the PI3K complex (i.e. p85-mediated GAP activity (arginine 
finger), p110β-mediated GAP activity (switch stabilization) and p110β-mediated lipid 
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generation) may yield different phenotypes and may explain the varying phenotypes observed 
during the course of these studies.  
The following model is proposed for cells expressing p85Δ110 or p85Δ110+R274A. In 
NIH3T3 cells, activated PDGFR complexes are internalized and loaded onto the early/sorting 
endosome via a Rab5-mediated pathway. From the early/sorting endosome PDGFRs are either 
deactivated and recycled back to the plasma membrane rapidly by a Rab4-dependent process, or 
slowly by a Rab4 and Rab11-dependent process, or ubiquitinated and sorted into a lysosomal 
degradation pathway. In this endocytic pathway, p85 functions as a GAP protein for Rab5 and 
Rab4 enhancing their intrinsic GTPase activity and maintaining the normal balance between 
activation and duration of signalling. p110β can bind to Rab5-GTP. Binding of p110β to Rab5 
can serve 2 functions: 1) provide a switch stabilization function to enhance GAP activity, and/or 
2) provide PI3,4,5P3 which can serve as a substrate for phosphatases associated with Rab5 and 
EEA1 to generate PI3P required for the tether formation during vesicle fusion. 
In p85∆110-expressing cells, it is proposed that p85 is unable to bind p110β preventing 
the formation of the p85-p110β-Rab5 complex. A slight increase in the rate of internalization 
will be expected since p110β cannot bind to p85-Rab5 and enhance its GAP activity. GAP 
activity will remain low since p110β is unable to provide the switch stabilization function. Also, 
the tether formation could be slightly impaired (Note: there are other sources of PI3P for tether 
formation). The rate of recycling and degradation will not be affected since p110β only regulated 
the function of Rab5 at the internalization step. Cells expressing p85∆110 were comparable to 
NIH 3T3 cells. 
In cells expressing p85R274A, p85 is RabGAP defective and is unable to inactivate Rab5 
and Rab4. This is expected to result in an increase in both receptor internalization (Rab5-
dependent) and recycling (Rab4-dependent), with limited receptor degradation. In support of this 
model, p85R274A-expressing cells show increased rate of PDGFR internalization and recycling 
(Chamberlain et al., 2010) and reduced PDGFR degradation (Chamberlain et al., 2004; 
Chamberlain et al., 2010). These cells also showed prolonged PDGFR activation and enhanced 
signalling (MAPK/Erk) (Chamberlain et al., 2004). Cells expressing p85R274A were also shown 
to be transformed (Chamberlain et al., 2008). 
It is postulated that in cells expressing p85∆110+R274A, the RabGAP defective p85 is 
unable to bind p110β preventing the formation of the p85-p110β-Rab5 complex. This effect is 
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expected to result in an increase in receptor internalization (Rab5-dependent) and recycling 
(Rab4-dependent), with limited receptor degradation. That is, we expect these cells to have 
phenotypes comparable to cells expressing p85R274A. Even though p85∆110+R274A-
expressing cells have prolonged PDGFR activation, enhanced signalling (MAPK/Erk) and 
reduced PDGFR degradation, these cells are not transformed.  
Based on the working model, it appears that a defect in GAP activity of p85 alone could 
be enough to lead to transformation of cells. When binding of p110β to the p85R274A RabGAP 
defective variant is abolished, cellular transformation seems to be reversed. Yet, receptor 
signalling remains enhanced, probably due to the fact that the receptor complexes are 
sequestered either at the plasma membrane or within the budding vesicle, and consequently are 
incapable of reaching the early/sorting endosome. These data support the involvement of p110β 
in the RabGAP function of p85.  
 
5.2 Role of the binding of p85 to the PDGFR in the RabGAP function of p85 
5.2.1 p85-PDGFR binding for full GAP function of p85  
It was hypothesized that PDGFR may help localize the RabGAP function of p85 through 
the binding of p85 to phosphorylated tyrosine residues on activated PDGFR. During 
internalization and uptake of activated receptor complexes into endosomes, Rab5 binds to both 
the internalized vesicle and the early sorting endosome and is therefore appropriately positioned 
to interact with p85. If p85-PDGFR binding is necessary to localize the RabGAP function of 
p85, p85∆R-expressing cells and cells expressing p85∆R+R274A would be expected to have 
similar phenotypes, but different from other p85 variants that would retain their ability to bind 
PDGFR. The hypothesis was tested by examining the levels of activated receptor and total 
receptor levels as well as the levels of molecules in downstream signalling cascades, such as 
MAPK/Erk. Whereas cells expressing p85∆R have normal signalling, e.g. similar to signalling in 
control NIH 3T3 cells and cells expressing p85wt, the cells expressing p85∆R+R274A have a 
much more prolonged activation of PDGFR, a slower degradation rate of PDGFR, and a 
sustained activation of the MAPK/Erk pathway, just like cells expressing p85R274A. Defects in 
receptor activation, signalling and down-regulation have been implicated in a number of 
different cancers (Bache et al., 2004; Knowles et al., 2009; Platt et al., 2009; Sebastian et al., 
2006). Cells expressing p85∆R+R274A were transformed, just like p85R274A-expressing cells. 
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Both p85R274A- and p85∆R+R274A-expressing cells had lost response to contact inhibition as 
demonstrated by the formation of foci in clones 2 and 4 of p85∆R+R274A-expressing cells and 
both clones of p85R274A-expressing cells. The R274A mutation also affected the cells’ ability 
for anchorage-dependent growth (e.g. clones 1 and 2 of p85∆R+R274A-expressing cells and 
both clones of p85R274A-expressing cells easily formed colonies in a semi-solid environment 
(soft agar)).  
As mentioned earlier, cell adhesion is important for cell-cell communication and for the 
maintenance of cellular structure. When adherent cells become transformed they can change 
their adherent properties by modifying how they interact with various components of the ECM. 
Cells expressing p85R274A or p85∆R+R274A (clones 2, 3 and 4) were less adherent to collagen 
I when compared to p85wt control cells. Collagen is important for providing and maintaining the 
integrity of the ECM. Loss of adherence to collagen suggests that these cells are able to detach 
from the extracellular matrix. The migration assay utilized in this research confirmed that cells 
expressing p85R274A as well as cells expressing p85∆R+R274A (clones 2, 3 and 4) were more 
migratory than cells expressing p85wt. This corroborates the observation that cells expressing 
p85R274A are invasive (Chamberlain et al., 2008). 
In summary, expression of p85R274A or p85∆R+R274A in cells leads to an increased 
PDGFR activation and sustained PDGFR-mediated signalling, and decreased PDGFR down-
regulation, which eventually culminates in changes in cellular behaviour that support a 
tumorigenic phenotype. The effects observed are more pronounced in p85∆R+R274A-expressing 
cells. Taken together, these results suggest that binding of p85 to PDGFR is not necessary for the 
localization of the RabGAP function of p85.  
 
5.2.2 p85 as a GDI displacement factor (GDF) 
Our laboratory has shown that p85 is able to bind both Rab5-GDP and Rab5-GTP 
(Chamberlain et al., 2004), unlike most GAP proteins that bind selectively to the GTP forms 
only. The inactive Rab5-GDP is cytosolic and exists in complex with a GDP-dissociation 
inhibitor (GDI) that obstructs the lipid geranylgeranylated site that is crucial for membrane 
insertion (Leung et al., 2007; Leung et al., 2006; Pfeffer and Aivazian, 2004; Wu et al., 2010). 
Rab5 is recruited to the vesicle that buds off from the plasma membrane and the early sorting 
endosome by the removal of the GDI and the subsequent exchange of GDP for GTP, which is  
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Figure 5.1: Mechanism of Rab5 regulation. A) Lipid prenylated Rab GTPases are cytosolic 
and inactive in their GDP-bound conformations bound to a cytosolic protein termed GDP-
dissociation inhibitor (GDI) that masks the lipid prenylation site. The GDI is displaced by a GDI 
displacement factor (GDF) and Rab5-GDP is delivered to both the membrane of the vesicle 
containing activated receptor tyrosine kinases (RTKs) that have budded off from the plasma 
membrane and the early endosomal membrane. This step has been speculated to occur in 
conjunction with unidentified targeting factors that may aid in Rab5-GDP recruitment (for e.g. 
PDGFR/p85?). B) A guanine nucleotide exchange factor (GEF) promotes the exchange of GDP 
for GTP resulting in an active form of Rab5. C) Rab5-GTP recruits effector proteins such as 
EEA1 to the membrane and vesicle fusion events are initiated. Active Rab5-GTP binds effector 
proteins like EEA1, a protein important in tethering two membranes together by binding both 
Rab5-GTP and the lipid phosphatidylinositol 3-phosphate (PI3P). D) Rab5 has the intrinsic 
ability to hydrolyse the bound GTP to GDP with the aid of GTPase activating protein (GAP 
proteins), returning Rab5 to an inactive state and resulting in the re-extraction of Rab5 from the 
membrane by binding to GDI. 
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facilitated by a guanine nucleotide exchange factor (GEF) (Pfeffer and Aivazian, 2004; Wu et 
al., 2010). The removal of the GDI is facilitated by a GDI displacement factor (GDF) (Figure 
5.1) (Pfeffer and Aivazian, 2004; Sivars et al., 2003; Wu et al., 2010).  
Since p85 binds to Rab5-GDP as well as activated PDGFR it may help recruit Rab5 to 
vesicle membranes containing activated PDGFR signalling complexes. The formation of a 
p85/Rab5-GDP/PDGFR complex places Rab5 in proximity to a membrane. This allows the GDI 
to be displaced, possibly, by p85 and allows Rab5 to be inserted into the membrane and be fully 
activated by the exchange of GDP for GTP. This hypothesis is being tested in our laboratory as 
components of three graduate thesis projects. (i) The first examines the importance of p85-
PDGFR binding for the normal functioning of the Rab5 pathway by measuring the levels of 
Rab5-GTP and its effects on signalling events initiated by PDGF (this thesis). (ii) The second 
project investigates p85 binding sites on Rab5 through mutational analysis (Dielle Detillieux, 
MSc thesis). (iii) The third project analyzes the effect of activated PDGFR on p85 Rab5GAP 
activity using GAP assays, and the effect of activated PDGFR on p85-Rab5 binding by using 
surface plasmon resonance (SPR) (Cody Bergman, MSc thesis). The last two theses are now 
complete. Specific binding sites on Rab5 that are important for interaction with p85 have not 
been identified. GAP assays performed by Cody Bergman to measure the effect of activated and 
inactivated PDGFR on p85 Rab5GAP activity suggested that PDGFR had no significant effect 
on p85 Rab5GAP activity. This finding supports my observation made in cells expressing 
p85∆R+R274A, where it was shown that p85-PDGFR interaction was not required for RabGAP 
function of p85.  
If the p85/Rab5-GDP/PDGFR complex is important for the GDF function of p85 then we 
expect that in cells expressing p85ΔR or p85ΔR+R274A Rab5-GDP cannot be recruited to the 
membrane and be activated. This will result in a sequestration of Rab-GDP in the cytosol and a 
reduction in the levels of Rab5-GTP. The levels of active Rab5-GTP were to be measured by 
immunoprecipitating Rab5-GTP with an anti-Rab5GTP antibody (an activation specific antibody 
that is supposed to recognize only Rab5 bound to GTP – the active form) followed by SDS-
PAGE and Western blot analysis using anti-Rab5 antibodies. Optimization experiments were 
carried out to determine the conditions required for this Rab5GTP antibody from New East 
Biosciences, which is the only activation specific Rab5 antibody available on the market. 
Experiments were performed using both purified Rab5 protein and cell lysates collected from 
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NIH 3T3 cells treated with growth factor for different times. The activation specific Rab5GTP 
antibody pulled down both GDP and GTP bound Rab5 and therefore could not be used for 
further experiments.  
 
5.2.3 A model for cells expressing p85ΔR or p85ΔR+R274A 
We hypothesized that since p85 binds to Rab5-GDP as well as Rab5-GTP, it may help 
recruit Rab5 to vesicle membranes containing activated PDGFR signalling complexes and 
thereby regulate PDGFR signalling events (Chamberlain et al., 2004) (Figure 5.1). In order to 
test this hypothesis, cells expressing either p85 unable to bind to the PDGFR (p85ΔR) or a 
RabGAP defective p85 unable to bind to the PDGFR (p85ΔR+R274A) were generated and 
tested for changes in PDGFR signalling, trafficking and degradation. Based on our model 
illustrated in Figure 5.2, cells expressing p85∆R have lower levels of Rab5-GTP presumably 
because Rab5-GDP cannot be recruited to the endosomal membrane. Sequestration of Rab5-
GDP in the cytosol would be expected to result in a slower rate of internalization of activated 
receptor complexes. In p85R274A-expressing cells, PDGFR-associated p85 may aid in Rab5-
GDP recruitment, however, p85 is RabGAP defective leading to an inability to inactive Rab5. 
The accumulation of Rab5-GTP leads to prolonged PDGFR-mediated signalling events. In 
p85∆R+R274A-expressing cells, p85 is unable to bind to the PDGFR preventing the recruitment 
of Rab5-GDP to the endosomal membrane. Rab5-GDP is sequestered in the cytosol. Cells 
expressing p85∆R+R274A were expected to have phenotypes comparable to p85∆R-expressing 
cells. However, it was observed that p85R274A-expressing cells and p85∆R-expressing cells 
were comparable to each other, which indicates that binding of p85 to PDGFR is not required for 
Rab5-GDP recruitment to endosomal membranes. 
 
5.3 Future studies 
 The results obtained have paved the way to better understand the non-canonical functions 
of the PI3K complex. The results have provided the basis for several interesting models of events 
that could be transpiring in cells when interactions between p85 and some of its signalling 
interactors are altered. However, the models that have been proposed remain simply conjecture 
at this point and will certainly need to be tested further to demonstrate biological or pathological 
relevance. Some suggested experiments are outlined below. 
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Figure 5.2: Model for cells expressing p85ΔR or p85ΔR+R274A. NIH3T3 cells: Activated 
PDGFR complexes are internalized and loaded onto the early/sorting endosome via a Rab5-
mediated pathway. Rab5-GDP is delivered to the early endosomal membrane. PDGFR-
associated p85 may aid in Rab5-GDP recruitment. A GEF promotes the exchange of GDP for 
GTP resulting in an active form of Rab5. The RabGAP function of p85 enhances the GTPase 
activity of Rab5. Observed phenotype: Normal signalling events, non-transformed cells. p85∆R-
expressing cells: p85 is unable to bind to the PDGFR preventing the recruitment of Rab5-GDP to 
the endosomal membrane. Rab5-GDP is sequestered in the cytosol. Observed phenotype: 
Normal signalling events, non-transformed cells. (Note: There are normal endogenous levels of 
p85 present in these cells). p85R274A-expressing cells: PDGFR-associated p85 may aid in Rab5-
GDP recruitment, however, p85 is RabGAP defective leading to an inability to inactivate Rab5. 
Accumulation of Rab5-GTP results in enhanced signalling events. Observed phenotype: 
Prolonged PDGFR activation, enhanced signalling (MAPK/Erk), reduced PDGFR degradation, 
transformed cells. (Note: There are normal endogenous levels of p85 present in these cells. It 
appears that the level of p85R274A present in the cells is enough to cause such a strong response 
in cells). p85∆R+R274A-expressing cells: p85 is unable to bind to the PDGFR preventing the 
recruitment of Rab5-GDP to the endosomal membrane. Rab5-GDP is sequestered in the cytosol. 
Observed phenotype: Prolonged PDGFR activation, enhanced signalling (MAPK/Erk), reduced 
PDGFR degradation, transformed cells. (Note: There are normal endogenous levels of p85 
present in these cells. It appears that the level of p85ΔR+R274A present in the cells is enough to 
cause such a strong response in cells indicating that binding of p85 to PDGFR is not required for 
Rab5-GDP recruitment to endosomal membranes). 
 
 
5.3.1 Role of p110β in the RabGAP function of p85-p110β complex 
It was shown in this thesis that expression of p85∆110+R274A in cells leads to sustained 
PDGFR signalling that does not result in cellular transformation. This effect was attributed to the 
varying functions of the PI3K complex (i.e. p85-mediated GAP activity (arginine finger), p110β-
mediated GAP activity (switch stabilization) and lipid generation). To determine whether p110β 
does indeed contribute GAP activity towards Rab5, a GAP assay (Chamberlain et al., 2004) can 
be performed using a recombinant stabilized p110β (p85iSH2-p110β; the iSH2 domain of p85 
bound to p110β) generated by Dielle Detillieux. In order to tease out possible functions of p110β 
in the RabGAP activity of the PI3K complex, p110β can be knocked down from cells expressing 
p85wt, p85∆110, p85R274A or p85∆110+R274A using shRNA-p110β lentiviral particles. After 
the knock-down experiments, p110β lacking kinase activity (p110∆kinase, K805R) (Yart et al., 
2002) or p110β unable to bind Rab generated by Dielle Detillieux (p110∆Rab: E238R and 
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Y244A, unpublished data) can be introduced into cells to determine the effects of p110β-
mediated lipid generation or p110β-mediated GAP activity on receptor signalling and trafficking.  
 
5.3.2 p85 as a GDI displacement factor (GDF) 
It was postulated that p85 binds to Rab5-GDP as well as activated PDGFR and may help 
recruit Rab5 to vesicle membranes containing activated PDGFR signalling complexes. This 
hypothesis was to be tested by examining the importance of p85-PDGFR binding for the normal 
functioning of the Rab5 pathway by measuring the levels of Rab5-GTP using an activation 
specific antibody for Rab5. However, the antibody used for these measurements 
immunoprecipitated both GDP and GTP bound Rab5. The Rab5-GTP (active Rab5) can be 
measured using a glutathione S-transferase (GST) pull down technique (Chamberlain et al., 
2010; Dou et al., 2013). In this assay a GST-tagged Rab5-binding domain of Rabaptin5 (residues 
739–862, R5BD) that binds specifically to Rab5-GTP (Liu et al., 2007) can be used to pull down 
and measure Rab5-GTP levels in response to growth factor treatment. The model predicts that 
cells expressing p85R274A will have higher levels of Rab5-GTP, whereas, cells expressing 
p85∆R or p85∆R+R274A will have lower levels of Rab5-GTP. 
Sequestration of Rab5-GDP by p85R274A, for example, can be further tested by 
immunoprecipitating FLAG-tagged p85 and Western blotting for bound Rab5. 
 
5.3.3 Monitor PDGFR trafficking  
The working model for p85-p110β-Rab5 binding suggests that cells in which p85 is 
unable to bind to p110β, the internalization of activated receptor complexes is increased due to 
the increase in levels of Rab5-GTP as a result of a loss of the switch stabilization function of 
p110β. In cells expressing the RabGAP defective p85, both internalization and recycling of 
receptor are increased due to the increase in levels of Rab5-GTP as a result of a reduction in 
RabGAP activity of p85 (Chamberlain et al., 2010). Based on these observations, it is proposed 
that the loss of RabGAP activity in a p85 molecule that is unable to bind to p110β (and in which 
the capacity for switch stabilization is presumably lost) leads to an even greater increase in 
internalization over the either one of these individual effects. It is also hypothesized that 
recycling of the receptor to the plasma membrane is also increased in these cells to the same 
extent as cells expressing the RabGAP defective p85. In order to validate this model a biotin 
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assay that involves cell-surface protein biotinylation, induction of endocytosis by growth factor 
stimulation and analysis of internalized receptors can be performed. Internalized biotinylated 
proteins can be immunoprecipitated using strepdavidin beads, followed by anti-PDGFR Western 
blot analysis (Chamberlain et al., 2010). 
Immunofluorescence experiments can also be performed using anti-PDGFR, anti-Rab5, 
anti-Rab4 or anti-Rab7 antibodies to determine the localization of the receptor with respect to its 
association with internalization, recycling or degradation endosomes. During these 
immunofluorescence experiments, the size of the early endosomes can also be measured as an 
indication of active Rab5 levels since an increase in Rab5-GTP results in enlarged early 
endosomes (Barbieri et al., 2000; Stenmark et al., 1994). 
 
5.3.4 Constitutive PDGFR ubiquitination in p85R274A-expressing cells 
 As mentioned above, the rate of PDGFR degradation is decreased in cells that express 
p85R274A. As this mutation disrupts the ability of p85 to enhance the GTPase activity of Rab5 
and Rab4, which would allow these Rab proteins to remain active, i.e. in their ‘on’ state for 
longer (Chamberlain et al., 2010), this would translate into a more rapid cycling and recycling of 
receptor-ligand complexes through the early/sorting endosome, with very few of these 
complexes being sorted into the late endosomal/lysosomal degradative pathway (Chamberlain et 
al., 2010). Monoubiquitination marks the receptor for late endosomal sorting and lysosomal 
degradation (Marmor and Yarden, 2004). The ubiquitinated receptor is sorted into multivesicular 
bodies within the lumen of the late endosome; these bodies are then delivered to the lysosome 
where the proteins are degraded by lysosomal enzymes (Marmor and Yarden, 2004). Even 
though PDGFR in cells expressing p85R274A are ubiquitinated, it is likely that the receptor-
ligand complexes are cycling through the early/sorting endosomes so quickly that they are 
unable to be sorted into the late endosome (Chamberlain et al., 2010). As such a constitutively 
ubiquitinated PDGF receptor may be sufficient to drive receptor-ligand complexes into the 
lysosomal degradation pathway, and restore normal degradation. This should decrease the 
downstream signalling observed in cells expressing the RabGAP defective p85R274A mutant 
since more of the receptor complexes would be expected to go down the lysosomal degradative 
pathway. To investigate this hypothesis, degradation rates (or half-lives) of a control PDGFR and 
its ubiquitin (Ub) chimera, with ubiquitin linked directly onto the receptor, could be determined. 
	   123	  
Receptor trafficking events and signalling kinetics in cells expressing these chimeras could also 
be studied and would be expected to impart a shorter half-life to the PDGFR-ubiquitin chimera 
than the half-life observed with the control PDGFR in p85R274A-expressing cells.  
 
5.4 Conclusions 
Expression of a RabGAP defective mutant p85R274A acts as a dominant negative mutant 
and blocks degradation of activated PDGFR, alters receptor trafficking and transforms cells 
(Chamberlain et al., 2004; Chamberlain et al., 2008). These observations suggest that the 
RabGAP activity of p85 is associated with PDGF receptor down-regulation. The properties of 
cells expressing this mutant were further characterized by investigating whether normal PDGFR 
signalling events can be restored by abolishing the binding of p85 to PDGFR or to p110β. In 
summary, expression of a RabGAP defective p85 mutant unable to bind PDGFR shows that p85-
PDGFR binding is not necessary for the RabGAP function of p85, since these cells had 
phenotypes similar to cells expressing the RabGAP defective mutant p85R274A. On the other 
hand, expression of a RabGAP defective p85 mutant unable to bind p110β resulted in the 
reversal of the tumorigenic properties observed in cells expressing the RabGAP defective mutant 
p85R274A, but not the enhanced signalling events in response to growth factor. This suggests 
some role of the p110β subunit in the RabGAP activity of p85. A better understanding of the 
role(s) that p110β has on p85’s non-canonical function would contribute to our understanding of 
the progression of cancers that result from specific mutations in both p85 and p110β, within 
regions implicated in regulation of RabGAP activity. In fact, in recent years a number of 
different p85 mutations have been reported in the following cancers; glioblastomas, colorectal, 
urothelial, ovarian, colon, breast and pancreatic cancers (Mellor et al., 2012; Ross et al., 2013). 
Some of these mutations occur within the nSH2, iSH2 and cSH2 domains of p85 and disrupt the 
physical interaction between p85 and p110 resulting in increased PI3K signalling (Mellor et al., 
2012; Ross et al., 2013). Other mutations occur within the GAP domain and may disrupt the 
GAP functions of p85 (Cheung et al., 2011; Ross et al., 2013).  The findings reported in this 
thesis corroborate these reports and provide a mechanism to explain how mutations within the 
GAP domain can alter signalling events and lead to the enhancement of tumour-associated 
phenotypes. This knowledge not only broadens out basic understanding of tumour progression, 
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but also could provide the groundwork for the development of small molecule inhibitors targeted 
at these specific cancers for better cancer prognosis.  
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